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Chapter I 
GENERAL INTRODUCTION 
I.1. LYSOSOMES AND LYSOSOMAL ENZYMES 
Lysosomes are cytoplasmic vesicles containing 
hydrolytic enzymes, with an acidic pH optimum. Primary 
lysosomes are formed at the trans side of the Golgi 
complex of eukaryotic cells in an area called Trans Golgi 
Reticulum (TGR). After fusion with endosomes or 
autophagosomes, they become digestive vacuoles or secondary 
lysosomes (for reviews see, de Duve, 1983; Mellman, 1984; 
Quinn, 1984). Although lysosomes are morphologically 
heterogeneous and undergo diverse transformations by the 
process of fusion with other cellular membranes, they share 
several functional characteristics. When a tissue 
homogenate, containing lysosomes, is prepared and acid hydro-
lases are assayed under isosmotic conditions, the activity 
of acid hydrolases is low. However, when the tissue is 
subjected to mechanical stress, or treatment with a 
detergent, much more activity is revealed. It was this 
phenomenon of latency which led to de Duve's discovery of 
lysosomes in 1955. The existence of lysosomes was later 
confirmed by the electron microscopic studies of Novikoff, 
(1961). The presence of an intact membrane around the lyso-
somal enzymes prevents the escape of macromolecular 
substrates and enzymes from the lysosomes.-
Some 70 lysosomal enzymes have been identified which 
are involved in the degradation of (glyco)proteins, (phos-
pho)lipids, glycosphingolipids, (muco)polysaccharides, DNA 
and RNA. After degradation the low molecular weight consti-
tuents diffuse through, or are transported across the lyso-
somal membrane into the cytoplasm, here they can be reuti-
lized in metabolic processes. The substrates for the lysoso-
mal enzymes are derived from intracellular as well as extra-
.cellular material entering the lysosomes via the mechanism 
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of autophagy or endocytosis. 
The lysosomal enzymes themselves are glycoproteins and 
thus it is a question why they are not degraded by the 
present acid proteases. This is especially relevant since it 
has been demonstrated that lysosomal enzymes tested are 
located within the same subcellular compartment (van Dongen 
et al., 1984). Probably a mechanism exists which protects 
the lysosomal enzymes against degradation by neighbouring 
acid hydrolases. It is possible that a special 
configuration, aggregation or interaction (binding) of the 
lysosomal enzymes to the lysosomal membrane plays a role in 
this protection. 
Lysosomal enzymes, along with secretory proteins and 
plasma membrane proteins are synthesized on ribosomes bound 
to the endoplasmic reticulum. The preproform of a lysosomal 
enzyme enters the rough endoplasmic reticulum (RER) where 
the "signal" sequence is removed by proteolytic cleavage and 
asparagine residues are glycosylated (Blobel, 1980, Erickson 
et al., 1984). From the RER they reach the Golgi compart-
ment. During passage through the Golgi apparatus the secre-
tory proteins, membrane proteins and lysosomal enzymes 
undergo a number of posttranslational modifications essen-
tial for their routing and destination. The oligosaccharides 
on secretory proteins and membrane glycoproteins and some 
lysosomal glycoproteins are modified to sialic-acid contai-
ning "complex" type units. However, most of the lysosomal 
enzymes undergo a different series of modifications. Speci-
fic "high-mannose" oligosaccharide chains are formed which 
can be phosphorylated at the 6-carbon position of the five 
outermost mannose residues. This is accomplished by two 
Golgi enzymes. First, N-acetylglucosaminylphosphotransferase 
transfers N-acetylglucosamine-1-phosphate to the mannose 
residues to give a phosphodiester intermediate (Reitman et 
al., 1981a,b; Waheed et al., 1982). Secondly N-
acetylglucosamine is removed by N-acetylglucosamine-1-phos-
phodiester a-N-acetylglucosaminidase (Varki and Kornfeld, 
1981; Waheed et al., 1981). This modification occurs in the 
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cis Golgi compartment (Goldberg and Kornfeld, 1983). The 
mannose 6-phosphate residue acts as a recognition marker for 
the mannose 6-phosphate (Man 6-P) receptors to ensure 
transport of lysosomal proteins to the lysosomes (Kaplan et 
al., 1977; for reviews see Creek and Sly, 1984; Kornfeld, 
1986; Von Figura and Hasilik, 1986). 
Two distinct Man 6-P receptors have been identified. 
The first is a glycoprotein with an apparent molecular mass 
of 215 kDa which binds acid hydrolases independently of 
cations (Sahagian et al., 1981; Steiner and Rome, 1982). 
This receptor is present in a variety of tissues, and con-
stitutes 0.1-0.5% of total membrane protein (Von Figura and 
Hasilik, 1986) . The second receptor has an apparent molecu-
lar mass of 46 kDa and requires divalent cations for high 
affinity binding with its ligand (Hoflack and Kornfeld, 
1985a,b). 
Both receptors require two phosphomannosyl residues in 
monoester linkage on the protein for high-affinity binding 
(Hoflack et al., 1987). They are immunologically unrelated 
(Stein et al., 1987). The Man 6-P receptors are present on 
the plasma membrane (probably less than 10%) and on intra-
cellular membranes especially in the Golgi apparatus (for 
reviews see Creek and Sly, 1984; Kornfeld, 1986; Braulke et 
al., 1987) . The results of immunoelectron microscopical 
studies have been conflicting. Some workers found Man 6-P 
receptors only in cisternae on the cis side of the Golgi 
stacks, and in lysosomes (Brown and Farguhar, 1984) whereas 
others demonstrated receptors throughout the Golgi cisternae 
and not in the lysosomes (Willingham et al., 1981; Geuze et 
al., 1985). The genes coding for the 215 kDa and the 46 kDa 
Man 6-P receptors have recently been cloned (Lobel et al., 
1987; Dahms et al., 1987; Pohlman et al., 1987). Knowledge 
of the protein structures will contribute to a better 
insight into the specific functions of both receptors (Stein 
et al., 1987). 
Receptor-bound enzymes are collected in vesicles of the 
Trans Golgi Reticulum which form pre-lysosomes where the low 
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pH causes dissociation of the enzyme from the receptors. The 
latter recycle to the Golgi apparatus where they can be 
reutilized. The acidification in the (pre) lysosome is 
mediated by an ATP driven anion dependent proton pump. To 
prevent over acidification, it is suggested that the ATPase 
is kinetically controlled by anion transporters which 
modulate the chloride concentrations and in this way control 
the acidification of the lysosomes (for review see Mellman 
et al., 1986). Recently such an ATPase has been purified 
from chromaffin granule membranes (Moriyama and Nelson, 
1987). 
In addition to the Man 6-P dependent routing there must 
be different pathways for lysosomal enzymes and lysosomal 
membrane proteins to reach their correct intracellular loca-
tion. Two major sets of data lead to this hypothesis. 
Various mouse cell lines lacking Man 6-P receptors still 
have lysosomal enzyme activity (Goldberg et al., 1983). 
Moreover in cells from patien-ts with "I-cell" disease, which 
are deficient in the phosphotransferase, required for the 
generation of the Man 6-P recognition marker, the activity 
of several lysosomal enzymes is close to normal (for reviews 
see Creek and Sly, 1984; Erickson et al., 1984; Von Figura 
and Hasilik, 1986). In this latter connection it should be 
noted that the highest activities in "I-cell" fibroblasts 
are those of membrane-bound lysosomal enzymes such as B-
glucocerebrosidase. This enzyme was found to be not 
phosphorylated in normal cells which would point to a 
different routing for lysosomal membrane (associated) 
proteins (Murray et al., 1985; Lewis et al., 1985; Tager et 
al., 1986; Krentler et al., 1986). 
Within the lysosomal compartment, lysosomal enzymes 
undergo their last posttranslational processing steps such 
as proteolytic and carbohydrate modifications. These speci-
fic steps may induce conformational changes necessary for 
activation or stabilization of the enzyme, or for protection 
against degradation by neighbouring lysosomal enzymes. 
Further interaction with substrates, activators and other 
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components may occur (for reviews see in: Barranger and 
Brady, eds., 1984; in: Dingle et al. (1984); Kornfeld, 1986; 
Von Figura and Hasilik, 1986). 
I.2. LYSOSOMAL STORAGE DISEASES 
The physiological importance of lysosomal enzymes for 
the degradation of many cellular substrates is revealed by 
the profound effects occuring if one single lysosomal enzyme 
is deficient. The storage diseases are associated with 
(severe) physical and mental handicaps and are often lethal 
in early life. out of the total number of 70 lysosomal 
enzymes known (Barrett and Heath, 1977) a genetic defect 
leading to a disease has been demonstrated for 32 of them 
(Galjaard and Reuser, 1984; Stanbury et al. (eds.), 1983; 
Wenger et al., 1986; Cooper et al., 1986; Van Diggelen et 
al., 1987). Nearly all lysosomal storage diseases have an 
autosomal-recessive pattern of inheritance but two of them, 
Fabry's disease (a-galactosidase deficiency) and Hunter's 
disease (sulfoiduronide sulfatase deficiency) are X-linked. 
Within each lysosomal storage disease a considerable 
clinical and biochemical heterogeneity is found (Galjaard, 
1980; Stanbury et al. (eds), 1983). To investigate the cause 
of this heterogeneity different approaches are used. 
At the genetic level complementation analysis after 
somatic cell hybridization using cultured fibroblasts from 
patients with different clinical variants of "the same" 
disease is a useful tool in determining whether different 
genes or different mutations within one gene were involved 
(for reviews see Ringertz and Savage, 1976; Bootsma and 
Galjaard, 1979; Galjaard and Reuser, 1984; Reuser, 1984 see 
also chapter III). 
Cultured cells from two patients with a different 
clinical phenotype and the same enzyme deficiency are fused 
and the restoration of enzyme activity is measured in 
heterokaryons. Different approaches have been used to 
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analyze heterokaryons carrying the genetic information from 
both parental cell strains in the presence of non fused 
cells or homokaryons (de Weerd-Kastelein et al., 1972; 
Galjaard et al., 1975; Jongkind et al., 1979; Nelson and 
Carey, 1985). If restoration of enzyme activity is observed 
after fusion this points to intergenic complementation, i.e. 
two different gene products are involved. Possible examples 
of intragenic complementation after human somatic cell 
hybridization are extremely rare. 
At the level of the enzyme protein, measurement of the 
catalytic activity in cells from controls, heterozygotes and 
patients is not only commonly used for biochemical diagnosis 
and genetic counseling (Galj aard, 1980, Stanbury et al. 
(eds), 1983), but also for understanding the cause of 
clinical heterogeneity (Brady and Barranger, 1983; O'Brien, 
1983; Conzelmann and Sandhoff, 1983/84; Reuser et al., 
1987). In this context it is important to note that many 
diagnostic enzyme assays are performed on easily accessible 
cell material such as leucocytes and skin fibroblasts 
whereas the clinical and pathological features are of course 
determined by cellular and metabolic abnormalities in a 
variety of organs. 
Also, in diagnostic enzyme assays there may be a discre-
pancy between the activity as measured with an artificial 
substrate and with the natural substrate for the enzyme 
(Dreyfus et al., 1975, Navon et al., 1976). 
Furthermore differences in residual enzyme activity may 
express differently in test tube assays then "in vivo" ana-
lyses where natural substrate is added to living fibroblasts 
and the metabolism of ingested substrate is followed by chro-
matography (Kudoh et al., 1981). 
These examples and theoretical considerations described 
by Conzelmann and Sandhoff (1983/84) make it clear that it 
will often be difficult to relate residual lysosomal enzyme 
activity directly to the clinical expression of a lysosomal 
storage disease. 
As has been outlined in the previous section the forma-
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tion of mature, active lysosomal enzymes involves transcrip-
tion, translation and a number of posttranslational modifica-
tions. In principle a particular lysosomal enzyme deficiency 
can be the result of a defect in each of these steps (Fig. 
1) (see also Tager, 1985; Kornfeld, 1986). 
Both when different gene products are involved and in 
the case of different mutations within one gene, studies on 
the biosynthesis and posttranslational modification of a 
particular (enzyme) protein in normal and mutant fibroblasts 
have proved to be of great help in obtaining insight in the 
molecular background of clinical heterogeneity. Cultivation 
of fibroblasts in the presence of radioactive labelled amino 
acid, monosaccharide or phosphate, followed by immunoprecipi-
tation and sodium dodecyl sulfate (SDS) polyacrylamide gel 
electrophoresis (Hasilik and Neufeld, 1980) enabled the 
exact delineation of the molecular defect(s) involved in 
different clinical variants of several lysosomal storage 
disorders (for reviews see in: Barranger and Brady, (eds.) 
1984) 
Biochemical data on the biosynthesis of (enzyme) 
proteins can also be related to subcellular morphology using 
immunoelectron microscopy. In this respect the use of 
ultrathin cryosections and colloidal gold conjugates meant 
an important step forward in the subcellular localization of 
normal and mutant lysosomal enzymes and their precursor 
forms (Geuze et al., 1981, 1985; van Dongen et al., 1984). 
The various approaches mentioned above will often 
provide a clue as far as the molecular impairment is 
concerned (see Fig. 1). For an ultimate understanding of the 
molecular pathogenesis and as a basis for future treatment, 
knowledge about the synthesis, the amino acid sequence and 
the tertiary structure of the normal and mutant protein(s) 
is of importance. Much progress is being made in the techno-
logy of amino acid sequencing and calculation of three-
dimensional protein structure. However, it is often dif-
ficult or impossible to obtain sufficient cell material from 
patients with the genetic metabolic disease of interest. 
DIFFERENT TYPES OF GENETICALLY DETERMINED (ENZYME) PROTEIN DEFECTS 
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Also the isolation of a mutant protein may be complicated by 
its abnormal kinetics and even worse, there might be no 
protein present at all. 
During the last few years the use of recombinant DNA 
technology has largely overcome the problems mentioned 
above. Thus far, the eDNA's coding for some 15 lysosomal 
enzymes, have been cloned. For a number of them the complete 
sequence of the normal gene has been reported and in a few 
cases the exact nature of the mutations different clinical 
variant.s has been elucidated (Myerowitz and Hogikyan, 1986; 
Tsuji et al., 1987; Kalata, 1987). In view of the rapid 
progress in this area of research, no doubt many different 
mutations involved in the 32 lysosomal storage diseases 
presently known, will be mapped within the next decade. 
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Chapter II 
THEORETICAL BACKGROUND OF THE EXPERIMENTAL WORK 
The experimental work presented in this thesis deals 
with the genetic and molecular basis of lysosomal B-
galactosidase deficiencies in man. The first section (II.1) 
deals with the characteristics of lysosomal B-
galactosidase and the second (II.2) with its major natural 
substrates, GM1-ganglioside and keratan sulfate, and the 
activator proteins. A single lysosomal B-galactosidase 
deficiency is the cause of the lysosomal storage diseases 
GM1 -gangliosidosis and Morquio B syndrome. The clinical 
pathological and biochemical features of the different 
variants of these diseases are summarized in section II.3. 
A B-galactosidase deficiency in man also occurs as part 
of a multiple lysosomal enzyme deficiency. In patients with 
galactosialidosis there is a coexistent deficiency of lysoso-
mal neuraminidase and lysosomal B-galactosidase, while in 
mucolipidosis II ("I-cell" disease) many lysosomal (enzyme) 
proteins, including B-galactosidase, are deficient due to a 
defective Man 6-P recognition marker (see Chapter I). The 
major features of these two diseases are summarized in 
section II.4. Finally, some aspects of therapy of lysosomal 
storage diseases and animal models are discussed in section 
II.S. 
II.l. B-GALACTOSIDASE 
a. Acid B-Galactosidase 
Acid B-galactosidase (E.C.3.2.1.23) is a glycoprotein 
which hydrolyses the terminal galactose from the natural 
substrates GM1-ganglioside, asialo-GM1-ganglioside, asialo-
fetuin, keratan sulfate and lactosylceramide (for reviews 
see Roden, 1980; Rittman and O'Brien, 1981; Suzuki and 
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Suzuki, 1983). The enzyme is also able to hydrolyse 
galactose from artificial substrates as p-nitrophenyl-B-D-
galactopyranoside and 4-methylumbelliferyl-B-D-
galactopyranoside (Gatt and Rapport, 1966; Robins et al., 
1968; Ockerman, 1968). Acid £-galactosidase has a pH optimum 
of 4.2, it is heat labile and can be activated with chloride 
ions (Ho and O'Brien, 1971a; for review see O'Brien, 1983). 
The acid £-galactosidase activity has been demonstrated 
in a wide variety of human tissues and body fluids. Initial-
ly it was most extensively studied in human liver (Ho et 
al., 1973; Norden et al., 1974; Suzuki and Suzuki, 1974; 
O'Brien, 1975; Tanaka et al., 1975; Cheetham and Dance, 
1976; Frost et al., 1978; Heyworth et al., 1981; Overdijk et 
al., 1986). Further £-galactosidase has also been studied in 
human brain (Norden and O'Brien, 1973; Lisman and 
Hooghwinkel, 1974; Bruns and Hultberg, 1975; Tanaka and 
Suzuki, 1976, 1977), in cultured human skin fibroblasts 
(Pinsky et al., 1974; Galjaard et al., 1975; Hoeksema et 
al., 1979; Van Diggelen et al., 1981, 1982; d'Azzo et al., 
1982; Hoogeveen et al., 1983, 1984, 1986), in placenta (Lo 
et al., 1979), in kidney and urine (Dance et al., 1969; 
Kress and Miller, 1978), in small intestine (Gray and 
Santiago, 1969; Asp, 1971) and in human leucocytes (Singer 
and Schafer, 1970; Kolodny and Mumford, 1976). 
In addition, £-galactosidase has been purified from 
other species such as calf, chicken, ox, pig, cat, dog, 
mouse, rabbit and monkey. The existence of multiple forms of 
£-galactosidase has been reported by many workers. These 
forms can be separated on the 
electrophoretic mobility and 
basis of their different 
molecular weight (Ho et 
al., 1973; Norden and 0' Brien, 1973) . The separation and 
purification studies of £-galactosidase demonstrated the 
existence of a monomeric, a dimeric and a multimeric form 
(Norden et al., 1974; Tomino and Meisler, 1975; Frost et 
al., 1978; Tanaka and Suzuki, 1976; Hoeksema et al., 1979; 
Yamamoto et al., 1982, Yamamoto and Nishimura, 1980, 1986; 
Rodrigues Berrocal et al., 1983). The molecular mass found 
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for the different B-galactosidase forms in the liver was 
65,000, 150,000 and 700,000 Da. (Norden and O'Brien, 1973; 
Cheetham and Dance, 1976; Frost et al., 1978). Because of 
their immunological relationship it was suggested that the 
high molecular weight form is a multimeric aggregate of the 
monomeric low molecular weight form (O'Brien, 1975). It has 
been demonstrated that the aggregation of B-galactosidase is 
enhanced by the presence of its substrate (Taguchi et al., 
1981), and by enzyme concentration (Cheetham and Dance, 
1976; Verheijen et al., 1982). 
In addition to the 65,000, 150,000 and 700,000 Da. 
molecular weight forms, several authors reported the presen-
ce of some low molecular weight proteins of 30,000 and 
20,000 Da. in human liver (Frost et al., 1978), human 
placenta (La et al., 1979), feline liver (Holmes and 
O'Brien, 1979), and porcine spleen (Yamamoto et al., 1982; 
Yamamoto and Nishimura, 1986), the significance of which was 
unclear. 
The first amino acid analysis for B-galactosidase was 
made by Frost et al. (1978), who isolated the dimeric form 
of B-galactosidase from human liver. They found a high 
content of neutral and acid amino acids and a low content of 
the basic and sulfur containing amino acids. Overdijk et 
al., (1986) found that the carbohydrate content of the 
enzyme from human liver was about 9% by weight and they 
reported B-galactosidase as the first soluble lysosomal 
hydrolase with a high content of N-acetyllactosamine-type 
(complex type) of carbohydrate (60%). The rest is of the 
oligomannoside type. An average of three carbohydrate chains 
per B-galactosidase molecule was calculated. Other human 
lysosomal enzymes tested have almost exclusively oligo-
mannoside-type side chains, such as B-glucuronidase from 
spleen (Natowicz et al., 1982; Howard et al., 1982), and 
glucosidase from placenta (Mutsaers et al., 1987). The 
membrane-bound proteins which are independent of the mannose 
6-phosphate receptor for their transport to the lysosome, 
also contain N-acetyllactosamine type carbohydrate chains 
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like B-galactosidase. An example is the 80% content of N-
acetyllactosamine type carbohydrate on the membrane bound 
lysosomal enzyme B-glucocerebrosidase (Takasaki et al., 
1984). These data are in agreement with the results of 
immunoelectron microscopic studies on B-glucocerebrosidase 
which suggest that the membrane association of this enzyme 
carries it to the lysosome independent of the mannose 6-
phosphate recognition system (Van Dongen et al., 1985). 
The structural gene coding for B-galactosidase was 
initially assigned to chromosome 22 (De Wit et al. 1977), 
but subsequently Bruns et al. (1978) and Shows et al. (1978) 
reported that the B-galactosidase locus is on chromosome 3. 
Later, De Wit et al. (1979) demonstrated that two structural 
gene loci on chromosome 3 and 22 were required for the full 
expression of B-galactosidase activity. More recently Sips 
et al. (1985), using monoclonal antibodies, confirmed the 
localization of the B-galactosidase structural gene on 
chromosome 3, while a gene on chromosome 22 coded for a 32 
kDa protein, necessary for the aggregation of B-galactosi-
dase molecules in the lysosome (Hoogeveen et al., 1983} (see 
also Chapter III). 
b. Galactosylcerebrosidase 
Another acid B-galactosidase is the enzyme which is 
deficient in Krabbe's disease (Suzuki and Suzuki, 1970; 
Tanaka and Suzuki, 1977; for review see Suzuki and Suzuki, 
1983) . This enzyme catalyzes the hydrolysis of B-linked 
galactose from galactosylcerebroside (Suzuki and Suzuki, 
1971} and does not hydrolyse GM1-ganglioside. Therefore it 
is called galactosylcerebroside-B-galactosidase or galacto-
sylcerebrosidase (EC 3.2.1.46). 
Antibodies raised against acid B-galactosidase do not 
cross-react with galactosylcerebrosidase (Norden et al., 
1974}, which apparently is a different protein. 
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c. Neutral B-Galactosidase 
Neutral B-galactosidase has a molecular mass of 45,000-
57,000 Da. and a pH optimum of 5.6-6.0. Neutral B-galactosi-
dase cleaves aryl-B-D-galactoside and aryl-B-D-glucoside lin-
kages and is inhibited by chloride ions (Ho and O'Brien, 
1971a). Studies in pig (Abrahams and Robinson, 1969), in man 
(Meisler, 1975; Chester et al., 1976) and in rabbit (Van 
zutphen et al., 1983), strongly suggest that the neutral B-D-
galactosidase and the neu~ral B-D-glucosidase are identical 
enzymes. To study the physiological role of neutral B-
galactosidase, the rabbit strain Y-IjJ which has a deficien-
cy for this enzyme, may serve as an interesting animal model 
(Van zutphen, 1983). 
Ho et al. (1973) demonstrated that the neutral B-
galactosidase does not cleave galactose from GM1-ganglio-
side. Antisera raised against acid B-galactosidase do not 
cross-react with neutral B-galactosidase (Norden et al. 
197 4) . These data indicate that the acid and neutral B-
galactosidase are genetically independent. 
II.2. NATURAL SUBSTRATES FOR B-GALACTOSIDASE AND ACTIVATOR 
PROTEINS 
a. Gangliosides 
Glycosphingolipids are complex derivatives of ceramide 
which contain one or more saccharide units on the primary 
alcohol group of the sphingosine. The oligosaccharide moiety 
may be a branched chain. It is usually composed of galac-
tose, fucose, glucose, N-acetylglucosamine and N-acetylga-
lactosamine. When the lipid contains a sialic acid residue, 
the lipid is called ganglioside (sialoglycosphingolipid). 
Gangliosides were first detected by Landsteiner and 
Levene (1925) in kidney and later by Walz (1927) in spleen 
and brain. They were rediscovered by Klenk ( 19 3 5) and 
isolated by Blix (1938) and Klenk (1942) from brain. Klenk 
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found the lipid mainly in the "ganglienzellen" (neuronal 
perikaryon cells) and named it ganglioside. In 1956 
Svennerholm postulated that gangliosides are heterogeneous 
in their carbohydrate composition. The gangliosides have a 
common basic structure of galactose - N-acetylgalactosamine -
galactose - glucose - N-acylsphingosine and may contain one, 
two or three sialic acid residues. The n0menclature still 
used today was based on these features (Svennerholm, 1962, 
1963). In 1963 Kuhn and Wiegandt analized the structure of 
the four major brain gangliosides. 
The ganglioside biosynthetic pathway is a stepwise pro-
cess in which monosaccharide units are added to the glycoli-
pid. The major monosialoganglioside in brain is GM1-ganglio-
side (GM1 ). For the biosynthesis of GMl five sugars are 
added to ceramide in a strict sequence by five different 
glycosyltransferases (Roseman, 1970). Gangliosides are 
especially abundant in nerve-ending membranes of the brain, 
however they are also found in extraneuronal tissues and 
cells such as spleen, liver, kidney, placenta, erythrocytes 
and also in serum. They are the characteristic lipid 
components of some neuronal membranes of the central nervous 
system, and are probably involved in the transmission of 
impulses along the neurons. 
Gangliosides are mainly present at the outer surface of 
the plasma membrane, where the hydrophobic tails of the 
lipid molecules interact with the hydrophobic regions of the 
membrane. The oligosaccharide chain is exposed to the 
external environment of the cell. In the normal plasma mem-
brane the lipid bilayer constitutes about 50% of the total 
mass since the proteins are much bigger than the lipids. 
Approximately one protein molecule is present for every 50 
lipid molecules. Although the basic structure of the biologi-
cal membrane is determined by the lipid bilayer, its speci-
fic functions are carried out mainly by the membrane 
proteins. Despite the knowledge of the structure, physical 
properties and localization of gangliosides, there are 
relatively few indications what their function might be. It 
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has been proposed that the variation in carbohydrate 
composition, exposed to the external environment make them 
ideal candidates to function as receptor molecules on the 
cell surface. For example, GM1-ganglioside acts as a cell 
surface receptor for cholera toxin (Holmgren et al., 1973). 
However the binding of toxins cannot be the "normal" 
function of gangliosides. But it gives an indication that 
the possible function for the gangliosides is, to serve as 
receptors for normal signalling between cells. 
They play a role in dynamic cellular processes such as 
the regulation of growth and proliferation (for reviews see 
Hakomori, 1981; Ledeen, 1983). Although the mechanism under-
lying these effects are unknown, several lines of evidence 
have emerged suggesting that gangliosides could mediate 
these processes by modulating protein kinase activities 
(Bremer et al., 1986; Kim et al., 1986; Kreutter et al., 
1987). Recently it has been proposed that the inhibition of 
protein kinase c by sphingolipids might cause the severe 
neuronal degeneration and loss of cells from the cerebral 
and cerebellar cortex and the demyelination which has been 
observed in patients with sphingolipidosis and which could 
not be explained by lysosphingolipid accumulation alone 
(Hannun and Bell, 1987). 
Gangliosides are catabolized by the stepwise removal 
of sugar molecules by hydrolases at the nonreducing end of 
the oligosaccharide chain (Ohman et al. 1970; Svennerholm, 
1976; Brady, 1978). If one of the hydrolases is deficient, 
further breakdown is blocked, even though the remaining 
hydro lases in the pathway are present (see fig. 2) . The 
amount and nature of lipid accumulation in the various 
organs will mainly depend on the normal distribution of the 
different sphingolipids and their rate of synthesis. 
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b. Carbohydrates 
Lysosomal B-galactosidase is not only involved in the 
intracellular degradation of gangliosides but also in the 
catabolism of keratan sulfate and galactose containing oligo-
saccharides derived from glycoproteins. As a consequence in 
patients with a B-galactosidase deficiency accumulation of 
gangliosides, keratan sulfate and galactose containig 
oligosaccharides occurs in various organs; the latter two 
compounds are also excreted in excessive amounts in the 
urine (for reviews see Strecker, 1981; Warner and O'Brien, 
1982; McKusick and Neufeld, 1983; O'Brien, 1983). 
Of the glycosaminoglycans keratan sulfate is the only 
galactose containing polymer; D-galactose residues, which 
may be sulfated or unsulfated, alternate with N-
acetylglucosamine residues. 
Two types of keratan sulfate (I and II) have been 
distinguished (Meijer, 1970). Keratan sulfate I is a major 
component of the cornea and in a native state, the corneal 
polysaccharide is part of a proteoglycan that contains no 
other polysaccharide chain (Berman, 1970) . Keratan sulfate I 
is linked to protein via the N-glycosylamine type of linkage 
between N-acetylglucosamine and the amide group of an 
asparagine residue (Baker et al., 1975). 
Keratan sulfate II is mainly found in skeletal tissues. 
It is always associated with chondroitin sulfate as part of 
the same proteoglycan. Keratan sulfate II is linked to 
protein via 0-glycosidic linkages between N-
acetylgalactosamine and the hydroxyl groups of threonine and 
serine residues (Bray et al., 1967). In addition to the 
components of the repeating disaccharide unit, keratan 
sulfate of both types contains additional monosaccharide 
components such as sialic acid, galactosamine, mannose and 
fucose. 
A number of enzymes, including B-galactosidase, is 
involved in the lysosomal catabolism of keratan sulfate and 
a genetic deficiency of each of these enzymes results in 
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intracellular accumulation and increased urinary excretion 
of keratan sulfate (for reviews see Buddecke and Kresse, 
1974; Cantz and Gehler, 1976; Roden, 1980; McKusick and 
Neufeld, 1983). 
A large number of glycoproteins have galactose-contai-
ning oligosaccharide side chains (Strecker and Montreuil, 
1979). In the case of a .B-galactosidase deficiency the 
catabolism of these glycoproteins will be impaired, but 
through the action of an endo-.B-N-acetylglucosaminidase the 
oligosaccharide chains are cleaved from the peptide moie-
ties. Depending on the nature of the other (terminal) 
sugars, sialic acid or fucose residues will be cleaved from 
the oligosaccharide chains but further degradation will be 
blocked. In patients with a .B-galactosidase deficiency a 
large variety of galactose-containing oligosaccharides have 
been identified in liver and urine (Wolfe et al., 1974; 
Strecker and Montreuil, 1979; Ohkuma et al., 1981; Yamashita 
et al., 1981) (for review see Strecker, 1981). 
c. Activator Proteins 
Some water soluble hydrolases require non-enzymic, low 
molecular mass proteins called activator proteins, for the 
degradation of sphingolipids in the lysosome. Activator 
proteins bind to lipids to form water soluble lipid-protein 
complexes. They act as a kind of specific physiological 
detergent which facilitates the interaction between a water 
soluble hydrolase and its glycolipid substrate (for reviews 
see Sandhoff, 1984; Li and Li, 1984). 
In 1964 Mehl and Jatzkewitz fractionated a partially 
purified arylsulfatase A preparation from porcine liver by 
carrier-free electrophoresis. The enzyme obtained, appeared 
to have lost the ability to degrade sulfatides in the absen-
ce of detergents. The enzyme activity could, however, be 
restored by addition of another enzymically inactive frac-
tion which was later shown to be the first activator protein 
detected. This activator protein was subsequently found in 
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normal human tissue (Mehl and Jatzkewitz, 1968). The cere-
broside sulfatase activator was purified and turned out to 
be a water-soluble glycoprotein with an apparent molecular 
weight of 21,500 (Jatzkewitz and Stinshoff, 1973). Stevens 
et al. (1981) reported two siblings of consanguineous 
parents with clinical features of juvenile metachromatic 
leucodystrophy who had, however, relatively high residual 
activities of arylsulfatase A in their fibroblasts. Addition 
of the sulfatide activator to the culture medium led to a 
normalization of the arylsulfatase A activity in the 
patient's cells. 
Li and Li (1976) purified an activator protein which 
accelerates the degradation of GM1-ganglioside (see also 
Wenger and Inui, 1984). Gartner et al. (1983) identified an 
activator protein specifically enhancing the hydrolysis of 
globotriaosylceramide by a-galactosidase. 
By using immunological methods and skin fibroblasts 
from the patients reported by Stevens et al. ( 1981) the 
identity of the three activator proteins mentioned above was 
demonstrated (Inui et al., 1983; Li et al., 1985). Paschke 
and Kresse (1982) found an increase of B-galactosidase acti-
vity after addition of GM1-ganglioside activator to fibro-
blasts from Morquio B patients. 
At present two other independent activators are known. 
One is unique in enhancing the hydrolyses of GM2-ganglioside 
by B-hexosaminidase A and has an apparent molecular weight 
of 22, 000 in kidney (Conzelmann and Sandhoff, 1979) and 
23,500 Da. in liver (Li et al., 1981). Several patients with 
a genetic deficiency of this GM 2-ganglioside activator 
protein have been described (for review see Sandhoff, 1984; 
Conzelmann and Sandhoff, 1987). The second is an activator 
protein which enhances the hydrolysis of glucosylceramide by 
glucocerebrosidase (Ho and O'Brien, 1971b; Vaccaro et al., 
1985) of galactosylceramide by B-galactocerebrosidase 
(Wenger et al., 1982) and of sphingomyelin by sphingomye-
linase (Christomanou et al., 1986). 
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II.3. SINGLE HUMAN B-GALACTOSIDASE DEFICIENCIES 
a. ~1-Gangliosidosis 
Jatzkewitz and Sandhoff (1963) demonstrated the presen-
ce of an excessive amount of ganglioside in the brain of a 
patient with infantile amaurotic idiocy. They defined this 
ganglioside storage disorder as different from Tay-Sachs 
disease (GM2-gangliosidosis). Landing et al. (1964) reported 
on eight patients with a lysosomal storage disease, which 
they called "familial neurovisceral lipidosis". They pointed 
out that patients described previously by various authors 
(Craig et al., 1959; Norman et al., 1959; Landing and 
Rubinstein, 1962) appeared to be examples of the same 
disease which they recognized as a specific clinical entity. 
Subsequently, other patients were identified (Gonatas and 
Gonatas, 1965; O'Brien et al. 1965) and on the basis of 
increased amounts of GM1-ganglioside in liver and spleen the 
disease was called "generalized gangliosidosis" (O'Brien et 
al., 1965). It was also postulated that the storage of GM1-
ganglioside is caused by a defect in the enzyme system 
involved in the degradation of these gangliosides. 
A low B-galactosidase activity was reported in patients 
with a GM1-ganglioside storage disease (Sacrez et al., 1967; 
Seringe et al., 1968; Dacremont and Kint, 1968). In the same 
year, 1968, Okada and O'Brien suggested that the B-galactosi-
dase deficiency is the responsible enzyme defect in this 
autosomal recessive disease. The enzyme activity can be 
assayed with its natural substrate, GM1-ganglioside, or with 
artificial substrates such as p-nitrophenyl-B-D-galactopyra-
noside and 4-methylumbelliferyl-B-D-galactopyranoside. 
Suzuki ( 1968) proposed the present nomenclature of GM1 -
gangliosidosis because GM1-ganglioside is the main storage 
product. During the last two decades different clinical 
forms of GM1-gangliosidosis have been reported (for reviews 
see Galjaard and Reuser, 1977; Rittman and O'Brien, 1981; 
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O'Brien, 1983). 
A profound deficiency of B-galactosidase activity has 
been demonstrated in a variety of tissues from patients with 
the infantile or the juvenile form of GM1-gangliosidosis. 
Both with the natural substrates GM1-ganglioside and its 
asialo derivative and with artificial substrate a decreased 
activity varying from less than 1% to 5% of control values 
is found in liver, brain and spleen (Norden and O'Brien, 
1974; O'Brien 1983), whereas the activity is hardly detecta-
ble in leucocytes and skin fibroblasts (Galjaard and Reuser, 
1977). 
In the adult form of GM1-gangliosidosis the residual 
activity of B-galactosidase is of the order of 10-15% of 
control values. 
The infantile form 
Patients with the infantile form of GM1-gangliosidosis 
show psychomotor retardation from birth on. Physical exami-
nation reveals gargoyle facial features, hepatosplenomegaly 
and skeletal deformities. The mental and motor development 
detoriate rapidly and ultimately the child has hardly any 
contact with the environment. If the patient survives the 
first year of life, the clinical course is that of 
decerebrate rigidity with blindness, deafness, spastic 
quadriplegia and unresponsiveness. Recurrent respiratory 
infections are usually responsible for an early death before 
the age of two years (Derry et al., 1968; van Hoof et al., 
1973; Galjaard, 1980; O'Brien, 1983). 
A 2-10 fold increase of GM1-ganglioside has been demon-
strated in the gray matter of brain (Gonatas and Gonatas, 
1965; Suzuki et al., 1971; Berra et al., 1974). In addition 
an accumulation of the asialoderivative also occurs (Suzuki 
et al., 1969). The abnormalities of the visceral organs seem 
to be caused mainly by the accumulation of certain glycosa-
minoglycans (keratan sulfate) and glycopeptides (Suzuki et 
al., 1969; Callahan and Wolfe, 1970). 
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The pathological changes in the infantile form include 
neuronal lipidosis, visceral histiocytosis and cytoplasmic 
ballooning of the renal glomerular epithelial cells. Neurons 
contain numerous cytoplasmic membraneous bodies. 
histiocytes are found in bone marrow, liver, spleen, 
nodes and most visceral organs. 
Foamy 
lymph 
Two patients have been reported with an atypical form 
of infantile GM1-gangliosidosis (Kohlschutter et al., 1982; 
Charrow and Hvizd, 1986). Impaired catabolism was 
demonstrated by ganglioside loading of cultured skin 
fibroblasts and a B-galactosidase activity of less than 1% 
of control values was found. Intermediate levels between 
controls and patient were found in leucocytes from both 
parents. The prominent feature is cardiac involvement 
suggestive for endocardial fibroelastosis but, with the 
recognition of developmental delay and skeletal myopathy 
glycogenesis type II (Pompe disease) was considered more 
likely. These atypical patients do not show seizures, coarse 
facies, macroglossia, and dysostosis multiplex. They died 
within the first year of life. Further genetic and molecular 
studies are needed for a correct classification of these 
atypical variants. 
The juvenile form 
In patients with the juvenile form of 
gangliosidosis the onset of clinical features usually starts 
at 1 or 2 years of age and the course of the disease is 
milder than in the infantile form. Mental and motor 
development is often normal during the first year. 
Subsequently psychomotor deterioration becomes apparent but 
hepatosplenomegaly and skeletal deformities are absent, at 
least initially. The progression of cerebral degeneration is 
slower than in patients with the infantile form. There is 
quite some variation among the different patients described 
(Derry et al., 1968; Hoeft et al., 1970; O'Brien et al., 
1971; Gilbert et al., 1975; for review see O'Brien, 1983). 
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Skeletal abnormalities of a mild nature may occur and 
radiological changes can be of diagnostic value. Often 
neurological abnormalities become apparent such as locomotor 
ataxia, seizures, loss of coordination and speech, muscular 
weakness, and progressive spasticity of upper and lower 
extremities. Recurrent bronchopneumonia usually leads to the 
patient's death; the life span varies from 3 to 10 years 
(O'Brien, 1983). 
In the juvenile form, neuronal lipidosis is found, but 
it is less prominent than in the infantile form. Visceral 
histiocytosis is usually present but not as abundant as in 
the infantile form. Renal glomerular cytoplasmic ballooning 
is similar to that in the infantile form. The accumulation 
of GM1-ganglioside in the brain of several patients with the 
juvenile form was similar to that in the infantile form, but 
no storage was found in visceral organs. In the latter, 
accumulation of keratan sulfate has been reported (Suzuki et 
al., 1971; Wolfe et al., 1970; Mamelle et al., 1975). 
The adult form 
In the adult form of GM1 -gangliosidosis clinical 
features usually start at age 3 to 10 years, but several 
patients have been diagnosed at a much later age. Intellec-
tual impairment has been mild but with time intellectual 
functions are lost. There is progressive dysarthria, gait 
disturbance and extrapyramidal symptoms such as dystonia. 
Radiologic studies reveal mild skeletal abnormalities. 
Progression is slow and patients survive onto late adulthood 
(O'Brien et al., 1976; Suzuki et al., 1977, 1979; Stevenson 
et al., 1978; Wenger et al., 1980, Goldman et al., 1981; 
Otha et al., 1985; Mutoh et al., 1986). A clear distinction 
between the juvenile and adult forms may be difficult. Also, 
biochemical and clinical studies have demonstrated that a 
number of patients originally described as adult GM1-gan-
gliosidosis, in fact are patients with galactosialidosis 
due to a combined deficiency of B-galactosidase and neurami-
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nidase (Suzuki et al., 1979; Wenger et al., 1980; Koster et 
al. 1976). 
b. Morquio B syndrome (Mucopolysaccharidosis type IVB) 
One of the mucopolysaccharidoses (MPS) i.e. type IV 
(Morquio disease) is caused by a deficiency of N-acetylga-
lactosamine 6-sulfate sulfatase (Matalon et al., 1974; Singh 
et al., 1976). Clinical variants were found with mild dysos-
tosis multiplex, corneal clouding, short stature, keratan-
sulfaturia but no detectable central nervous system abnorma-
lities (O'Brien et al., 1976; Arbisser et al., 1977). In 
these variants a markedly reduced activity of B-galactosi-
dase was found while the N-acetylgalactosamine 6-sulfate 
sulfatase was normal. This mild form was called Morquio B 
syndrome (MPS IVB) (Groebe et al., 1980; Troj ac et al., 
1980; Van Gemund et al., 1983). The residual B-galactosidase 
activity (5-10% of controls) exhibits normal thermal 
stability and has a normal pH optimum. However, the Km for p-
nitrophenyl S-O-galactoside is 5 times higher than normal. 
The idea that the B-galactosidase deficiency is the primary 
defect in Morquio B syndrome was further supported by the 
intermediate enzyme levels found in leucocytes and fibro-
blasts from the parents (Groebe et al., 1980). Morquio B 
syndrome is thus a separate genetic and biochemical entity 
from the mucopolysaccharidosis IV A (Morquio A syndrome). 
Paschke and Kresse (1982) as well as Van der Horst et 
al. (1983) found no detectable affinity of the mutant B-
galactosidase in Morquio B towards keratan sulfate and oli-
gosaccharides isolated from the patient's urine. This 
explains the mucopolysaccharidosis-like phenotype of Morquio 
B patients. However, a very high residual activity of the 
mutant enzyme was found when GM1-ganglioside was used as a 
substrate (Paschke and Kresse, 1982). This might explain the 
absence of neurological abnormalities. After hybridization 
of Morquio B and GM1-gangliosidosis fibroblasts no restora-
tion of B-galactosidase activity was observed which in 
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combination with other results indicates that these two 
syndromes are caused by allelic mutations in the gene coding 
forB-galactosidase (Vander Horst et al., 1983). 
II.4. MULTIPLE LYSOSOMAL ENZYME DEFICIENCIES 
a. Galactosialidosis 
Several patients with clinical features somewhat diffe-
rent from those in the "classical" forms of GM1_gangliosido-
sis were designated as atypical variants of this disease 
(Pinsky et al, 1974; Wenger et al., 1974; Loonen et al., 
1974; Yamamoto et al., 1974; Andria et al., 1978). Comple-
mentation studies revealed that the mutation involved in the 
patients described by Pinsky et al., (1974) and Loonen et 
al., (1974) had to be localized in a gene different from 
that involved in the infantile and juvenile forms of GM1-
gangliosidosis (Galjaard et al., 1975). Later, similar 
somatic cell hybridization studies revealed that the 
patients described by Wenger et al., (1974), Suzuki et al., 
(1977); Andria et al., (1978) also belonged to the same 
complementation group (Reuser et al., 1979; Suzuki et al., 
1979; Wenger et al., 1980). These atypical variants of GM1-
gangliosidosis seem to be caused by allelic mutations in a 
gene different from the one coding for B-galactosidase. 
The explanation was provided by Wenger et al., (1978) 
who found a coexistent B-galactosidase and neuraminidase 
deficiency in one of their atypical variants. Later on such 
a combined lysosomal enzyme deficiency was found in all 
patients belonging to the complementation group mentioned 
above (Miyatake et al 1979; Kleijer et al., 1979; Hoogeveen 
et al., 1980, for reviews see Wenger et al., 1980; Galjaard 
et al., 1984). 
The syndrome associated with a combined B-galactosidase 
and neuraminidase has been designated as galactosialidosis 
by Andria et al. (1981). These authors also summarized 
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clinical heterogeneity among patients with this syndrome 
(see also Galjaard et al. 1986). 
In patients with the most severe and progressive early 
infantile form there is kidney involvement and edema around 
birth, coarse facies, skeletal abnormalities, visceromegaly 
and ocular changes, and death occurs shortly after birth 
(Kleijer et al., 1979; Gravel et al., 1979). 
Patients with the late infantile form show an onset of 
symptoms after 6-12 months of age and the main features are 
skeletal dysplasia, visceromegaly, macular cherry-red spot 
and mild mental retardation (Pinsky et al., 1974; Andria et 
al., 1981; Strisciuglio et al., 1984). 
Still other patients have been diagnosed later in 
childhood or at (young) adult age and have gradually progres-
sive skeletal abnormalities, coarse facies, angiokeratoma, 
neurological manifestations including myoclonus, mental 
retardation and loss of vision, corneal clouding and macular 
cherry-red spot (Loonen et al., 1974, 1984; Wenger et al., 
1974; Suzuki et al., 1983, 1984). The patients mentioned in 
the last group are mainly of Japanese origin; some of them 
live up to 40-60 years of age. 
All the patients with galactosialidosis have 10-15% 
residual activity of B-galactosidase, while the neuramini-
dase activity varies from 0-5% (Hoogeveen et al., 1980; 
Suzuki et al., 1984; Palmeri et al., 1986). 
The primary defect in galactosialidosis is the 
deficiency of a 32 kDa glycoprotein (D'Azzo et al., 1982) 
which is needed for the aggregation of B-galactosidase mono-
mers (Hoogeveen et al., 1983) and which is most probably an 
essential subunit of lysosomal neuraminidase (Verheijen et 
al., 1985, 1987). Part of the clinical heterogeneity in 
galactosialidosis has been explained by differences in the 
molecular processing of the 32 kD "protective protein" 
(Palmeri et al., 1986). 
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b. Mucolipidosis II ("I-cell" disease) 
Mucolipidosis II is a disorder of childhood with an 
autosomal recessive mode of inheritance. It is apparent from 
birth, slowly progressive and usually has a fatal outcome in 
three to four years. Some patients succumb within the first 
year of life others reach the age of twelve years. The first 
patients were described by DeMars and Leroy (1967) who also 
designated this syndrome as "I-cell" disease because of the 
peculiar inclusions of cultured fibroblasts (see also Leroy 
et al., 1969). At birth often orthopedic abnormalities can 
be noted and there is generalized hypotonia, severe growth 
failure, coarsening of facial features, progressive psycho-
motor retardation and recurrent respiratory infections. 
Patients usually die because of bronchopneumonia or conges-
tive heart failure (see for reviews Galjaard, 1980; Leroy, 
1981; McKusick and Neufeld, 1983). 
Cultured skin fibroblasts from patients with "I-cell" 
disease show a deficiency of a large number of lysosomal 
enzymes and at the same time the activity of these enzymes 
is markedly eleva ted in the medium above the cul ti va ted 
mutant cells as well as in body fluids from the patients 
(Leroy and Spranger, 1970; Wiesmann et al., 1971). 
Hickman and Neufeld (1972) were first to hypothesize 
that the multiple lysosomal enzyme deficiency was related to 
a defective recognition site common to various hydrolases. 
As mentioned in the previous Chapter most lysosomal enzymes, 
including B-galactosidase, are dependent on the specific 
mannose 6-phosphate (M6P) recognition marker to reach the 
lysosomes (Kaplan et al., 1977; Hickman et al., 1974; Sly 
and Stahl 1978; Natowicz et al., 1979). Evidence of an 
impaired phosphorylation of the lysosomal enzymes in "I-
cell" disease (Bach et al., 1979; Hasilik et al., 1980), led 
to the elucidation of the basic defect, a deficiency of N-
acetylglucosamine-1-phosphotransferase (Hasilik et al., 
1981; Reitman et al., 1981) (see Chapter I.1.). The lack of a 
mannose 6-phosphate marker results in the secretion of 
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precursor forms of those lysosomal enzymes which are depen-
dent on this pathway for their correct subcellular 
compartmentalization. 
In the context of this thesis it is interesting to note 
that in fibroblasts the main pathway of lysosomal enzymes is 
via the M6P receptor. When the lysosomal enzyme activities 
in fibroblasts from patients with "I-cell" disease are com-
pared with the activities measured in some visceral organs, 
higher or normal activities are found in the latter, indi-
cating a M6P independent pathway. However, in liver, brain 
and spleen the activities of B-galactosidase and neuramini-
dase are reduced, while the catalytic activity of other 
hydrolases are within the normal range. (Leroy et al., 
1972; Wenger et al., 1976; Cantz and Messer, 1979; Pittman 
et al., 1979; Miller et al., 1979; Minami et al.,1979; Eto 
et al., 1979; Pallman et al., 1980). 
II.5. THERAPY AND ANIMAL MODELS 
The demonstration that lysosomal storage diseases are 
due to inherited lysosomal enzyme deficiencies have 
initiated studies on the correction of these diseases by 
enzyme replacement therapy. Fratantoni et al. (1968) demon-
strated mutual correction of intracellular mucopolysaccha-
ride accumulation when fibroblasts from patients with 
Hurler's (mucopolysaccharidosis I) and Hunter's syndrome 
(MPS II) were cultivated together. This correction was due 
to secretion and uptake of the respective normal enzymes 
involved in mucopolysaccharide degradation. Since then 
several other in vitro studies have shown that exogenous 
lysosomal enzymes can be taken up by (mutant) fibroblasts 
(for reviews see Tager et al. 1980; in: Barranger and Brady 
(eds), 1984). It has become clear that in various cell types 
ingested lysosomal enzymes are able to reach the subcellular 
compartments where in mutant cells storage material has 
accumulated (Vander Ploeg et al., 1987). 
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Parallel to these model studies on cultured cells, nume-
rous attempts have been made by clinicians to improve the 
condition of patients with a genetic metabolic disease by 
enzyme replacement therapy (for reviews see in: Barranger 
and Brady, 1984; Krivit and Paul (eds), 1986). The first 
effort was the intramuscular administration of fungal a-
glucosidase to a patient with glycogenesis II {Baudhuin et 
al., 1964). Since then various other attempts have been made 
either by injection of purified enzyme, or by transplanta-
tion of organs (kidney, liver) or cells (fibroblasts, amnio-
tic fluid cells, bone marrow). 
In case of enzyme injection a constant finding is, that 
the enzyme is rapidly cleared from the circulation. To over-
come this problem efforts have been made to stabilize the 
enzyme by coupling to polyvinylpyrrolidone {Specht et al., 
1979), albumin (Poznansky and Bhardwaj, 1980) or polye-
thylene glycol (Herschfield et al., 1987). In some instan-
ces as in Gaucher's disease there is no such problem since 
the storage of glucocerebrosides also occurs in the Kupffer 
cells (Brady et al., 1974). 
Another possible problem in enzyme replacement is the 
formation of antibodies against the injected foreign enzyme 
in patients where a mutation interferes with the production 
of the enzyme. In a patient with Gaucher's disease where 
cross reactive material against (mutant) glucocerebrosidase 
was present, injection of normal enzyme did not lead to any 
immunological complication (Britton et al., 1978). 
In all instances where a genetic enzyme deficiency 
results in brain damage by intracellular accumulation of non 
degraded products, passage through the blood-brain barrier 
is a major complication in enzyme replacement therapy both 
by injection of purified enzyme and by transplantation. The 
vast majority of lysosomal storage diseases is associated 
with cerebral damage and the prospects of satisfactory 
results of therapy either by enzyme administration or bone 
marrow transplantation or gene correction may not be effec-
tive. 
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Yet, in some patients with Fabry disease kidney trans-
plantation has provided relief from uremia but apart from a 
functional replacement of a damaged organ the transplanta-
tion does not act as a source of sufficient amounts of 
normal enzyme to be distributed all over the body (Van den 
Bergh et al., 1976). The same applies to liver transplanta-
tion in some patients with Gaucher disease (Brady, 1984). 
Trials with fibroblast or amniotic fluid cell transplanta-
tion on patients with muc.opolysaccharidoses, B-galactosidase 
deficiency in Morquio B disease and "I-cell" disease have 
been unsuccessful, probably for the same reason of inade-
quate production, secretion and uptake by all mutant cells 
in need of normal enzyme (Gibbs et al., 1980, 1983; Tylki-
Szymanska et al., 1985). 
During the last 5 years treatment of lysosomal storage 
diseases by bone marrow transplantation has gained an increa-
sing interest. In some cases this approach has led to 
improvement of the clinical condition of the patient and to 
a normalization of certain biochemical parameters. Studies 
by Ginns et al. ( 1984a) and Svennerholm et al., ( 1984) 
showed that certain pathologic manifestations in patients 
with the type 3 or Norrbottnian form of disease such as 
elevated plasma glucocerebroside and the number of Gaucher 
cells in the bone marrow are reduced after marrow transplan-
tation. Svennerholm (1984) recommends splenectomy prior to 
bone marrow transplantation in order to avoid severe throm-
bocytopenia and to avoid delay in the degradation of gluco-
sylceramide from vital organs such as brain, lungs and liver 
by the large deposite in Gaucher cells accumulated in the 
spleen (see also Hobbs et al., 1987). It is thought that 
after bone marrow transplantation just a few stem cells gain 
access to the nervous system, therefore one would not expect 
improvement of the neurological manifestations or mental 
deterioriation, if present. This is confirmed by the results 
of somewhat larger series of bone marrow transplantations in 
patients with different types of mucopolysaccharidoses, 
metachromatic leucodystrophy, the neuropathic forms of 
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Gaucher disease, ~1- and ~2-gangliosidosis and some other 
lysosomal storage diseases (see in: Barranger and Brady 
(eds), 1984; Hobbs, 1985; in: Krivit and Paul (eds) 1986). A 
serious practical limitation in bone marrow transplantation 
is the high mortality rate, mainly because of the graft 
versus host reaction and the minimal availability of HLA 
matched siblings (Hobbs et al., 1982; Ramsay et al., 1982). 
Finally, in most lysosomal storage disorders the genetic 
enzyme deficiency will exert its effect already during 
intrauterine development; as a consequence newborns may have 
intracellular storage in many cell types including those of 
the central nervous system which forms another complication 
in successful enzyme replacement therapy. 
Animal models with a particular genetic enzyme 
deficiency may be a useful tool in testing the different 
problems involved in therapy before its use on humans. Since 
GM1-gangliosidosis is the main topic of this thesis, data on 
a number of mammalian species other than man with a genetic 
deficiency of B-galactosidase are summarized. 
A B-galactosidase deficiency and neuronal storage of 
GM1-ganglioside is found in Siamese cats (Baker et al., 
1971; Baker and Lindsey, 1974). The clinical features of 
these cats show similarities with the human juvenile variant 
of GM1-gangliosidosis (Handa and Yamakawa, 1971; Holmes and 
O'Brien, 1979). Cells of the mutant animals show cross 
reactivity against B-galactosidase antibodies and the enzyme 
was found to have different electrophoretic properties and 
thermostability compared with normal enzyme. 
GM1-gangliosidosis was also demonstrated in calves 
(Donnelly et al., 1973; Cheetham and Robinson, 1974) and 
again the features closely resembled those of the human 
juvenile variant with some residual enzyme activity and 
ganglioside storage largely confined to the nervous tissue. 
GM1-gangliosidosis in dogs was first described by Read 
et al., (1976). These authors demonstrated accumulation of 
GM1 -ganglioside in the brain, liver and spleen due to a 
generalized B-galactosidase deficiency. Pedigree analysis 
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indicated an autosomal recessive pattern of inheritance. 
Rittman et al. (1980) purified B-galactosidase from normal 
and affected dog liver and compared the normal and mutant 
enzyme. Immunologically, they found only 1% of the normal 
amount of cross reactive material against B-galactosidase 
antiserum in fibroblasts; the kinetic properties of these 
residual enzyme molecules were normal. 
Thus far, experiments on animal models have not 
provided impressive new knowledge about the possible fate of 
exogenous B-galactosidase in patients with various forms of 
B-galactosidase deficiency. More experimental work is needed 
in this area and another prerequisite for successful enzyme 
or gene replacement therapy is knowledge of the exact 
molecular nature of the disease to be treated. The next 
Chapter deals with experimental work focussed on the eluci-
dation of the genetic and molecular nature of various human 
B-galactosidase deficiencies. 
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Chapter III 
RESULTS AND DISCUSSION OF THE EXPERIMENTAL WORK 
III.1. S-GALACTOSIDASE AND ITS RELATION TO NEURAMINIDASE 
Previous experimental work using somatic cell hybridi-
zation (Galjaard et al., 1975; Reuser et al., 1979) indi-
cated that the GM1-gangliosidoses are based on mutations in 
a gene different from that involved in the combined s-
galactosidase - neuraminidase deficiency in patients with 
galactosialidosis. 
The complementation studies described in Appendix paper 
~ were aimed at the elucidation of the genetic background of 
galactosialidosis and diseases with a single neuraminidase 
deficiency such as both clinical variants of mucolipidosis 
I, (sialidosis) (Cantz et al., 1977; Spranger et al., 1977; 
Durand et al., 1977). Also, cells from a patient with mucoli-
pidosis II ("I-cell" disease) with a multiple lysosomal 
enzyme deficiency including that of neuraminidase (Thomas et 
al., 1976; Strecker et al., 1976) were included in the cell 
hybridization studies. 
Cultured fibroblasts from patients were fused using 
polyethylene glycol yielding 70-90% of multikaryons, the 
majority of which containing the genetic information of both 
parental cell strains. At 4 days after fusion a cell homoge-
nate was prepared and the neuraminidase activity was 
compared with that of both parental cell strains (each fused 
with itself). An additional control was the overall neurami-
nidase activity after 4 days of cocultivation of both paren-
tal enzyme deficient cell strains. The neuraminidase activi-
ty was measured with the fluorogenic substrate 4-methylumbel-
liferyl-a-2 N-acetylneuraminic acid and with N-acetylneura-
minosyl-D-lactose. 
Restoration of neuraminidase activity was observed 
after fusion of both galactosialidosis cell strains with 
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either fibroblasts from patients with "I-cell" disease or 
mucolipidosis I (sialidosis) . No complementation occurred 
after fusion of cells from the late infantile with the adult 
form of galactosialidosis. Neither was complementation found 
after fusion of different clinical variants of mucolipidosis 
I (sialidosis). The main conclusion of this work was that 
the combined B-galactosidasejneuraminidase deficiency was 
based on a mutation in a different gene than the one invol-
ved in mucolipidosis I (sialidosis) and the one in "I-cell" 
disease. The different clinical variants within galactosia-
lidosis and within mucolipidosis I (sialidosis) are probably 
due to allelic mutations. Later, the complementation was 
confirmed for other clinical and biochemical variants of 
galactosialidosis and mucolipidosis I, respectively, using 
natural glycoprotein substrates. (Swallow et al., 1981). 
An interesting observation was made in the controls for-
med by cocultivated cells from galactosialidosis and 
mucolipidosis I (sialidosis). After co-cultivation the 
neuraminidase activity in the cell mixture became higher 
than the average of both parental deficient cell strains. To 
investigate the cause of this partial correction the two 
mutant cell strains were labelled in vivo with fluorescent 
polystyrene beads. After 3 days of cocultivation the two 
cell strains were separated by flow sorting using a FACS II 
cell sorter according to Jongkind et al. (1979). Enzyme 
assays on the isolated cell population showed that the 
increased neuraminidase activity was present in the galacto-
sialidosis cells only. This suggested for the first time 
that the neuraminidase deficiency in galactosialidosis could 
be partly corrected by a factor secreted by other fibro-
blasts including neuraminidase deficient cells. Fibroblasts 
from "I-cell" patients, however, did not accomplish this 
partial correction which suggested that the unknown "correc-
tive factor" was the phosphorylated precursor form of a 
lysosomal glycoprotein. 
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III.2. B-GALACTOSIDASE AND ITS CORRECTIVE FACTOR 
The biochemical studies described in Appendix paper II 
were performed to obtain more information about the correc-
tion of galactosialidosis fibroblasts. First, Concanavalin A 
(Con A) fractions of human placenta and liver were prepared 
and used for correction studies. After addition for 2 days 
to the culture medium above cells from a patient with late 
infantile galactosialidosis, a 5-7 fold increase of neurami-
nidase activity was observed. The same experiment on neura-
minidase deficient cells from mucolipidosis I (sialidosis) 
had no such effect. 
It was demonstrated that NH4Cl treatment of human fibro-
blasts induced the secretion of precursor forms of lysosomal 
glycoproteins into the medium and that such molecules were 
more easily taken up by other cells (Hasilik and Neufeld, 
1980; Gonzalez-Noriega et al., 1980). This effect is due to 
the presence of the mannose 6-phosphate markers on the pre-
cursor forms whereas this marker no longer occurs in mature 
lysosomal glycoproteins as isolated from placenta or liver. 
We therefore treated fibroblasts from controls, GM1-
gangliosidosis and mucolipidosis I (sialidosis) with NH4cl, 
collected the medium after 2-3 days and subsequently 
dialyzed and concentrated the proteins from the medium. 
Aliquots of this concentrate were then added to 
galactosialidosis fibroblasts and after 3-4 days both the 
neuraminidase and B-galactosidase activity were nearly norma-
lized. This remarkable effect was most likely due to the 
efficient uptake of the "corrective factor" because of its 
mannose 6-phosphate marker. When concentrated medium was 
added together with mannose 6-phosphate no correction 
occurred which can be explained by competitive inhibition 
(Hasilik and Neufeld, 1980; Reitman et al., 1981b). Addition 
of concentrated medium to other mutant cells had no effect. 
The conclusion of the experiments described in ~endix 
paper II is that an intracellular glycoprotein must exist 
which is capable of correcting both the B-galactosidase and 
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neuraminidase deficiency in galactosialidosis cells. 
In parallel experiments, van Diggelen et al., 
(1981,1982) measured the turnover time of B-galactosidase in 
fibroblasts from controls and different types of B-galactosi-
dase deficient patients. For these experiments they used a 
suicide substrate, B-D-galactopyranosylmethyl-p-nitrophenyl-
triazene (B-gal-MNT) (Sinnot and Smith, 1976,1978; van 
Diggelen et al., 1980). The turnover time of B-galactosidase 
in normal fibroblasts, and GM1-gangliosidosis cells was 
found to be about 10 days. In galactosialidosis fibroblasts, 
however, it was reduced to less than 1 day. 
When purified bovine testicular B-galactosidase in a 
monomeric form was added to the culture medium above control 
fibroblasts or GM1-gangliosidosis cells the enzyme was inter-
nalized and remained stable for several days. In contrast, 
when the same enzyme preparation was added to galactosialido-
sis cells it was taken up by the cells in a similar way as 
by control cells but once internalized it was degraded 
within several hours. It thus appeared that the reduced 
turnover time of B-galactosidase was due to enhanced 
degradation (Van Diggelen et al., 1982)). 
III.3. B-GALACTOSIDASE AND ITS PROTECTIVE PROTEIN 
The experimental work described in the Appendix papers 
III and IV has led to the elucidation of the molecular 
defect responsible for the combined B-galactosidase and 
neuraminidase deficiency and of the nature and function of 
the "corrective factor". 
First, B-galactosidase was purified from human placenta 
via affinity chromatography (van Diggelen et al., 1981) and 
polyacrylamide gel electrophoresis in the presence of sodium 
dodecyl sulfate (SDS PAGE) was performed. A major band of 64 
kDa molecular mass and a minor band of 32 kDa were visible. 
Similar observations had been made for mouse macrophages by 
Skudlarek and Schwank (1979). Antiserum was raised by injec-
ting the purified sample into a rabbit. 
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Using these antibodies the biosynthesis of 8-galactosi-
dase was studied in normal and galactosialidosis fibroblasts 
(Appendix paper III). The cellular proteins were pulse label-
led by addition of [ 3H]-leucine to the culture medium and 
after a chase period varying from 3 to 20 hours immunopre-
cipitation was performed according to the methods of 
Laemmli, (1970), Bonner and Laskey, (1974) and Hasilik and 
Neufeld (1980a). 
In normal fibroblasts B-galactosidase appeared to be 
synthesized as a 85 kDa precursor which is processed to a 
64 kDa mature form within hours. In galactosialidosis cells 
the 85 kDa precursor is synthesized in normal amounts but a 
66 kDa (intermediate?) form disappears within a 20 hours 
chase period. A remarkable finding was the absence of two 
bands of 32 kDa and 20 kDa molecular mass in the galactosia-
lidosis cells. After NH4cl treatment the medium above con-
trol fibroblasts contained an 88 kDa 8-galactosidase 
precursor and a 54 kDa band which was absent in medium above 
galactosialidosis fibroblasts. These results suggested that 
the 54 kDa intracellular protein could be the precursor of 
the 32 kDa and 20 kDa bands (see also D'Azzo, 1982). 
To study the cause of the enhanced degradation of B-
galactosidase in galactosialidosis the effect of leupeptin, 
a thiol protease inhibitor (Aoyagi and Umizawa, 1975) was 
studied. Addition of leupeptin to the culture medium during 
2-5 days resulted in a 7 fold increase of 8-galactosidase 
activity (i.e. to the low normal range) in galactosialidosis 
fibroblasts. Immunoprecipitation studies after leupeptin 
treatment indicated an increase of both the 85 kDa and the 
66 kDa band. The fact that leupeptin treatment results in an 
increase of the 85 kDa B-galactosidase precursor cannot be 
explained satisfactorily; it may be possible that a normal 
distribution between the 85 kDa, 66 kDa and 64 kDa forms is 
disturbed when the final processing step is not performed as 
seems the case in galactosialidosis. In this context it is 
interesting to note that addition of leupeptin results in a 
marked increase of B-galactosidase activity in 
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galactosialidosis cells which also has normal kinetic 
properties. This implies that a possible 66 kDa intermediate 
form has similar properties as mature 64 kDa B-galactosidase 
(see also Appendix paper VIII) . 
When concentrated "corrective factor" (see Appendix 
paper II) is added to the medium above galactosialidosis 
fibroblasts a complete normalization of the immunoprecipita-
tion pattern for B-galactosidase is observed i.e. the 85 kDa 
precursor is fully processed into the mature 64 kDa enzyme. 
on the basis of the results described so far it was 
hypothesized that the combined B-galactosidase and neurami-
nidase deficiency in galactosialidosis was caused by a gene-
tic defect of a 32 kDa protein with a 54 kDa precursor that 
is identical to the "corrective factor". 
The work reported in Appendix paper IV led to the eluci-
dation of the function of the 32 kDa protein which was named 
"protective protein" since it prevents enhanced degradation 
of the 66 kDa form of B-galactosidase. Previous gel 
filtration experiments on normal and galactosialidosis 
fibroblasts (Hoeksema et al., 1979) had shown the absence of 
multimeric B-galactosidase in the mutant cells whereas this 
is the major component in normal fibroblasts and human liver 
(Norden et al., 1974). 
Sucrose density gradient centrifugation of lysosomal B-
galactosidase in normal and human fibroblasts indicated that 
under the experimental conditions mentioned in Appendix 
paper IV, 85% of the enzyme exists as a high molecular 
weight complex (600-700 kDa) at pH 6.0, whereas at pH 4.0 
all B-galactosidase exists as a high molecular weight 
multimer. In galactosialidosis fibroblasts the 10-15% 
residual B-galactosidase activity is due to the monomeric 
form only. Addition of leupeptin results in an increased 
amount of these monomers. When, however, a concentrate of 
the "corrective factor" is added to galactosialidosis cells 
the multimeric form of B-galactosidase appears. 
Immunoprecipitation studies on pooled fractions after 
sucrose density gradient centrifugation showed that the high 
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molecular weight B-galactosidase aggregate contains proteins 
of 64 kDa, 32 kDa and 20 kDa molecular mass. In addition 
there is an "excess" of free 32 kDa and 20 kDa molecules. 
The relationship between the 54 kDa precursor and the 
32 kDa and 20 kDa bands was further investigated with the 
following experiment. The secretion of 54 kDa molecules by 
[ 3H]leucine labelled normal fibroblasts was induced by NH4Cl 
treatment and the medium was added for 2 days to galactosia-
lidosis fibroblasts which do not contain any radioactive 
labelled molecules. The results described in Appendix paper 
IV showed uptake of labelled 54 kDa precursor and appearance 
of a strong 32 kDa band and a fainter 20 kDa band. This 
experiment proves the earlier suggestion that the 54 kDa 
protein is a precursor of the 32 kDa "protective protein" 
and the 20 kDa protein. Similar molecules have been identi-
fied in human liver (Frost et al., 1978), human placenta (Lo 
et al., 1979), feline liver (Holmes and O'Brien, 1979) and 
porcine spleen (Yamamoto et al., 1982, 1986). In these 
studies no functional significance was attributed to these 
molecules. 
On the basis of the experiments described in Appendix 
papers II, III and IV, we conclude that the 32 kDa protein 
and perhaps the 20 kDa protein are normally required for the 
aggregation of B-galactosidase monomers into a high mole-
cular weight aggregate. In galactosialidosis a genetic 
defect of the 54 kDa precursor of the "protective protein" 
results in an inability of B-galactosidase monomers to 
aggregate and as a consequence they are rapidly degraded by 
lysosomal proteases. 
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III.4. PROCESSING OF B-GALACTOSIDASE IN GM1-GANGLIOSIDOSIS 
AND MOROUIO B SYNDROME 
The experimental work reported in Appendix papers V and 
VI deals with immunoprecipitation studies to elucidate the 
molecular defect(s) in GM1-gangliosidosis and Morquio B syn-
drome (see also Chapter II). 
After in vivo labelling with [ 3H]-leucine, immune-
precipitation studies using anti-B-galactosidase antibodies 
were performed on skin fibroblasts from patients with the 
infantile or adult form of GM1-gangliosidosis, on cells from 
a Morquio B patient and on medium collected 2 days after 
NH 4 Cl stimulation of mutant and normal fibroblasts. The 
results described in Appendix paper V show the presence of 
the 85 kDa precursor form of B-galactosidase in all mutant 
cells tested, which is in agreement with the finding of an 
88 kDa band in the medium after NH4Cl treatment. However, in 
steady state, cells from infantile and adult GM1-gangliosi-
dosis have only 4-12% of the normal radioactivity at the 64 
kDa position. In pulse chase experiments no formation of 
mature B-galactosidase was found despite an apparently nor-
mal synthesis of the precursor form. 
In Morquio B fibroblasts a normal amount of mature 64 
kDa B-galactosidase is present which is in agreement with 
the normal biosynthesis of the enzyme in this mutant 
(Paschke and Kresse, 1982; van der Horst et al., 1983). In 
this syndrome a normal amount of mutant enzyme seems to be 
present and the mutation mainly affects the hydrolysis of 
galactose from keratan sulfate whereas the affinity of the 
mutant enzyme for GM1-ganglioside remains unaffected 
(Paschke and Kresse, 1982; van der Horst et al., 1983; see 
also Appendix paper VIII). 
In all single B-galactosidase deficient cell strains 
tested normal amounts of the 32 kDa protective protein and 
its 54 kDa precursor were present. 
Sucrose density gradient centrifugation studies indi-
cated only a minor amount of B-galactosidase monomer in the 
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infantile form of GM1-gangliosidosis. In the adult form 
about 25% of the residual B-galactosidase activity is in the 
multimeric form and in Morquio B this is about 50% (see also 
Paschke and Kresse, 1982). It should be taken into account 
that the activities of B-galactosidase in all mutants are 
low and hence the catalytic activity of precursor B-galacto-
sidase may disturb a correct interpretation of the relative 
amounts of monomeric and multimeric forrn of B-galactosidase. 
The deficiency of mature B-galactosidase in both GM1-
gangliosidosis variants cannot be explained in the same way 
as in galactosialidosis since the protective protein is 
present. Also addition of leupeptin did not result in an 
increase of B-galactosidase molecules. It was therefore 
hypothesized that the mutant precursor form of B-galactosi-
dase might be degraded at an early stage of processing by 
proteases not sensitive to leupeptin as was reported for 
glycogenesis II variants (Steckel et al., 1982). 
The immunological data presented here seem in contra-
diction with previous studies where the presence of cross 
reactive material was mentioned in different GM1-gangliosi-
dosis variants (Meissler and Ratazzi, 1974; Norden and 
O'Brien, 1975; Ben-Yoseph et al., 1977) and even in mutant 
fibroblasts now known to be derived from galactosialidosis 
patients (O'Brien and Norden, 1977). We can only explain 
these previous observations by cross reactivity with non-S-
galactosidase proteins known to be present in purified 
preparations used for immunization such as the 54 kDa, 32 
kDa and 20 kDa proteins mentioned in paragraph 2. Also, in 
the previous immunotitration studies the results might be 
influenced by different relative amounts of B-galactosidase 
monomers and multimers. 
The use of pulse labelling studies (Appendix paper V) 
left no doubt that in both variants of GM1-gangliosidosis 
only minor amounts of mature B-galactosidase are present 
despite a normal synthesis of precursor form. To investigate 
the molecular background of this phenomenon some early 
processing steps in normal and mutant fibroblasts were 
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studied (Appendix paper VI). 
The first remarkable observation was the presence of 
relatively large amounts of 88 kDa 8-galactosidase precursor 
in medium above GM1-gangliosidosis fibroblasts without NH4Cl 
treatment. The amount of secreted precursor was comparable 
with that in medium above "I-cell" fibroblasts. This pointed 
to the possibility of a defective recognition marker on 8-
galactosidase in GM1-gangliosidosis. Studies with [ 32 P] 
phosphate revealed that the 88 kDa precursor secreted by 
infantile and adult GM1-gangliosidosis fibroblasts is not 
phosphorylated in contrast to that in medium above control 
cells after NH4 Cl treatment. The defective phosphorylation 
does not seem to be due to an altered glycosylation, because 
immunoprecipitation studies after [ 3H] mannose labelling 
gave a similar pattern in normal and GM1-gangliosidosis 
fibroblasts. 
These results may be explained by a defective recogni-
tion marker on the mutant 8-galactosidase for N-acetylgluco-
saminylphosphotransferase. As a consequence there will be no 
binding to the M6P receptors, required for a correct lysoso-
mal compartmentalization (Neufeld et al., 1981; Creek and 
Sly, 1984); instead 8-galactosidase precursor will be 
secreted. The N-acetylglucosaminylphosphotransferase itself 
must be normal because other lysosomal proteins such as the 
54 kDa precursor of the protective protein are normally 
phosphorylated. Impaired phosphorylation has also been 
demonstrated for a-glucosidase in some variants of glycoge-
nesis II (Reuser et al., 1985). 
The hypothesis of a defective M6P recognition marker on 
mutant 8-galactosidase precursor was tested by uptake expe-
riments described in Appendix paper VI. Radiolabelled 
precursor 8-galactosidase secreted by GM1-gangliosidosis 
fibroblasts was concentrated from the medium and added to 
normal fibroblasts. No uptake could be shown in contrast to 
labelled precursor 8-galactosidase secreted by normal fibro-
blasts after NH4Cl stimulation. 
It thus seems that the allelic mutations involved in 
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all forms of GM1-gangliosidosis tested interfere with the 
phosphorylation of precursor B-galactosidase. This phenome-
non might be explained by a change of the tertiary structure 
of the precursor protein resulting in an impaired accessibi-
lity of enzymes involved in the oligosaccharide modifica-
tion. In the case of GM1-gangliosidosis the conformation 
change would affect the proper action of N-acetylglucosami-
nylphosphotransferase (Varki et al., 1981; Lang et al., 
1984, 1985; for review see Kornfeld, 1986). 
Several studies have been performed to determine the 
common recognition marker for N-acetylglucosaminylphospho-
transferase that is unique to lysosomal enzymes. It has been 
proposed that the N-acetylglucosaminylphosphotransferase has 
an active site and a second binding site which is involved 
in the specific recognition of lysosomal enzymes (Varki et 
al., 1981; Lang et al., 1985). Studies on the oligosaccha-
ride units of several lysosomal enzymes have been performed 
(Hasilik et al., 1980; Goldberg and Kornfeld, 1981; Natowicz 
et al., 1982; Takahashi et al., 1983; Nakao et al., 1984; 
Mutsaers et al., 1987). It was demonstrated that phosphory-
lation occurs on high mannose oligosaccharide units typical 
for lysosomal enzymes even when these are slightly altered 
(Gabel and Kornfeld, 1982). Isolated high mannose oligosac-
charide units, however, are poor substrates for phosphoryla-
tion (Waheed et al., 1982; Lang et al., 1984) and the combi-
nation with part of the protein is needed for the binding of 
the phosphotransferas.e. Lang et al., (1984) showed that 
removal of oligosaccharides make lysosomal enzymes potent 
inhibitors of the phosphorylation of other, intact, lysoso-
mal enzymes. Trypsin treatment and heat denaturation of 
lysosomal enzymes strongly reduces the rate of phosphoryla-
tion but does not impair the binding to the phosphotransfe-
rase (Lang et al., 1984). 
For a proper function of the active site and the bin-
ding site of the phosphotransferase both the conformation of 
the protein part as well as the carbohydrate structure are 
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essential. 
45 
As far as B-galactosidase is concerned it is interes-
ting that Overdijk et al. (1986) reported that human liver B-
galactosidase is the only soluble lysosomal enzyme with a 
low content of the high-mannose type of carbohydrate. This 
enzyme therefore has relatively few sites for phosphoryla-
tion and consequently is maybe more sensitive to impairment 
of this process. Detailed studies on the aminoacid sequence 
of normal B-galactosidase and the various mutants are likely 
to provide answers to many of the remaining questions. 
III.5. IN SITU LOCALIZATION OF B-GALACTOSIDASE 
Thus far most studies on 8-galactosidase were based on 
(immuno)biochemical analyses on cell homogenates. The possi-
bility of immunoelectron microscopy on ultrathin frozen 
sections of human cultured fibroblasts using the gold label-
ling technique (Tokuyasu, 1973; Geuze et al., .1981) enabled 
us to follow the intracellular compartmentalization of B-
galactosidase in normal and mutant fibroblasts. The results 
of such studies are reported in Appendix paper VII. 
We have used polyclonal antibodies raised against human 
placental 8-galactosidase, which react with the precursor 
form and the monomeric and multimeric form of mature 8-galac-
tosidase as well as with the protective protein and its 
precursor (D'Azzo et al., 1982). In addition monoclonal anti-
bodies were prepared which reacted only with the precursor 
form and the monomeric mature form of B-galactosidase and 
not with the multimeric form (Sips et al., 1985). 
Immunoelectron microscopic studies with monoclonal antibo-
dies revealed gold labelling of cells in the rough endoplas-
mic reticulum (RER), the cis and trans parts of the Golgi 
apparatus and weak labelling of the plasma membrane. Proba-
bly this labelling represents the 85 kDa precursor form of B-
galactosidase. When polyclonal antibodies were used, the 
same labelling pattern was found, but in addition there was 
a clear labelling of the lysosomes. The latter must repre-
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sent the presence of multimeric aggregates of B-galactosi-
dase molecules. The absence of lysosomal labelling with the 
monoclonal antibody indicates that no or hardly any monome-
ric B-galactosidase is present under in vivo conditions. 
In fibroblasts from patients with GM1-gangliosidosis a 
normal labelling pattern of the RER and Golgi apparatus was 
found. However, no labelling was observed in the lysosomes 
either with monoclonal or with polyclonal antibodies. This 
confirms the immunobiochemical observation of the absence of 
64 kDa mature B-galactosidase in different variants of GM1-
gangliosidosis. The reason why no lysosomal labelling was 
found despite the presence of the 32 kDa protective protein 
might be that essential determinants on the 32 kDa protein 
are lost under conditions appropiate for immunoelectron 
microscopy. 
Immunoelectron microscopy was also performed on fibro-
blasts from patients with galactosialidosis. A similar label-
ling pattern was found as described for GM1-gangliosidosis. 
Addition of leupeptin to galactosialidosis cells resulted in 
a marked increase of gold labelling in the lysosomes, both 
with monoclonal and polyclonal antibodies. This points to an 
increase of the number of monomeric B-galactosidase 
molecules. When a preparation containing the precursor of 
the protective protein was added, increased lysosomal 
labelling occurred only when polyclonal antibodies were 
used. This implies that the restoration of the aggregation 
of B-galactosidase monomers also occurs under in vivo 
conditions. 
III.6. IN VIVO METABOLISM OF GANGLIOSIDES 
The experimental work so far described has led to the 
elucidation of the molecular defects responsible for GM1-
gangliosidosis and galactosialidosis. Our immunoprecipita-
tion studies and immunoelectron microscopic observations 
did, however, not reveal a significant difference between 
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fibroblasts from patients with the infantile and the juve-
nile/adult form of GM1 -gangliosidosis and galactosialidosis 
respectively. The electron microscopical methodology used 
does not enable the detection of less than 10% of normal 
amounts of enzyme molecules and the enzyme activity mea-
surements were based on in vitro assays with artificial 
substrates. 
In order to approach the in vivo situation we have per-
formed loading experiments with a radioactive labelled 
natural substrate for B-galactosidase (Appendix paper VIII) 
GM1 -ganglioside, labelled with [ 3H] in the ceramide portion 
(Schwarzmann, 1978), was kindly prepared for us by Prof. L. 
Svennerholm and Dr. J.E. Mansson (Dept. of Neurochemistry, 
University of Goteborg, St. Jorgen Hospital, Sweden). Pre-
vious experiments had indicated that GM1 -ganglioside added 
to the medium was ingested by cultured cells and after 
uptake its metabolism could be followed by chromatographic 
procedures (Moss et al., 1976; suzuki et al., 1978; Fishman 
et al., 1976,1978, 1983). 
In experiments on normal and mutant fibroblasts 5-7% of 
the total amount of [ 3H] GM1-ganglioside added to the medium. 
was ingested after 16 hours of incubation (Appendix paper 
VIII). After 8-48 hours "chase" it was shown that the inges-
ted GM1 -ganglioside was degraded to GM2 - and GM3 -ganglioside 
and further to smaller metabolites. After 48 hours some of 
the ingested substrate still remained undegraded. In fibro-
blasts from a patient with infantile GM1 -gangliosidosis all 
GM1 -ganglioside remains undegraded and no other products are 
seen after thin-layer chromatography. In cells from an adult 
patient with GM1 -gangliosidosis clearly some of the GM1 -gan-
gliosides are metabolized to GM2 - and GM3 -ganglioside. This 
is likely to be due to the residual 4-12% B-galactosidase 
molecules which have been demonstrated by 
immunoprecipitation studies (see Appendix paper V) and which 
were shown to have normal kinetic properties (for review see 
O'Brien, 1983). 
Since the ingested GM1-gangliosides will be degraded in 
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the lysosomes 4-12% of the (mutant) B-galactosidase mole-
cules must have found their way to the lysosome independent 
of the mannose 6-phosphate receptor (see Appendix paper VI). 
The catalytic activity per molecule seems to be normal. 
In the infantile form of GM1-gangliosidosis also 4-12% 
of mature 64 kDa. B-galactosidase molecules are found. Here, 
the catalytic activity is less than 1% probably because the 
mutation not only interferes with the phosphorylation but 
also leads to impairment of the catalytic site. 
The degradation of ingested ganglioside by Morquio B 
fibroblasts proceeds like in control cells; this finding is 
in support of previous data by Paschke and Kresse (1982} 
that the mutation in Morquio B interferes mainly with the 
catalytic properties of B-galactosidase towards keratan 
sulfate. The amount of mutant B-galactosidase molecules is 
normal and the activity per molecule varies with the 
substrate. 
Radioactively labelled GM1 -ganglioside ingested by 
galactosialidosis fibroblasts are metabolized to GM2 - and 
GM3-gangliosides but then further degradation seems to be 
blocked. We believe that this is due to the coexistent 
deficiency of lysosomal neuraminidase. To test this hypothe-
sis GM1-ganglioside metabolism was studied in fibroblasts 
from a patient with mucolipidosis I and again the catabolism 
appeared to be blocked at GM3-ganglioside. These results 
suggest a role of lysosomal neuraminidase in the degradation 
of GM3-ganglioside. Up to now it was thought that the hydro-
lysis of neuraminic acid from gangliosides was performed by 
a specific ganglioside neuraminidase, located on the plasma 
membrane (Cantz and Messer, 1979); Zeigler and Bach, 1981, 
1985}. An alternative hypothesis explaining the block at GM3-
ganglioside degradation is an inhibition of the ganglioside 
neuraminidase by accumulated sialic acid containing storage 
products. Since human lysosomal neuraminidase has recently 
been purified (Verheijen et al., 1987}) the remaining 
questions on its role in ganglioside degradation will soon 
be resolved (Cantz, personal communication, 1987). 
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Finally, comparison of the in vivo degradation of GM1-
ganglioside in cells from the early infantile form and adult 
form of galactosialidosis did not reveal any difference. 
This is in agreement with the earlier observation on the 
residual B-galactosidase activity of about 10% in in vitro 
studies in both mutant cell strains (see Appendix paper I). 
This residual enzyme activity must be due to monomeric B-
galactosidase since no aggregation to multimeric forms 
occurs because of a defective 32 kDa protective protein (see 
previous sections) . The clinical and pathological differen-
ces between the various forms of galactosialidosis are most 
likely due to differences in the biosynthesis and processing 
of the 32 kDa protective protein and their effects on lyso-
somal neuraminidase activity (Palmeri et al., 1986; 
Verheijen, 1986). 
In normal human fibroblasts nearly all B-galactosidase 
in the lysosomes exists as a high molecular weight complex 
with neuraminidase (Verheijen et al., 1987) an.d the 32 kDa 
protective protein (Appendix paper IV). Yet, the in vivo 
studies of 3H GM1-ganglioside in galactosialidosis before 
and after leupeptin treatment show that monomeric B-galacto-
sidase also is capable of degrading GM1-gangliosides. The 
exact molecular relationships between the monomeric and 
multimeric form of B-galactosidase and its functions towards 
different substrates must await more detailed molecular 
analysis. This is also true for the relationship between the 
soluble lysosomal proteins B-galactosidase and the 32 kDa 
protective protein with the membrane-bound neuraminidase. 
Some indications for these relationships can, however, 
already be derived from the experimental work described in 
this thesis. Purified B-galactosidase from bovine testis 
remains stable when added to GM1-gangliosidosis fibroblasts, 
this must be due to an aggregation of B-galactosidase mono-
mers into high molecular weight multimers; this aggregation 
must occur in the lysosome (see also Appendix paper VII). 
Also the generation of the 32 kDa protective protein from 
its 54 kDa precursor seems to occur in the lysosome 
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(Appendix paper IV). The 32 kDa protein was most probably 
shown to be an essential subunit of lysosomal neuraminidase 
by V~rheijen et al. (1987). Hence this protein fulfills a 
dual function but the number of 32 kDa protein molecules 
required for a normal functioning of lysosomal neuraminidase 
and of B-galactosidase may be different. Also the effects of 
different mutations in each of the components of the B-
galactosidase-protective protein-neuraminidase complex may 
have very different biochemical, pathological and clinical 
consequences. 
51 
SUMMARY 
The importance of lysosomal enzymes in the 
intracellular degradation of many substrates is revealed by 
the profound effects of the genetic deficiency of single 
lysosomal enzymes in lysosomal storage diseases which are 
usually associated with severe physical and mental 
handicaps. 
Some 70 lysosomal enzymes have been identified and more 
than 30 of them are involved in lysosomal storage diseases. 
During the last decade much has been learned about the 
biosynthesis, posttranslational modification and 
intracellular routing of the lysosomal enzymes. In many 
instances the study of cultured skin fibroblasts from 
patients with a deficiency of one or more lysosomal enzymes 
has significantly contributed to a better understanding of 
normal molecular and cell biological mechanisms. 
The present thesis deals with experimental work on the 
lysosomal enzyme B-galactosidase and its involvement in 
human genetic diseases such as GM1-gangliosidosis, Morquio B 
syndrome and galactosialidosis. 
Chapter I provides a general introduction on lysosomal 
enzymes and lysosomal storage diseases and summarizes the 
main approaches towards the study of the genetic and 
molecular back-ground of the clinical heterogeneity that is 
often observed among patients with "the same" enzyme 
deficiency. 
Chapter II provides the theoretical background of the 
experimental work. The main characteristics of normal acid B-
galactosidase are described as well as the function of this 
enzyme in the degradation of gangliosides, keratan sulfate 
and galactose containing oligosaccharides derived from 
glycoproteins. In the same Chapter the clinical, 
pathological, biochemical and genetic aspects are described 
of those diseases in which acid B-galactosidase is 
deficient. In patients with GM1-gangliosidosis the three 
different clinical phenotypes are most likely based on 
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allelic mutations in a gene on chromosome 3 which codes for 
the B-galactosidase polypeptide. Patients with the severe, 
progressive infantile form of GM1-gangliosidosis and those 
with the milder juvenile form have hardly any detectable B-
galactosidase activity (less than 1% in fibroblasts), but in 
the adult form of the disease a residual activity of 10-15% 
of control values is present. In all clinical forms, 
neurological manifestations, skeletal abnormalities and 
intellectual impairment are present. Differences mainly 
concern the age of onset, the progression of the disease and 
the severity of the clinical features. 
The mucopolysaccharidosis-like disease Morquio B 
syndrome is also caused by a mutation in the gene coding for 
B- galactosidase. Here, the pathological abnormalities are, 
however, mainly restricted to the skeletal system whereas 
neurological manifestations are absent. This can be 
explained by the fact that the mutation affects the B-
galactosidase molecule in such a way that its catalytic 
function towards keratan sulfate is impaired whereas the 
hydrolysis of GM1-gangliosides remains intact. 
Chapter II also summarizes the main characteristics of 
two diseases where a B-galactosidase deficiency is part of a 
multiple lysosomal enzyme deficiency: mucolipidosis II ("!-
cell" disease) and galactosialidosis. In the former disease 
a defective phosphotransferase results in the lack of a 
mannose 6-phosphate marker on the precursor forms of many 
lysosomal enzymes, and as a consequence the lysosomal 
enzymes are secreted instead of being transported to the 
lysosomes. In galactosialidosis the combined deficiency of 
lysosomal B-galactosidase and neuraminidase is due to the 
genetic defect of another glycoprotein, called the "protec-
tive protein". 
Finally, the last section of Chapter II discusses the 
animal models available for the study of B-galactosidase 
deficiencies and their use in studying the possible 
aproaches for therapy. The major problems encountered in the 
treatment of patients either by enzyme replacement or gene 
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therapy are mentioned. 
Chapter III deals with the results and discussion of 
the experimental work which is basically described in eight 
articles published by scientific journals (Appendix papers I 
to VIII). 
The aim of the experiments described in Appendix paper 
~ was to study the genetic background of the single 
neuraminidase deficiency as present in patients with the 
lysosomal storage disease mucolipidosis I (sialidosis) and 
the combined neuraminidase and B-galactosidase deficiency in 
patients with different clinical variants of the disease 
galactosialidosis. Cultured fibroblasts from various 
patients were hybridized and possible restoration of 
neuraminidase activity was measured in heterokaryons 
(containing the genome from both parental cell strains). 
These complementation studies indicated that galac-
tosialidosis must be caused by a mutation in a gene 
different than the one involved in muco1ipidosis I. 
Surprisingly co-cultivation experiments performed as a 
control, revealed some restoration of neuraminidase activity 
in galactosialidosis cells indicating the transfer of a 
"corrective factor" which was secreted even by neuraminidase 
deficient cells. 
The nature of this "corrective factor" was further 
investigated (Appendix paper II) . The secretion of the pre-
cursor form of the "corrective factor", was induced by the 
addition of NH4Cl to human fibroblasts. Application of a 
concentrate of this factor to the medium above 
galactosialidosis fibroblasts resulted in a complete 
restoration of the B-galactosidase and neuraminidase 
activity and had no effect on the B-galactosidase deficiency 
in GM1 -gangliosidosis. It was also shown that the 
"corrective factor" was a glycoprotein whose uptake by 
cultured fibroblasts could be inhibited by mannose 6-
phosphate. 
The experimental work described in the Appendix papers-
III and IV has led to the elucidation of the molecular 
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defect responsible for the combined .B-galactosidase and 
neuraminidase deficiency and of the nature and function of 
the "corrective factor". Immunoprecipitation studies using 
3H-leucine labelled fibroblasts and antibodies against 
purified placental human .B-galactosidase gave insight in the 
biosynthesis of .B-galactosidase in normal fibroblasts and 
galactosialidosis cells (Appendix paper III). Normal .B-
galactosidase is synthesized as a 85 kDa precursor which is 
processed into 64 kDa mature, fully active enzyme. The 
antiserum also reacted with a number of other proteins with 
a molecular mass of 54 kDa, 32 kDa and 20 kDa. In 
galactosialidosis the 85 kDa precursor .B-galactosidase was 
synthesized and processed normally, but the 64 kDa mature 
form was found to be degraded rapidly. This appeared to be 
due to the absence of the 32 kDa glycoprotein and its 54 kDa 
precursor. A relationship between the absence of this 
"protective protein" and an enhanced degradation of mature .B-
galactosidase was supported by the fact that addition of the 
"corrective factor" resulted in a complete normalization of 
.B-galactosidase processing in galactosialidosis cells. The 
"corrective factor" described above thus seemed to be 
identical with the 32 kDa protective protein or its 
precursor. Furthermore, addition of leupeptin, a 
thiolcathepsin inhibitor prevented enhanced degradation of .B-
galactosidase, but had hardly any effect on neuraminidase 
activity. 
The experimental work in Appendix paper IV showed first 
of all that the 32 kDa "protective protein" is derived from 
the 54 kDa precursor. Sucrose-density gradient 
centrifugation studies indicated that in normal fibroblasts 
85% of all .B-galactosidase exists as a high molecular weight 
multimer (600-700 kDa) together with the 32 kDa protective 
protein. In galactosialidosis cells only a small amount of 
monomeric 64 kDa .B-galactosidase is present but addition of 
the protective protein results in a normalization of the 
aggregation process. The combined results of the two sets of 
experiments suggest that the 32 kDa glycoprotein is required 
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for the aggregation of B-galactosidase monomers. If there is 
a deficiency of this protective protein as in galacto-
sialidosis, B-galactosidase monomers cannot aggregate and 
are then sensitive to enhanced degradation by lysosomal 
proteases. 
The work reported in Appendix papers V and VI involves 
a similar experimental approach towards the molecular 
processing of B-galactosidase in patients with different 
clinical variants of GM1-gangliosidosis and with Morquio B 
syndrome. In all mutant fibroblasts 85 kDa precursor B-
galactosidase is synthesized at a normal rate. In Morquio B 
also mature 64 kDa B-galactosidase is formed which has a 
nearly normal affinity and activity towards ganglioside 
substrates but an impaired activity towards keratan sulfate 
and galactose-containing oligosaccharides because of its 
mutation. In none of the GM1-gangliosidosis variants, 
however is a 64 kDa band seen and pulse-chase studies 
indicate that the normal processing of B-galactosidase 
molecules must be impaired within hours after the synthesis 
of the 85 kDa precursor. Studies reported in Appendix paper 
VI provide the explanation for this phenomenon: the mutation 
of the B-galactosidase precursor interferes with a normal 
phosphorylation and hence the molecules lack the mannose 6-
phosphate marker required for a correct compartmentalization 
in the lysosome. As a consequence, the mutant precursor B-
galactosidase is secreted by the cell. The observation that 
in all cell lines studied so far from patients with the 
three different clinical phenotypes the mutation impairs 
phosphorylation, might be explained by a change of the three-
dimensional structure of the B-galactosidase precursor. Such 
a conformational change may interfere with the recognition 
site for N-acetylglucosaminylphosphotransferase, normally 
involved in the generation of the M6P marker. 
All studies mentioned so far dealt with genetic, bio-
chemical or immunological analyses on cell homogenates from 
cultured fibroblasts. In order to investigate whether some 
of the mechanisms are also operational under in vivo 
56 
conditions, immunoelectron microscopic 
performed on frozen sections using the 
studies were 
gold-labelling 
technique (Appendix paper VI). The intracellular 
localization of B-galactosidase in normal and mutant 
fibroblasts was compared using polyclonal antibodies 
(reacting with both monomeric and multimeric B-
galactosidase) and monoclonal antibodies which only reacted 
with the monomeric form. It could be shown that also under 
in vivo conditions B-galactosidase exists as a multimer in 
the lysosome of normal fibroblasts. In ~1-gangliosidosis no 
cross reactive material could be detected in the lysosomes, 
but some label was found in the endoplasmic reticulum and 
Golgi apparatus (precursor forms) and at the cell membrane. 
These findings are in agreement with the biochemical data on 
secretion of the precursor form. In galactosialidosis cells 
the lysosomes contain some B-galactosidase but only in its 
monomeric form. Addition of the 54 kDa precursor of the 32 
kDa protective protein to these cells results in a strong 
labelling with polyclonal antibodies and no labelling with 
monoclonal antibodies which indicates that the 
multimerization process has been normalized in vivo. 
Although more insight has been gained in the exact 
nature of the molecular defect(s) involved in human B-
galactosidase deficiencies the pathogenesis of the different 
clinical phenotypes within each of the syndromes remains 
difficult to explain. Test tube assays may not be sufficient 
for a correct understanding of in vivo mechanisms. As a 
first approach to study the in vivo metabolism, GM1 -
ganglioside labelled in its ceramide moiety was fed to 
various types of mutant fibroblasts and the intracellular 
degradation after ingestion was studied by thin layer 
chromatography (Appendix paper VIII). The first observation 
was that there is no difference in the rate of GM1 -
ganglioside degradation by monomeric and mul timeric B-
galactosidase. 
Also, it was shown that the residual amount of 5-15% of 
B-galactosidase molecules in the adult variant of GM1-
57 
gangliosidosis is sufficient to degrade the ingested GM1 -
ganglioside. The occurrence of pathological manifestations 
in patients may be related to different metabolic conditions 
in the various cell types, still to be studied. Further an 
increasing accumulation of substrate over a long period may 
affect the rate of hydrolysis by a decreased amount of 
enzyme. In cells from patients with the infantile forms of 
GMl -gangliosidosis no degradation of GM1 -ganglioside was 
observed which is in agreement with the early and more 
severe manifestations in these patients. 
In all galactosialidosis variants the residual amount 
of monomeric B-galactosidase was found to be capable of GM1-
ganglioside degradation. The clinical manifestations in the 
most severe early infantile and late infantile forms are 
probably mainly caused by the co-existent neuraminidase 
deficiency. For the B-galactosidase deficiency in the adult 
variant of galactosialidosis similar considerations apply as 
in adult GM1-gangliosidosis. Further studies on the exact 
nature of the neuraminidase deficiency in the different 
variants of galactosialidosis and sialidosis are required. 
This also applies to the finding in Appendix paper VIII that 
in all cells with a lysosomal neuraminidase deficiency the 
ganglioside degradation is blocked at GM3-ganglioside. This 
might point to a role of lysosomal neuraminidase in ganglio-
side degradation, a role which hitherto has been attributed 
to a distinct enzyme, ganglioside neuraminidase. 
The experimental work described in this thesis has 
further clarified the relationship between B-galactosidase 
and the protein which is required for its aggregation and 
thereby protecting the enzyme from rapid proteolytic 
degradation. The aggregation of B-galactosidase monomers was 
also demonstrated under in vivo conditions. No difference 
was found in the degradation of GM1-ganglioside by the 
monomeric or multimeric forms of 8-galactosidase. Our work 
has also revealed that the deficiency of B-galactosidase 
molecules in the different clinical variants of GM1 -
gangliosidosis is due to impaired phosphorylation of the 
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precursor form resulting in its secretion instead of a 
correct processing and compartmentalization in the lysosome. 
Future work has to elucidate the exact molecular interaction 
between 8-galactosidase, protective protein and 
neuraminidase and clarify the pathological effects of 
different mutations in the genes coding for each of these 
proteins. Knowledge of the exact biochemical background of 
inherited diseases is essential for optimal genetic 
counseling and therapy. 
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SAMENVATTING 
Lysosomale enzymen spelen een belangrijke rol bij de 
afbraak van biologisch materiaal. Dit komt tot uiting bij 
lysosomale stapelingsziekten, waar het genetisch defect van 
een enkel enzym vaak leidt tot ernstige lichamelijke en gees-
telijke handicaps. 
Van de 70 bekende lysosomale enzymen zijn er ongeveer 
30 betrokken bij lysosomale stapelingsziekten. 
In de afgelopen 10 jaar is veel bekend geworden over de 
biosynthese van lysosomale enzymen en de veranderingen die 
ze ondergaan na translatie en over het transport van de 
lysosomale enzymen naar het lysosoom. In veel gevallen 
hebben de studies aan fibroblasten van controle personen en 
patienten een grote bijdrage geleverd tot het begrip van 
normale moleculaire en celbiologische processen. 
Het in dit proefschrift beschreven experimentele werk 
handelt over het lysosomale enzym B-galactosidase en zijn 
rol in lysosomale stapelingsziekten zoals GM1-
gangliosidosis, Morquio B syndroom en galactosialidosis. 
Hoofdstuk I geeft naast een algemene beschouwing over 
lysosomale enzymen en lysosomale stapelingsziekten, een 
samenvatting van een aantal methoden om de genetische en 
moleculaire achtergrond van de klinische heterogeniteit te 
bestuderen, die men vaak binnen eenzelfde ziekte waarneemt. 
Hoofdstuk II beschrijft de theoretische achtergrond van 
het experimentele werk. Naast de belangrijkste karakteristie-
ken van normale zure B-galactosidase, wordt de functie van 
het enzym, de afsplitsing van galactose van GMl ganglioside, 
keratan sulfaat en oligosacchariden beschreven. In hetzelfde 
hoofdstuk worden de klinische, pathologische, biochemische 
en genetische aspecten van ziekten met een B-galactosidase 
deficientie belicht. De verschillende klinische varianten 
van GM1-gangliosidosis worden hoogstwaarschijnlijk 
veroorzaakt door een verschillend defect in het gen voor B-
galactosidase, dat zich op chromosoom 3 bevindt. Bij 
patienten met de ernstige, progressieve, infantiele vorm en 
60 
bij patienten met de wat mildere juveniele vorm van GM1 -
gangliosidosis wordt een lage B-galactosidase activiteit 
gevonden (in fibroblasten zelfs minder dan 1% ten opzichte 
van centrale) . Echter in fibroblasten van patienten met de 
adulte vorm van GM1-gangliosidosis wordt een restactiviteit 
gemeten van 10-15%. Alle klinische vormen worden gekenmerkt 
door neurologische en skelet afwijkingen en mentale 
retardatie. De varianten verschillen meestal in de aanvang, 
de progressie en de ernst van de klinische verschijnselen. 
Bij Morquio B syndroom een ziektebeeld dat veel op mucopoly-
saccharidosis lijkt wordt oak een mutatie gevonden in het 
gen dat codeert voor B-galactosidase. Hier zijn de pathologi-
sche afwijkingen beperkt tot het skelet, terwijl de 
neurologische verschijnselen afwezig zijn. Dit kan worden 
verklaard uit het feit dat het gemuteerde B-galactosidase 
een verlaagde affiniteit heeft voor keratan sulfaat terwijl 
de affiniteit voor GM1-ganglioside normaal is. In hoofdstuk 
II worden oak de karakteristieken van twee andere ziekten 
beschreven, waar naast een B-galactosidase deficientie oak 
andere lysosomale enzym deficienties worden gevonden nl. 
mucolipidosis II ("I-cell" disease ) en galactosialidosis. 
In mucolipidosis II is het primaire defect een mutatie in 
een fosfotransferase, hierdoor kunnen precursors van lyso-
somale enzymen niet voorzien worden van de M6P marker. Deze 
M6P marker is nodig om lysosomale enzymen naar het lysosoom 
te transporteren. Het ontbreken van deze marker heeft als 
gevolg dat de meeste lysosomale enzymen door de cellen 
worden uitgescheiden. In galactosialidosis zijn de 
lysosomale enzymen B-galactosidase en neuraminidase 
deficient als een gevolg van een genetisch defect in een 
ander glycoproteine dat "protective protein" wordt genoemd, 
omdat het B-galactosidase beschermt tegen proteolytische 
afbraak. Tenslotte worden in hoofdstuk II de beschikbare 
diermodellen beschreven voor de bestudering van B-
galactosidase deficienties en om uit te zoeken wat mogelijk 
de juiste methode zou zijn voor eventuele therapy. De 
belangrijkste problemen die zich voordoen bij de behandeling 
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van patienten hetzij bij enzym, orgaan of gen therapy worden 
genoemd. 
In hoofdstuk III worden de resultaten van het experimen-
tele werk dat gebaseerd is op 8 artikelen, gepubliceerd in 
wetenschappelijke tijdschriften (Appendix papers I-VIII), 
vermeld. Het doel van het experimentele werk beschreven, in 
Appendix paper I, was het bestuderen van de genetische 
achtergrond bij klinische varianten van de lysosomale 
stapelingsziekte mucolipidosis I (sialidosis) en de 
gecombineerde neuraminidase en B-galactosidase deficienties 
in klinische varianten van galactosialidosis. De gekweekte 
fibroblasten van de verschillende patienten werden met 
elkaar gefuseerd en de mogelijke verhoging van neuraminidase 
activiteit gemeten in de heterokaryons (deze bevatten het 
genoom van beide ouderlijnen). Deze fusie experimenten 
toonden aan dat galactosialidosis wordt veroorzaakt door een 
mutatie in een gen anders dan het gen dat betrokken is bij 
de mutatie in mucolipidosis I. Een onverwacht~ vinding was 
dat na samenkweek, bedoeld als controle experiment, de 
neuraminidase activiteit in fibroblasten van patienten met 
galactosialidosis verhoogd was. Dit wees op het transport 
van een corrigerende faktor uitgescheiden door zowel 
controle als neuraminidase deficiente cellen. De aard van 
deze corrigerende faktor is verder onderzocht in Appendix 
paper II. Door het toevoegen van NH4Cl aan het medium van 
fibroblasten, kon de uitscheiding van de corrigerende faktor 
worden verhoogd. Zodat deze in geconcentreerde vorm 
toegevoegd kon worden aan fibroblasten van patienten met 
galactosialidosis. Het resultaat was een volledige correctie 
van zowel B-galactosidase als neuraminidase. Toevoeging van 
de faktor aan B-galactosidase deficiente fibroblasten van 
patienten met GM1-gangliosidosis had geen effect. Verder 
werd aangetoond dat deze faktor een glycoproteine was en dat 
de opname ervan geremd kon worden door toevoeging van 
mannose 6-fosfaat aan het medium. 
Het experimentele werk beschreven in de Appendix papers 
III en IV heeft geleid tot de oplossing van het moleculaire 
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defect verantwoordelijk voor de gecombineerde deficiency van 
B-galactosidase en neuraminidase in galactosialidosis en tot 
het begrijpen van de aard en functie van de corrective 
faktor. Door gebruik te maken van leucine gelabelde 
fibroblasten en antilichamen gericht tegen B-galactosidase, 
werd meer inzicht verkregen in de biosynthese van B-
galactosidase in normale en galactosialidosis cellen. De 85 
kDa precursor vorm van normale B-galactosidase wordt 
"geprocessed" in een enzymatisch actieve 64 kDa mature vorm. 
Het antiserum reageert behalve met B-galactosidase ook met 
een aantal andere eiwitten met molecuulgewichten van 54 
kDa, 32kDa en 20 kDa In galactosialidosis werd aangetoond 
dat de 85 kDa precursor vorm normaal gemodificeerd wordt 
tot een 64 kDa vorm, maar dat de mature vorm in 
tegenstelling tot controle versneld wordt afgebroken. Dit 
als een gevolg van het ontbreken van een glycoproteine met 
een molecuul gewicht van 32 kDa. Toevoeging van de 
corrigerende faktor resulteerde in een normaal B-galactosi-
dase patroon. Uit de combinatie van de resultaten werd gecon-
cludeerd dat het beschermende eiwit en de corrigerende 
faktor hetzelfde waren. Tenslotte werd nog aangetoond dat 
door toevoeging van leupeptine (een thiolprotease remmer) de 
versnelde afbraak van B-galactosidase moleculen voorkomen 
kan worden. Leupeptine had echter weinig effect op de 
neuraminidase activiteit. 
Het experimentele werk beschreven in Appendix paper IV 
toont de relatie tussen de 54 kDa, 32kDa en de 20 kDa eiwit-
ten. De 54 kDa precursor wordt na toevoeging aan fibro-
blasten binnen de eel omgezet in een 32kDa en een 20 kDa 
eiwit. Experimenten met sucrose gradienten tonen aan dat in 
normale fibroblasten, 85% van de B-galactosidase moleculen 
samen met de 32 kDa "protective protein " en het 20 kDa 
geaggregeerd voorkomen in een multimeer met een molecuul ge-
wicht van 600-700 kDa In fibroblasten van patienten met 
galactosialidosis wordt echter een kleine hoeveelheid 
monomere B-galactosidase gevonden. Toevoeging van het 
"protective protein" resulteert in een normaal aggregatie 
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patroon van a-galactosidase en "protective protein" 
moleculen. Wanneer we de resultaten samenvatten wijst dit 
erop dat het 32 kDa eiwit noodzakelijk is voor de aggregatie 
van a-galactosidase moleculen, als dit eiwit ontbreekt zeals 
in galactosialidosis heeft dit tot gevolg dat de a-
galactosidase monomeren niet kunnen aggregeren en hierdoor 
zijn zij meer gevoelig voor afbraak door lysosomale 
proteasen. 
De bestudering van de moleculaire processing van a-
galactosidase in cellen van verschillende klinische 
varianten van GM1-gangliosidosis en Morquio B syndrome wordt 
beschreven in de Appendix papers V en VI. De experimentele 
benadering is ongeveer hetzelfde als beschreven in Appendix 
paper IV. Er werd aangetoond dat in alle gemuteerde 
fibroblasten de 85 kDa precursor van a-galactosidase normaal 
wordt gesynthetiseerd. In Morquio B syndroom wordt een 
normale hoeveelheid 64 kDa mature enzym gevonden, dat een 
normale affiniteit vertoont voor ganglioside substraten maar 
als gevolg van de mutatie een verlaagde affiniteit heeft 
voor keratan sulfaat en galactose bevattende oligosac-
chariden. In geen van de GM1-gangliosidosis varianten die 
zijn getest wordt een 64 kDa mature vorm van a-galactosidase 
gevonden, zelfs niet in pulse chase experimenten, waar 
modificaties in nieuw gevormd a-galactosidase enkele uren na 
synthese kan worden bestudeerd. De normale processing van a-
galactosidase lijkt al binnen enkele uren na synthese 
verstoord. Studies vermelt in Appendix paper VI geven een 
verklaring voor dit verschijnsel. De mutatie in de a-galacto-
sidase precursor staat een normale fosforylering in de weg. 
Dit heeft als gevolg dat er geen M6P marker ontstaat, die 
nodig is voor het transport van a-galactosidase naar het 
lysosoom. De gemuteerde precursor van a-galactosidase wordt 
nu door de eel uitgescheiden. Omdat de verschillende 
mutaties bij de verschillende varianten niet tot een normale 
fosforylering leiden, zou een verklaring kunnen zijn dat een 
verandering in de driedimensionale structuur van het 
gemuteerde a-galactosidase molecuul interfereert met het 
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herkenningspunt van N-acetylglucosaminylfosfotransferase, 
verantwoordelijk voor de vorming van de M6P marker. 
Alle genetische, biochemische en immunologische studies 
tot nu toe vermeld werden uitgevoerd met celhomogenaten van 
gekweekte fibroblasten. Om te onderzoeken of de mechanismen 
eerder genoemd voor B-galactosidase oak gelden onder in vivo 
condities werden immunoelectronen microscopische studies uit-
gevoerd op bevroren coupes met gebruik van de immune-gaud 
markerings techniek (Appendix paper VII). De intracellulaire 
localizatie van B-galactosidase in normale en gemuteerde fi-
broblasten werd vergeleken met behulp van polyclonale antili-
chamen (welke reageren met zowel de monomere als de 
mul timere vorm van B-galactosidase) en monoclonale 
antilichamen die alleen reageren met B-galactosidase in zijn 
monomere vorm. Er werd aangetoond dat oak onder in vivo 
condities B-galactosidase in lysosomen van normale 
fibroblasten als een mul timeer voorkomt. In cell en van 
patienten met GM1-gangliosidosis werd geen kruisreagerend 
materiaal gevonden in het lysosoom, wel werd label 
aangetoond in het endoplasmatisch reticulum, Golgi apparaat 
(precursor vormen) en op de plasma membraan. Deze 
waarnemingen vormen dus een bevestiging van de biochemische 
resultaten. In cellen van patienten met galactosialidosis 
werd een sterk verlaagde hoeveelheid B-galactosidase 
moleculen gevonden in een monomere vorm. Toevoeging van het 
54 kDa eiwit (de corrigerende faktor) resulteerde in een 
sterke labeling van het lysosoom met het polyclonale 
antiserum, geen labeling werd gevonden wanneer het 
monoclonale antiserum werd gebruikt. Dit wijst op een 
normaal aggregatie patroon onder in vivo omstandigheden. 
Alhoewel er meer inzicht is verkregen in de aard van de 
moleculaire defect(en) in B-galactosidase deficienties, 
blijft tach de pathogenese van de verschillende klinische 
phenotypen binnen elk van de syndromen moeilijk te 
begrijpen. Bepalingen in de reageerbuis zijn misschien niet 
voldoende voor het geed begrijpen van de in vivo 
mechanismen. 
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Als een eerste benadering om de functie van B-galactosi-
dase onder in vivo omstandigheden te bestuderen, werd GM1-
ganglioside (gelabeld in het ceramide gedeelte) toegevoegd 
aan fibroblasten van de verschillende patienten, en de 
intracellulaire afbraak werd na opname bestudeerd met behulp 
van dunne laag chromatography (Appendix paper VIII). De 
eerste waarneming was dat er geen verschil werd gevonden in 
de afbraak van GM1-ganglioside door monomere of multimere B-
galactosidase. Ook werd aangetoond dat de restactiviteit van 
B-galactosidase in de adulte variant van GM1-gangliosidosis 
voldoende was om de opgenomen hoeveelheid GM1-ganglioside 
af te breken. De pathologische verschijnselen in vivo worden 
waarschijnlijk veroorzaakt door de verschillende metabole 
condi ties in de verschillende eel typen. Di t zal verder 
onderzocht moeten worden. Een toenemende stapeling van 
substraat in de tijd, 
kunnen remmen. In de 
zou de verminderde hoeveelheid enzym 
fibroblasten van patienten met de 
infantiele en juveniele vorm van GM1-gangliosidosis werd 
geen afbraak van GM1-ganglioside gevonden, hetgeen in 
overeenstemming is met de vroege en ernstige symptomen bij 
deze patienten. In fibroblasten van alle galactosialidosis 
varianten werd aangetoond dat de restactiviteit van monomere 
B-galactosidase voldoende is om GM1-ganglioside af te 
breken. De ernstige klinische verschijnselen van de vroeg 
en laat infantiele vorm worden waarschijnlijk in hoofdzaak 
veroorzaakt door de eveneens aanwezige neuraminidase 
deficientie. Voor de adulte variant van Galactosialidosis 
gelden dezelfde overwegingen als voor de adulte variant van 
GM1-gangliosidosis. Verdere studies zijn nodig naar de pre-
ciese aard van de neuraminidase deficientie in de verschil-
lende vormen van galactosialidosis en salidosis. Dit geldt 
ook voor de waarneming vermeld in Appendix paper VIII, dat 
in cellen met een neuraminidase deficientie de afbraak van 
GM3 ganglioside geblokkeerd wordt. Dit wijst op een rol van 
een lysosomale neuraminidase in de afbraak van ganglioside, 
een taak die wordt toegeschreven aan een ganglioside 
neuraminidase. 
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Het experimentele werk dat in dit proefschrift wordt 
beschreven maakt de relatie duidelijk tussen B-galactosidase 
en het eiwit dat nodig is voor zijn aggregatie en bescher-
ming daardoor tegen versnelde afbraak. Deze aggregatie werd 
ook onder in vivo omstandigheden aangetoond. Verder werd er 
geen verschil gevonden in de afbraak van GM1-ganglioside 
door de monomere en multimere vorm van B-galactosidase. Ook 
werd aangetoond dat de afwezigheid van B-galactosidase 
moleculen in de verschillende klinische varianten van GM1-
gangliosidosis een gevolg is van een defecte fosforylering 
van de precursor , wat resulteert in een uitscheiding van 
het eiwit in plaats van een normaal transport naar het 
lysosoom. Verdere studies zijn nodig om een antwoord te 
geven op de vraag hoe de moleculaire interactie tussen B-
galactosidase, het beschermende eiwit en neuraminidase 
plaats vindt en om de pathologie, veroorzaakt door 
verschillende mutaties in de genen coderend voor elk van 
deze eiwi tten te begrijpen. Kennis van de exacte 
biochemische achtergrond van erfelijke ziekten is 
noodzakelijk voor een goede erfelijkheidsvoorlichting en 
eventuele therapie. 
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Genetic heterogeneity in 
human neuraminidase deficiency 
A. T. Hoogeveen, F. W. Verheijen, A. d'Azzo & 
H. Galjaard 
Department of Cell Biology and Genetics. Erasmus University, 
Rotterdam, The Netherlands 
There is a deficiency of human :r:-N-acetylneuraminidase in 
several inherited diseases. In patients with mucolipidosis I (refs 
l, 2) and in adults with a variant form without bony 
abnormalities and mental retardation 3·\ both also classified as 
sialidoses4, it is the only deficient enzyme. In mucolipidosis II 
("!-cell' disease) neuraminidase is one of many deficient 
lysosomal hydrolases5-7 and a third manifestation combines 
deficiency of neuraminidase and p-galactosidase 11·~. We have 
investigated the genetic background of these various 
neuraminidase deficiencies by somatic cell hybridization and co-
cultivation. The principal conclusions from work on mutant 
fibroblasts, reported here, are that at least three gene mutations 
are involved and that the combined p-galactosidase/ 
neuraminidase deficiency is likely to be due to defective post~ 
translational modification of these enzymes. 
Table 1 summarizes the neuraminic acid content and the 
activities of ,8-galactosidase and neuraminidase in the different 
mutant fibroblasts and 4 days after fusion of each cell type 
with itself (parental fusion). The activity of neuraminidase was 
measured with N-acetylneuraminosyl-o-lactose and with 4-
methylumbelliferyl-::x-2-N-acetylneuraminic acid (provided by 
Dr J. S. O'Brien}. and similar results were obtained with both 
substrates. Because of its simplicity and high sensitivity. we 
have used principally the f1uorometric assay. the results of 
which are reported here. As Table 1 shows, the neuraminidase 
activity in fibroblasts from a severely mentally retarded 11-yr-
old girl with the classical form of mucolipidosis I (ML I), also 
classified as sialidosis 2 (ref. 4). was 1 '~"of control values. Cells 
from a patient with a variant form described by Durand et 
Table 2 CeU hybridiZation and co-cultivation of neuraminidase-
deficient human fibroblasts 
Combination of cell strains 
1-ceiland class. MLI 
1-ce!l and variant ML I 
I-ce!! and adult ,6-gal- jneur-
1-cell and infantile 
,1]-gal-;neur-
Class. ML I and variant ML I 
Adult ,1]-gal- jneur- and 
infant. ,8-gal- jneur-
Class. MLI and adult 
,1]-gal- /neur-
Class. ML I and infant. 
,1]-gal- /neur-
Variant MLI and adult 
,1]-gal- ;neur-
Variant ML I and infant. 
,1]-gal-;neur-
Neuraminidase activity 
( x to-<~ mol perh permgprotein) 
Hybridization Co-cultivation 
6.2 0.5 
9.6 1.2 
3.5 0.6 
5.8 0.2 
1.6 1.2 
0.8 1.0 
9.4 3.7 
5.0 3.0 
7.0 4.0 
6.8 4.9 
Values are the means of three to six independent experiments. 
Hybridization was carried out with polyethylene glycol as before15 
adapted for human fibroblasts in monolayer. lot'' cells of both cell 
strains were mixed 4 days before fusion and cultivated in Ham's FlO 
medium with IO/o fetal calf serum. The medium was changed after 3 
days and I day later cells were rinsed twice with medium without 
serum. and after removal of the medium. hybridization was carried out 
as follows: I ml of 42/o polyethylene glycol (PEG) molecular weight 
1,000 (Koch-Light) in Hum's FlO with 15');, DMSO was added. The 
mixture was rocked for 2min, I ml 25~%, PEG in Ham's FlO was 
added. the mixture was rocked again and 8ml Ham's FlO was added 
twice. After rocking, the medium was removed. the cells rinsed with 
Ham's FlO and then Ham's FlO with 10';~, fetal calf serum was added. 
After 4 days of cultivation in the same medium, the heterokaryon 
population was collected and analysed for neuraminidase activity 
using 4-methylumbelliferyl as substrate. Microscopy of staint:d 
preparations after cell fusion revealed that 70-90'X, of the cells 
contained more than one nucleus, and autoradiography after 
incorporation of 3 H-thymidine showed that nearly all multinucleate 
cells were heterokaryons. 
Table 1 Activities of ,I]-galactosidase and neuraminidase. and neuraminic acid content in mutant human fibroblasts and effect of cell fusion 
Neuraminidase 
Total neuraminic acid {3-Galactosidase Unfused After parental 
Cell type {10- 9 mol per mg) fusion 
I-Cell* 117 4 0.3 0.2 
Classical ML I* 71 730 1.3 0.7 
Variant ML I* 40 850 3.8 3.9 
Adult ,1]-gal- /neur- 60 45 1.3 1.5 
Infantile ,8-gal-/neur- 59 48 0.6 0.7 
Heterozygous mother 16 574 31 
Heterozygous father 17 627 34 
Control fibroblasts 
Mean 22 630 82 
Range 15-31 350-1.050 43-129 
(n~17) (n~36) (n~17) 
Activities are expressed as nmol per h per mg protein and the values given are the means of three to six independent experiments on each 
mutant strain and on a large number of control fibroblasts. In all instances fibroblasts were cultured in Ham's FlO medium with 10% fetal calf 
serum and they were collected by trypsinization, rinsed in saline and centrifuged. Cells were disrupted by addition of bidistilled water to the pellet, 
and after shaking, the homogenate was used directly for biochemical analysis. Neuraminidase activity was determined with methylumbelliferyl 
substrate {provided by Drs T. Warner and J. S. O'Brien. see ref. 20 for synthesis). Cell homogenate (1 ).l.l) was incubated with 2 ).l.l 2mM substrate 
in 0.25 M Na-acetate butTer. pH 4.3, for 1-2 h at 37 'C: the fluorescence of the liberated methylumbelliferone was measured after addition of 500 Jll 
0.5M sodium carbonate buffer. pH 10.7. at 448nm. The activity of {3-galactosidase was also measured with methylumbelliferyl substrate as before9 • 
Total neuraminic acid content was measured after hydrolysis of the cells for 1 hat 80'C in 0.1 N H1 S04 according to Warren 21 • 
*Cultured fibroblasts from a patient with mucolipidosis I were provided by Dr H. D. Bakker: those from a patient with a variant form (De PF 
in ref. 3) by Dr P. Durand. and those from a patient with I-cell disease by Dr A. Boue. 
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a/. 3, and sometimes classified as sialidosis 1 (ref. 4), had a 
residual activity of 4--5 '%1• This higher residual activity is 
probably responsible for the lower neuraminic acid content in 
these fibroblasts. 
Fibroblasts from a mentally retarded adult male with 
myoclonus and ataxia 10 and from a 2-yr-old boy with Hurler-
like features but no neurological abnormalities'' had a 
profound neuraminidase deficiency in addition to a 10% 
residual activity of [!-galactosidase (Table 1 ). These two 
patients had previously been classified as variant forms of 
GM 1-gangliosidosis 12 or #-galactosidase deficiency 13 on the 
basis of complementation after fusion with fibroblasts from 
patients with a primary defect of /!-galactosidase. Fibroblasts 
from both parents of the patient with infantile {3-
galactosidase/neuraminidase deficiency ({3-gal- /neur-) had 
normal activity of /)-galactosidase but neuraminidase activity 
was about half the mean control value (Table 1 ). This makes it 
unlikely that />-galactosidase deficiency is the primary defect in 
this condition. One of our patients with #-gal- /neur- has 
recently been classified as sialidosis II (ref. 4). Because the 
primary defect in this condition has not yet been resolved and 
the syndromes included in the category sia\idosis 2 are so 
different clinically, biochemically and even genetically. such 
classification seems somewhat premature. 
We have studied the genetic background of the various 
neuraminidase deficiencies by complementu.tion analysis after 
somatic cell hybridization. The results of enzyme assays 4 days 
after fusion of each cell strain with itself (parental fusion in 
Table I) indicate that the polyethylene glycol (PEG) method 
of hybridization'* does not affect neuraminidase activity. The 
restilts of fusions of different mutant cell strains are 
summarized in the second column of Table 2. Compared with 
parental fusions. there was 4 15 tirri.es as much neuraminidase 
activity after fusion of I-cells with each of the other mutant 
fibroblasts. The activities :1fter co-cultivation {third column of 
Table 1) were not higher than the average values for t:ach pair 
of parental cells. The complementation observed after fusion of 
I·cells with each of the other mutant fibroblasts is most 
probably due to a correction of the post-translational defect in 
I-cdl disease'. The rapid generation of neuraminidase activity 
and of nther lysosomal hydrolases after fusion of 1-cells with 
various other mutant fibroblasts 15 would agree with a 
normulization of the processing and,'or activation of preformed 
glycosidases. 
The fusions of classical M L I x variant ML I did not result 
in complementation and these conditions probably represent 
different mutations within one gene. The same is true for the 
adult type and infantile type of #-gal- jneur- deuciency. 
Fusions of each of the ML I strains with each of the 
#-gal- jneur- deficient fibroblasts, however, resulted in a clear 
increase in neuraminidase activity (3-9 times the values after 
parental fusion). This indicates that two different gene 
mutations are involved in the neuraminidase deficiency of 
sialidosis I and the combined #-gal- /neur-. The restoration of 
neuraminidase activity after fusion of ML I cells with 
f:i-gal-, ncur- fibroblasts might result because one cell type, 
most probably M L I. is deficient in the structural part of the 
enzyme and the other is defective in a modifying enzyme or a 
regulatory factor. Another explanation 1 could be that 
neuraminidase is made up of different subunits which must be 
normal for the expression of its activity. 
Neuraminidase activity also increased after co-cultivation of 
the different types of MLI cells with each of the {3-gal-;neur-
fibrob\asts (compare last column Table 2 with average values 
of both parental strains in Table 1 ). This partial restoration of 
neuraminidase activity was investigated further by labelling the 
mutant fibroblasts with fluorescent polystyrene beads, followed 
by co-cultivation for 3 days, separation of the two cell 
populations by two-colour flow sorting {F ACS II) according 
to Jongkind er a/. 10 and assay of neuraminidase. Table 3 
shows a marked increase in neuraminidase activity in the 
combined p-ga\- /neur- Gbroblasts whereas the ML I cells 
remain deficient. We could find no neuraminidase activity in 
the culture medium above the mutant cells and the labelling 
did not affect the enzyme activity. These experiments suggest 
the transfer of an unknown factor from ML I cells to 
fibroblasts with a combined ,8-gal- /neur- deficiency, a factor 
which can increase the neuraminidase activity in the latter cells 
four- to sevenfold. Normal human fibroblasts also secrete this 
'correction factor'. We found no evidence of an activator that 
cou1d act in vitro. for mixing of homogenates of the two kinds 
of cells did not affect enzyme activity. The correction observed 
after hybridization (Table 2) and after co-cultivation (Table 3) 
may represent a normalization of the post-translational 
Table 3 Co-cultivation of different neuraminidase·deficient cell 
strains and enzyme assays after two-colour flow sorting (FACS II) 
Neuraminidase activity 
l x 10-'l mol perh permgprotein) 
Before After 3d 
Cell type 
Classical M L I 
co-cultivation 
0.7 
0.8 
0.7 
co-cultivation 
0.7 
Infantile ,8-gal- /neur-
Mixed cell population 
5.3 
2.9 
Red polystyrene beads were added to the culture medium above 
classical M L I cells, left for 2 days, and cells were collected by 
trypsinization, rinsed and centrifuged {l,OOOr.p.m. for 5-tOmin). The 
same was done with green beads for /3-gal-/neur- fibroblasts. About 2 
x lOb cells of each labelled type were seeded and co~cultivated in 
connuency for 3 days. The two labelled cell populations were then 
separated and collected with a F ACS II cell sorter according to 
Jongkind et af.'t> and neuraminidase activity was .measured as 
described in Table l. The values given are the mean of three 
independent experiments which gave very similar values. 
processing of neuraminidase and /3-galactosidase. It remains to 
be seen how neuraminidase is related to these processes, for 
neuraminidase deficiency can also occur without {3-
galactosidase deficiency. N-acetylneuraminic acid is, however, 
common component of glycoproteins, certain 
glycosaminoglycans and gangliosides 17 •18, and different 
neuraminidases have a role in the degradation of these 
compounds11 • 19 • A better understanding of the nature of the 
neuraminidase deficiency in the various mutant cells might 
resolve the interrelationship with /3-galactosidase deficiency. 
Further characterization of the correction factor is in progress~ 
its heat lability, affinity for concanavalin A and the fact that !-
cells cannot provide it (co-cultivation studies in Table 2) 
suggest that it is a glycoprotein. 
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SUMMARY 
The combined deficiency of S-galactosidase and neuramini-
dase in human fibroblasts can be corrected to nearly normal 
values. This can be accomplished by addition of concentrated 
culture medium obtained after NH 4Cl stimulation of different types of human fibroblasts, including those with an isolated s-
galactosidase or neuraminidase deficiency. The correctige factor 
is a macromolecular glycoprotein, which is labile at 60 C. Its 
uptake by human fibroblasts is competitively inhib!ted by mannose-
6-phosphate and its corrective action within S-gal /neur fibro-
blasts continues during a "chase" of 72 hours. 
INTRODUCTION 
Various patients with skeletal abnormalities, skin lesions, 
retinal cherry-red spot, myoclonus and dementia have been found 
to have a combined deficiency of S-galactosidase and neuramini-
dase (1-4). The nature of this combined lysosomal enzyme defic-
iency has not yet been resolved but complementation studies 
after fusion of different types of human mutant fibroblasts 
indicate that the responsible gene mutation is different from 
that involved in the isolated S-galactosidase deficiency in 
GM1-gangliosidosis (5, 6) and that causing isolated neuramini-
dase deficiency in muc~lipidosis I (4, 7). 
When fibroblasts with a combined deficiency of S-galacto-
sidase and neuraminidase (S-gal-/neur-) were co-cultivated with 
other human fibroblasts, including those with an isolated 
neuraminidase deficiency (neur-), a slight increase of neura-
minidase activity in the S-gal-/neur cells was observed (4). 
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Preliminary experiments suggested that this partial correction 
was due to the uptake of a glycoprotein that is secreted by 
other cells into the culture medium. 
The present studies were carried out to obtain more infor-
mation about the nature of the correction of this combined 
lysosomal enzyme deficiency. 
MATERIALS AND METHODS 
Cell cultivation and analysis 
Human skin fibroblasts were cultivated in Ham's FlO medium 
supplemented with 10% fetal calf serum and antibiotics. Fibro-
blasts from patients with infantile and adult GM1-gangliosidosis 
were kindly provided by Dr. H. Goldman (MontreaT) and Dr. Y. 
Suzuki (Tokyo) respectively. Cells with an isolated neuraminidase 
deficiency were derived from a patient with mucolipidosis I 
(Dr. Bakker, Amsterdam) and two cell strains with a combined 
deficiency of ~-galactosidase and neuraminidase were derived 
from a 2-year-old boy described by Andria et al. (8) and from an 
affected 21-week-old fetus described by Kleijer et al. (3). The 
cells were free of mycoplasm as judged by the method of Chen (9). 
Enzyme analyses were performed after trypsinization, rinsing in 
saline, centrifugation (10 min. 100 g) and lysis in double dis-
tilled water. The activities of ~-galactosidase and neuraminidase 
were assayed with 4-methylumbelliferyl-~-D-galactopyranoside 
(Koch-Light) and 4-methylumbelliferyl-a-D-N-acetylneuraminic acid 
(prepared in Institut fur Biochemie II (Med. Fak.), Universitat 
Heidelberg) . 
To stimulate the secretion of "high-uptake" forms of ~lyco­
proteins, fibroblasts were grown to confluency in a 200 em 
flask, whereafter the growth medium was replaced by 40 ml of. 
serum free medium to which NH 4Cl was added in a final concen-tration of 10 mM. After 2 or 3 days the medium was collected, 
dialyzed against Dulbecco's phosphate buffered saline and con-
centrated on an Amicon PM 10 filter to a final volume of 1 ml 
(concentrate). In case cells with normal ~-galactosidase activ-
ity were used, the ~-galactosidase secreted into the medium 
after NH 4Cl treatment was removed by affinity column chromato-graphy using a p-aminophenylthiogalactoside-CH-sepharose affinity 
matrix (10). 
Correction 
To study the corrective effect an aliquot of 40 ~1 concen-
trated medium after NH 4cl treatment was added to 1 ml of Ham's 
FlO medium supplemented with fetal calf serum and left for a few 
hours up to three days on different types of mutant fibroblasts. 
Correction was also studied by addition of a Concanavalin A 
preparations of human placenta and liver. Concanavalin A - sepha-
rose 4B (Pharmacia, Uppsala) was used according to a procedure 
described earlier (11). After elution at 20°C with 0.75 M a-
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Table I 
EFFECT OF CONCANAVALIN A PREPARATIONS FROM HUMAN PLACENTA AND 
LIVER ON THE ~-GALACTOSIDASE AND NEURAMINIDASE ACTIVITY IN 
NEURAMINIDASE DEFICIENT FIBROBLASTS% 
ENDOGENOUS ACTIVITY AFTER ADDITION OF 
CON.A PREPARATIONS 
~-gal. neur. ~-gal. neur. 
S-GAL-/NEUR - (8) 59.3 1.3 ( 1) 58.7 3.6 
(2) 67.7 5.9 
MUCOLIPIDOSIS I 640 0.4 ( 2) 650 0.3 
~Activities have been measured with 4-methylumbelliferyl substrate 
-9 -1 -1 
and are expressed as 10 .moles.mg .hr . (1) represent? Con.A 
preparation from human liver and (2) from placenta. 
methylglucoside and dialysis against 10 mM Na-phosphate buffer 
pH.7 the preparation was concentrated on an Amicon PM 10 filter 
till a final protein concentration of 15 mg/ml. An aliquot of 
50 ~l of this preparation was added to l ml medium. 
Inhibition of S-galactosidase activity 
Irreversible inhibition of S-galactosidase activity in cul-
tured human fibroblasts was performed by growing cells for 
2 hours in medium containing 0.2 mM S-D-galactopyranosylmethyl-
p-nitrophenyltriazene (S-galMNT) kindly provided by Dr. M. 
Sinnott (School of Chemistry, University of Bristol) according 
to procedures described earlier (12, 13). After refreshing the 
medium, the reappearance of S-galactosidase activity was studied 
during a period of 3 days. 
RESULTS 
Concanavalin A - sepharose 4B (Con.A) preparations of human 
placenta and human liver were added for two days to the medium 
above S-gal-/neur fibroblasts and to cells with an isolated 
neuraminidase deficiency (neur-). The results in Table l show a 
3 to 5 times increase of the neuraminidase activity in S-gal-/ 
110 
Vol. 103, No.1, 1981 BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 
Table II 
EFFECT OF CONCENTRATED "CORRECTIVE FACTOR" ON THE ACTIVITIES OF 
~-GALACTOSIDASE AND NEURAMINIDASE IN DIFFERENT TYPES OF HUMAN 
MUTANT FIBROBLASTS2 
MUTANT CELL STRAlN ~-GALACTOSIDASE NEURAMINIDASE 
endo- after addition endo- after 
genous "corrective genous addition 
factor" "corrective 
factor" 
~-GAL-/NEUR - (8) 64 474 2.2 32 
~-GAL-/NEUR (3) 80 380 1.0 21 
INFANTILE 
GM1-GANGLIOSIDOSIS 5.5 4.5 90 82 
ADULT VARIANT 
GM1-GANGLIOSIDOSIS (15) 65 55 170 172 
MUCOLIPIDOSIS I 610 540 0.5 1.0 
CONTROL FIBROBLASTS 350-1050 43-172 
-
X = 630 x = 82 
2Activities are measured with 4-methylumbelliferyl substrate and 
are expressed as 10-9moles.mg- 1 .hr-1 . The concentrate of 
"corrective factor" in these experiments is prepared from medium 
above GM1-gangliosidosis fibroblasts (infantile type) after 
NH 4Cl stimulation (see Materials and methods). 
neur fibroblasts. This increase cannot be due to uptake of 
neuraminidase, because the activity of neur fibroblasts did not 
increase. Heat inactivation (15' at 100°C) of the Con.A fraction 
abolishes the partial restoration of the neuraminidase activity 
of S-gal-/neur- fibroblasts. These observations suggest that the 
correction factor is a glycoprotein. 
To achieve a more efficient uptake of the correction factor 
another source of glycoproteins was found in media of various 
types of human fibroblasts that were treated with NH 4Cl to 
stimulate the secretion of precursor forms of glycoproteins (14). 
The medium containing these "high-uptake" forms of glycoproteins 
was then concentrated and dialyzed on an Amicon pM 10 filter, 
to remove most of the molecules with a molecular weight lower 
than 20 x 10 3 . The concentrated medium obtained in this way was 
111 
Vol. 103, No.1, 1981 BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 
Fig. 1 
B- GALACTOSIDASE 
ACTIVITY 
(lo-9 mol.,s. mg-1.hr-1) 
200 
150 
100 
so 
., 0-GAL-/NEUR-(+) 
CONTROL (+) 
CONTROL (-) 
..-• 0- GAL- I NEUR- (+) 
11-GAL-/NEUR-(-) 
0 20 40 60 80 
HOURS AFTER B- GAL INHIBITION 
CORRECTION FOR a-GALACTOSIDASE ACTIVITY IN a-GAL-/NEUR-
FIBROBLASTS. 
After irreversible inhibition of a-galactosidase with 
a triazene analogue the reappearance of_a-gal~ctosi­
dase was studied in two different a-gal /neur cell 
strains with and without addition of "corrective 
factor" prepared from 1!\edium above GM1-gangliosidosis fibroblasts after NH 4cl stimulation. 
0 a-gal-/neur fibroblasts (8) 
0 a-gal-/neur- fibroblasts (3) 
1::.. normal fibroblasts. 
Closed symbols represent the activity of a-galactosi-
dase in the same cell strains but after addition of 
"corrective factor". 
added to the culture medium above various types of human mutant 
fibroblasts and left for 2-3 days. Table II summarizes the effect 
of concentrate on the ~-galactosidase and neuraminidase activity 
in the different cell types. There was no effect on fibroblasts 
with an isolated ~-galactosidase deficiency (S-gal-) nor on neur 
cells. In two different strains of S-gal-/neur- fibroblasts, 
however, the activity of both S-galactosidase and neuraminidase 
increases markedly and approaches low control values. In the 
experiment illustrated in Table II concentrated medium containing 
"corrective factor" was prepared from NH 4cl stimulated medium of 
GM1-gangliosidosis fibroblasts (S-gal-), but similar results were 
obtained with concentrates from normal and mucolipidosis I media. 
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Addition of mannose-6-phosphate (1 roM) interferes with the 
reappearance of a-galactosidase and neuraminidase activities in 
a-gal-/neur cells after addition of "corrective factor". Heat 
treatment (15 min. at 60°C) of the corrective factor results in 
a complete loss of its effect, but at 50°C correction is still 
retained (data not shown) . 
The reappearance of newly synthesized a-galactosidase mole-
cules after correction of a-gal /neur cells could be studied 
with the use of an irreversible inhibitor of a-galactosidase (10, 
12, 13). Addition of this inhibitor to the medium above a-gal I 
neur fibroblasts results in a 94% inhibition of the residual 
a-galactosidase activity. Fig. 1 shows the reappearance of a-
galactosidase activity during 65 hours after removal of the 
inhibitor. In a-gal-/neur cells the a-galactosidase activity 
reaches its original value within 24 hours and subsequently 
levels off. When a concentrate of "corrective factor" was added, 
however, the activity of a-galactosidase continues to progress as 
in control fibroblasts. The reappearance of a-galactosidase activ-
ity in control fibroblasts is not affected by addition of "cor-
rective factor". 
In subsequent experiments "corrective factor" was added to 
the medium above a-gal-/neur cells during 16 hours followed by 
a chase of 72 hours (Fig. 2). The intracellular increase of both 
neuraminidase and a-galactosidase activity was found to continue 
during 3 days after removal of the "corrective factor" from the 
medium. In contrast, medium from a-gal-/neur fibroblasts, pre-
pared in the same way, had no effect on the intracellular activ-
ities of a-galactosidase or neuraminidase in the mutant cells. 
DISCUSSION 
The complementation for a-galactosidase after fusion of 
different types of human a-galactosidase deficient cell strains 
(5) was surprising in view of the fact that normal human a-galac-
tosidase consists of one polypeptide of about 70,000 m.w. which 
also occurs in an aggregate of molecular weight 700,000 (16). 
Later, Wenger et al. (1) found a coexistent deficiency of neura-
minidase in one of their atypical patients with S-galactosidase 
deficiency. Fibroblasts from several other patients were sub-
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sequently found to have this combined ~-galactosidase/neuramini­
dase deficiency (2, 4) . Analysis of interspecies and intraspecies 
hybrids, Hoeksema et al. (17, 18) showed that the isolated S-
galactosidase deficiency in classical forms of GM1-gangliosidosis 
is due to a structural mutation in the gene on chromosome 3 
coding for the S-galactosidase polypeptide chain. In variants, 
later identified as S-gal-/neur-, the residual S-galactosidase 
activity consists of the monomeric form of S-galactosidase and 
aggregation to higher molecular weight forms seems to be impaired. 
Using an irreversible inhibitor of S-galactosidase, van 
Diggelen et al. (10) observed that the turnover time of S-galac-
tosidase in normal human fibroblasts and in GM1-gangliosidosis 
cells is about 10 days whereas that in S-gal-/neur- fibroblasts 
is reduced to less than 1 day. This was found to be due to 
enhanced degradation of S-galactosidase in these mutant cells 
( 10) . 
In co-cultivation studies the neuraminidase activity of 
S-gal-/neur- cells increased 5-7 fold as a result of transfer of 
a •corrective factor" secreted by other fibroblasts including 
those with an isolated neuraminidase deficiency (4). In the 
present study a similar effect was found after addition of a 
Con.A preparation of human liver or human placenta to medium above 
S-gal-/neur cells. In both instances only a partial restoration 
of neuraminidase activity (up to 10-15% of control values) and 
none of S-galactosidase occurs. When concentrates of culture media 
from NH4cl stimulated fibroblasts are used, however, a complete 
restoration of the activity of both neuraminidase and S-galacto-
sidase in S-gal-/neur cells is achieved. The rate of reappearance 
of S-galactosidase in S-gal-/neur fibroblasts in the presence of 
corrective factor (Fig. 1) is similar to that in control fibro-
blasts. 
The corrective factor or its precursor form is secreted by 
various types of human fibroblasts including those from GM1-
gangliosidosis (S-gal-) and mucolipidosis I (neur-). No correc-
tion is obtained with concentrate prepared from medium after 
NH4cl stimulation of S-gal-/neur fibroblasts. This points to the 
specific nature of the corrective factor. The experimental 
results presented indicate that the corrective factor is a macro-
molecular glycoprotein, excluded by an Amicon PM ]0 filter, which 
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Fig. 2 
ENZYME ACTIVITIES 
( x 10-9 moles. mg -1. hr-1) 
13- GALACTOSIDASE NEURAMINIDASE 
400 40 
300 30 
200 
100 
/ 
/ 
/ 
/ 
I 
I 
--------x----0: 
o t"chase"zo 40 60 80 
HOURS AFTER REMOVAL OF CORRECTIVE 
FACTOR FROM THE MEDIUM 
ACTIVITIES OF S-GALACTOSIDASE AND NEURAMINIDASE IN 
S-GAL-/NEUR- FIBROBLASTS AFTER ADDITION AND "CHASE" OF 
CORRECTIVE FACTOR. 
During a period of 16 hours corEectiv~ factor was 
added to the medium above S-gal /neur fibroblasts. 
Subsequently a "chase" was carried out during 72 hours 
and the intracellular activities of S-galactosidase 
(full line) and neuraminidase (dotted line) were 
measured. 
0 and ,6. represent activities after addition of 
corrective factor prepared from medium 
above G 1-gangliosidosis cells after NH 4Cl stimula~~on. , 
8 and .A represent activiti~s aft~r addition of 
medium above S-gal /neur cells, treated 
in the same way. 
is stable at S0°C but loses its activity at 60°C. I-cell secreted 
glycoproteins which are not phosphorylated, are not taken up by 
other fibroblasts (19). Our observation that I-cell medium cannot 
correct S-gal-/neur fibroblasts (4) is in agreement with the 
phosphoglycoprotein nature of the "corrective factor" described 
in the present paper.' This is also supported by the fact that 
mannose-6-phosphate inhibits the uptake of the "corrective factor" 
(14, 20, 21, 22)-
The finding that the S-galactosidase and neuraminidase 
activities in S-gal-/neur cells continue to increase after 
removal of the corrective factor from the medium (Fig. 2) might 
point to a (lysosomal) enzymic nature of the corrective factor. 
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Molecular defect in combined /3-galactosidase and neuraminidase 
deficiency in man 
(precursor /3-galactosidase/leupeptin/ corrective factor) 
A. D'Azzo, A. HooGEVEE:\, A. J. J. REUSER, D. RoBINso:-.:*, AND H. GALJAARD 
Department of Cell Biology and Genetics, :\fedical Faculty, Erasmus University, Rotterdam, the :t\etherlands 
Communicated by Victor A. McKusick, April 5, 1982 
ABSTRACT In normal human fibroblasts, an enzymically ac-
tive 85,000-dalton precursor form of /J-galactosidase is processed, 
via a number of intermediates, into a mature 64,000-dalton form. 
In addition there is an enzymically inactive 32,000-dalton com-
ponent and its 54,000-dalton precursor. In fibroblasts from pa-
tients with a combined deficiency of /J-galactosidase and neur-
aminidase these last two components are absent and hardly any 
mature /J-galactosidase can be demonstrated. Nevertheless, in the 
mutant fibroblasts, precursor /1-galactosidase is synthesized and 
processed normally. The excessive intralysosomal degradation 
that is responsible for the deficiency of mature /J-galactosidase 
can be partially corrected by addition of the protease inhibitor 
leupeptin, which results in the accumulation of85,000-dalton pre-
cursor /J-galactosidase and of a partially processed 66,000-dalton 
form. \.Yhen mutant cells were grown in the presence of a "cor-
rective factor" purified from the medium of NH4Cl-stimulated 
cell cultures, both p-galactosidase and neuraminidase activities 
were restored to low control levels. The immunoprecipitation pat-
tern was completely normal after addition of the corrective factor, 
and mature 64,000-dalton /J-galactosidase accumulated in the 
mutant fibroblasts. We propose that the combined /J-galactosi-
dase/neuraminidase deficiency is caused by a defective 32,000-
dalton glycoprotein which is normally required to protect /J-ga-
lactosidase and neuraminidase against excessive intralysosomal 
degradation and to give these enzymes their full hydrolytic 
activity. 
Acid j3-galactosidase in human liver (1) and cultured fibroblasts 
(2) consists of a 70,000-dalton (Dal) monomeric form and an ag-
gregate of the same polypeptide (600,000-800.000 Dal). Since 
the observation bv Okada and O'Brien (.3) that the autosomal 
recessive disease G,wgangliosidosis is due to a j3-galactosidase 
deficiency, various patients with infantile, juvenile. and adult 
forms of this disease have been reported (4-7). Analyses of in-
terspecies hybrids indicated that the j3-galactosidase deficiency 
in the various forms of G,wgangliosidosis is based on a mutation 
of a structural gene on chromosome 3 coding for the enzyme 
polypeptide (8). 
A number of patients have been described with a coexistent 
deficiency of j3-galactosidase and neuraminidase (6. 7. 9, 10). 
Previous studies on fibroblasts from these types of patients had 
shown that the 10-15% residual j3-galactosidase had normal 
kinetic properties (11) and that the aggregation of monomeric 
j3-galactosidase was impaired (2). No evidence for a mutation 
of the structural locus was found (8). 
Neuraminidase deficiencY, however, also can occur without 
any abnormality of j3-galactosidase, as in various types of pa-
tients with sialidosis (mucolipidosis I) (12-15). Complementa-
tion studies after somatic cell hybridization (10) indicated that 
The publication costs of this article were defrayed in part by page charge 
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three different gene mutations are responsible for the enzyme 
deficiencies in G,wgangliosidosis [j3-galactosidase deficiency 
(j3-ganJ. sialidosis [neuraminidase deficiency (neur-)], and 
combined j3-galactosidase and neuraminidase deficiency ()3-
gal-/neur-). 
The turnover time of j3-galactosidase has been measured in 
different cell strains (16, 17). In normal fibroblasts and in G,11-
gangliosidosis cells, the enzyme has a half-life of approximately 
10 days, whereas in j3-gal-/neur- fibroblasts it is <24 hr. Sub-
sequent studies revealed that this reduction is due to enhanced 
degradation of j3-galactosidase; the enzyme is synthesized at a 
normal rate (18). It was also shown that both the /J-galactosidase 
and neuraminidase activities in p-gal-/neur- fibroblasts could 
be restored by a "corrective factor" of a glycoprotein nature that 
is produced by normal fibroblasts and other mutant cells, in-
cluding G,11-gangliosidosis fibroblasts (19). Because the latter 
contain no measurable amount of j3-galactosidase, a convenient 
source of this factor is the medium obtained when these mutant 
cells are cultured in the presence of ammonium chloride which 
diverts newly synthesized precursor forms of glycoproteins into 
the medium, thus enhancing their secretion (20-22). 
In this paper we examine the molecular nature of the genetic 
defect responsible for )3-gal-/neur-. Using immunoprecipita-
tion studies on radiolabeled j3-galactosidase and related com-
ponents, we demonstrate the sequence of events involved in 
the processing of mature j3-galactosidase from its precursor 
forms in control and mutant fibroblasts. We also show the mo-
lecular background of leupeptin inhibition of the excessive deg-
radation of j3-galactosidase in j3-gal-/neur- cells and that of full 
correction by addition of the putative factor. 
MATERIALS AND METHODS 
Cell Culture. Human skin fibroblasts were maintained in 
Ham's FlO medium (Flow Laboratories, :;1cLean, VA) supple-
mented with 10% fetal calf serum and antibiotics. Fibroblasts 
from patients with the infantile or adult form of G,wganglio-
sidosis were kindly provided by H. Goldman (:'v!ontreal) andY. 
Suzuki (Tok-yo), respectively. Cells with isolated neur- were 
derived from a patient with classical mucolipidosis I (sialidosis) 
(from H. D. Bakker. Amsterdam). Two cell strains with j3-gal-/ 
neur- were obtained from patients described earlier (23, 24). 
Preparation and Assay of NH,Cl-Induced Secretions. Nor-
mal culture medium above confluent cultures was replaced by 
serum-free medium supplemented with NH4Cl at a final con-
centration of 10 m:V!. Two days later the medium was collected 
Abbreviations: f3-gal-, f3-galactosidase deficiency or deficient; ,(3-gal- / 
neur-, ,8-galactosidase and neuraminidase deficiency or deficient: 
neur-, neuraminidase deficiencv or deficient; Dal, dalton. 
*Permanent address: Dept. Biochemistry, Queen Elizabeth College, 
University of London. 
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and centrifuged (90 X g, 5 min) and enzymic activities were 
measured in 20-j.Ll aliquots. The cells were harvested by tryp-
sinization; rinsed in saline, and disrupted in distilled water. 
Enzymic analyses were carried out by using the appropriate 4-
methylumbelliferyl substrates (Koch-Light) as described by 
Galjaard (25). Activities measured in 1 ml of culture medium 
are derived from approximately 106 fibroblasts corresponding 
to 0.3 mg of cellular protein. 
Enzyme Purification. Fibroblasts were grown to confluency 
in 200-cm2 flasks and subcultured for 2 days in 40 ml of serum-
free medium containing 10 mM l\H4Cl. The medium was col-
lected and ultrafiltered to approximately 5 ml on an Amicon 
PM10filter; then its pH was adjusted to 5.2with20m:\1 sodium 
acetatel0.1 :\1 1\aCI. The concentrate was applied to a 2.5-ml 
p-aminophenyl thiogalactoside-CH -Sepharose affinity matrix 
(17). The column was washed with 20 mM sodium acetate, pH 
5.211 M NaCl and eluted with 20 mM sodium acetate, pH 5.21 
0.5 M NaCl containing 0.1 M y-galactonolactone. The eluate 
was dialyzed against Dulbecco's phosphate-buffered saline and 
concentrated on an Amicon PM10 filter to a final volume of 
about 1 mi. The whole procedure was performed at 4'C. 
Gel filtration studies of {3-galactosidase were carried out on 
Sephracryl S-200 as described by Hoeksema et al. (2). 
Uptake Studies. Cells were seeded at near confluency in 24-
well plates (Costar) and cultured for 3-4 days. The purified {3-
galactosidase (2.5 X 10-s unit) was added to the medium (1 unit 
hydrolyzes 1 ,u.mol of 4-methylumbelliferyl-{3-D-galactopyran-
oside per min). After 16-hr incubation in the presence of ex-
ogenous enzyme, the cells were cultured in fresh medium for 
2 days prior to analysis. Where appropriate mannose 6-phos-
phate was used at a final concentration of 1 m:\1. 
Immunoprecipitation of Labeled /3-Galactosidase. This was 
carried out by using purified specific immunoglobulins im-
mobilized to Sepharose-4B beads. The rabbit antiserum used 
for their production was raised against a highly purified human 
placental {3-galactosidase prepared by affinity chromatography. 
It was virtually homogeneous and showed one 64,000-Dal band 
on polyacrylamide gel electrophoresis, corresponding to the 
k-nown size of mature human {3-galactosidase with traces of a 
smaller molecule (30,000 Dal). The amount of coupled IgG that 
precipitated 95% of the {3-galactosidase in the cells was judged 
from a previously determined enzyme activityllgG ratio. 
Normal and mutant fibroblasts were grown in 75-cm2 flasks 
for 2 weeks, to a cell density equivalent to 1. 5 mg of protein per 
flask. At 3-4 days before labeling, Ham's FlO medium was re-
placed by Dulbecco's modification of Eagle's medium (Flow 
Laboratories, McLean, VA) supplemented with 10% fetal calf 
serum and antibiotics. Prior to labeling, the cultures were 
rinsed and incubated for 1 hr with 6 ml of the medium free of 
leucine to induce the depletion of the intracellular leucine pool. 
The labeling medium (6 ml) was this same medium supple-
mented with 0.2 ml of dialyzed fetal calf serum and 0.2 ml of 
L -[4,5-3H]leucine (0.2 mCi; 135 Ci/mmol; Alllersham Radio-
chemical Center; 1 Ci = 3. 7 X 1010 becquerels). After incu-
bation in the presence of the label, the cells were harvested and 
processed according to the method of Hasilik and 1\ eufeld (20). 
Polyacrylamide Gel Electrophoresis and Fluorography. 
Electrophoresis in the presence of NaDodS04 was performed 
on 12% slab gels according to Laemmli (26), except that the 
ratio of acrylamide to methylene-bisacrylamide was changed to 
30:0.312. The gels were prepared for fluorography as described 
(27). [14C]methyl-labeled protein molecular weight standards 
(from Amersham Radiochemical Center) were: phosphorylase 
B, 92, 000; bovine serum albumin, 69, 000; ovalbumin, 46, 000; 
carbonic anhvdrase, 30,000. 
Protease I~hibition. In these experiments leupeptin (Sigma) 
Proc. Natl. Acad. Sci. USA 79 (1982) 
was included in the medium above normal and mutant fibro-
blasts at a final concentration of 0.02 mM. The incubation pe-
riod varied between 2 and 5 days. 
Correction Studies. The corrective factor from GM 1-ganglio-
sidosis fibroblasts was prepared as described (19). {3-gal-I 
neur- fibroblasts were incubated with concentrated corrective 
factor for 2 days in the presence of [3H]leucine and the radio-
labeled products were then examined by NaDodS04 electro-
phoresis. 
RESULTS 
Because the {3-galactosidase deficiency in {3-gal-I neur-cells is 
due to enhanced degradation (7, 17), the effect ofleupeptin, a 
thiol protease inhibitor, was studied. Addition of 0.02 mM leu-
peptin to the culture medium for 5 days resulted in an increase 
in {3-galactosidase activity from 40 and 47 nmol/hr per mg of 
protein in two different {3-gal-lneur- cell strains (from patients 
described in refs. 23 and 24) to 305 and 315 nmol/hr per mg. 
This is a restoration to low control levels (activity range in nor-
mal fibroblasts is 350-1,050). The effect ofleupeptin on neur-
aminidase activity was less clear. Only in one cell strain (23) was 
there a significant increase and that only reached 10% of normal 
levels. 
In medium from cultures of normal and different types of 
mutant fibroblasts, hardly any {3-galactosidase activity could be 
detected (0.3-0.4 nmol/hr per ml). Addition of KH4Cl in-
creased the extracellular {3-galactosidase activity to 10-14nmol/ 
hr per ml for both {3-gal-lneur- fibroblasts and control cells. 
Such increase did not occur for Gs11-gangliosidosis fibroblasts. 
Neuraminidase activitv could not be detected in the medium 
from any of the cells iested. The ahility of ,6-gal-lneur- cells 
to synthesize {3-galactosidase precursor therefore is not impaired. 
This extracellular {3-galactosidase was purified from both nor-
mal and {3-gal-lneur- culture media by affinity chromatogra-
phy. Comparison of the two preparations showed them to be 
identical with regard to a number of criteria. 
Gel filtration studies indicated an apparent size of 80,000-
90,000 Dal, consistent with this being the precursor form of the 
enzyme. Both samples had a pH optimum of 3.9 and a Km of 
1.4 mM, compared to values of 4.3 and 0.25 m.VI for the mature 
intracellular enzvme. 
Both preparaiions were taken up from medium from G" 1-
gangliosidosis fibroblasts, and this uptake could be strongly in-
hibited by 1 m.VI mannose 6-phosphate (Table 1). A similar 
amount of {3-galactosidase was ingested after a 16-hr incubation 
period when either preparation was used, and the levels in the 
recipient cells remained unchanged when cultured for a further 
48 hrin fresh medium. However, when purified {3-galactosidase 
precursor from control fibroblasts was administered to {3-gal-I 
neur- fibroblasts, no increase in enzyme activity could be de-
tected after a 16-hr incubation. The excessive degradation of {3-
galactosidase in {3-gal-lneur- cells therefore is not due to ob-
vious mutant properties of the {3-galactosidase precursor. 
In order to study possible molecular differences in the en-
zyme components. immunoprecipitation was carried out on ra-
diolabeled normal and mutant cells and on media collected from 
the different cultures after l\H4Cl treatment. The constituent 
polypeptides were then examined by gel electrophoresis under 
reducing and denaturing conditions. 
Control Fibroblasts. After incubation for 24 hr in the pres-
ence of [3H]leucine, control fibroblasts showed four radiola-
beled immunoprecipitable components (Fig. 1). Two of these 
corresponded to the components of the placental preparations 
that showed a prominent 64,000-Dal form and traces of a 32,000-
Dal form in Coomassie blue-stained gels. The 85,000-Dal pre-
cursor form that was also seen and the 64,000-Dal mature {3-
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Table 1. Uptake of Jl-galactosidase precursor purified from control medinm and Jl-gal-/neur- medium by human 
mutant fibroblasts 
Cell strain 
Jl-gal-* 
Incubation 
16 hr 
16 hr followed by 
48-hr chase 
16 hr in presence 
of 1 mM Man-6-P 
16hr 
* From GM1-gangliosidosis. 
No addition 
3.7 
3.3 
3.0 
40.5 
tEach value is the mean of two or three separate experiments. 
galactosidase were enzymically active. The 51.000- and 32,000-
Dal components were inactive, as can also be deduced from 
their presence in G",-gangliosidosis fibroblasts which have less 
than 1% enzyme activity (unpublished data). After NH4Cl stim-
ulation the immunoprecipitable forms in the medium had ap-
parent sizes of 88,000 and 54,000 Dal but the cells lacked the 
64,000- and 32,000-Dal components. This suggests that the 
medium forms are precursors of the mature 64,000-Dal (3-ga-
lactosidase and of the enzymically inactive 32,000-Dal 
component. 
The sequence of events and the relationship among these 
different constituents were clarified in pulse-chase experi-
ments. After a 3-hr pulse, almost all immunoprecipitable ra-
dioactivity was present in the 85,000-Dal form of (3-galactosid-
ase (Fig. 1). After a 5-hr chase this band disappeared and 
transient intermediates gave rise to the 64,000-Dal mature form 
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FIG. 1. NaDodS04/polyacrylamide gel electrophoresis of Jl-galac-
tosidase from normal fibroblasts and culture medium immunoprecip-
itated with antisernm after [3H]Ieucine labeling. Lanes: A, placental 
Jl-galactosidase (40 l'g) stained with Coomassie blue; B, radiolabeled 
marker proteins; C, control fibroblasts labeled for 24 hr; D, control fi-
broblasts labeled for 24 hr in the presence of NH4CI; E, medium from 
control cells labeled for 24 hr in the presence of NH4CI. Lanes F-I show 
pulse labeling of Jl-galactosidase from control fibroblasts: F, 3-hr la-
beling; G, 3-hrs labeling followed by 5-hr chase in the presence of un-
labeled leucine; H, 3-hr labeling and 20-hr chase; I, 3-hr labeling and 
70-hr chase. Nnmbers show sizes in kDal. 
,B-Galactosidase activity, nmolfhr/mg proteint 
With 
Jl-galactosidase from 
control medium 
13.0 
12.6 
3.9 
42.0 
With 
Jl-galactosidase from 
Jl-gal-/neur- medinm 
15.1 
14.5 
3.8 
39.5 
that was fully established over a period of 3 days. The 32,000-
Dal component, which was not seen after the 3-hr pulse. be-
came evident after the shortest period of chase with a concom-
itant disappearance of a 54,000-Dal component. A 51,000-Dal 
component was visible during the whole period of the pulse-
chase experiment. 
f:l-gal-/neur- fibroblasts. Corresponding immunoprecipi-
tation e'Jleriments with radiolabeled (3-gal-/neur- fibroblasts 
showed clear differences from control cells. Intracellularlv. the 
mature 64,000-Dal (3-galactosidase was barely visible au'd the 
32,000-Dal component was absent (Fig. 2). As with the controls, 
85,000- and 51,000-Dal bands were visible. After NH4Cl stim-
ulation the intracellular pattern remained unchanged. Extra-
cellularlv. unlike the control, the 54,000-Dal band was absent 
and the .onlv detectable constituent was 88,000 Dal. 
In pulse.:_chase experiments on (3-gal-/neur- cells the la-
beling pattern after 3 hr was similar to that in control cells. After 
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FIG. 2. NaDodS04/polyacrylamide gel electrophoresis of Jl-galac-
tosidase from Jl-ga]· /neur- fibroblasts and culture medium immu-
noprecipitated with antisernm after [3H]Ieucine labeling. Lanes: A, 
radiolabeled marker proteins; B, Jl-gal- /neur- cells labeled for 24 hr; 
C, Jl-gal-/neur- cells labeled for 24 hr in the presence of NH.Cl; D, 
medium from Jl-ga]· /neur· cells labeled for 24 hr in the presence of 
NH.CI. Lanes E-H show pulse labeling of Jl-galactosidase from Jl-ga]· I 
neur- fibroblasts: E, 3-hr labeling; F, 3-hr labeling followed by 5-hr 
chase; G, 3-hr labeling and 20-hr chase; H, 3-hr labeling and 70-hr 
chase. 
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a 5-hr chase, when 85,000-Dal precursor f3-galactosidase was 
still present, a 66,000-Dal form appeared (Fig. 2). Subse-
quently, both these bands disappeared but, unlike with the con-
trols, mature 64,000-Dal f3-galactosidase did not accumulate in 
siguificant quantity. Another feature was the absence of the 
32,000-Dal component in f3-gal-/neur- cells during the whole 
period of chase, whereas the 51,000-Dal band was visible, as 
in controls. 
Treatment with leupeptin led to an accumulation of both 
85,000-Dal precursor f3-galactosidase and of a partially pro-
cessed 66,000-Dal form in f3-gal-/neur- cells and in control 
fibroblasts (Fig. 3). 
Addition of the corrective factor (19) had an effect quite dif-
ferent from that of leupeptin: a complete normalization of the 
f3-galactosidase labeling pattern occurred (Fig. 3). There was 
no accumulation of precursor form but instead, as in control 
cells, this was rapidly converted to the mature 64,000-Dal /3-
galactosidase whicb seemed to be resistant to excessive intra-
lysosomal degradation. 
DISCUSSION 
Previous studies (2. 7. 17) indicated that the 10-15% residual 
f3-galactosidase activity in f3-gal-/neur- fibroblasts has normal 
properties but that there is an excessive intralysosomal degra-
dation of f3-galactosidase. shortening its half-life to about 
!/10th (17, 18). The present paper shows that. in normal human 
fibroblasts, mature 64,000-Dal f3-galactosidase is produced via 
an 85,000-Dal precursor form. Similar observations have been 
made for f3-galactosidase in mouse macrophages (28). We have 
shown that in /3-gal-/neur- fibroblasts the 85.000-Dal form is 
synthesized normally and that all properties tested are similar 
85 
66 
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32 
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FIG. 3. Effects ofleupeptinandcorrectivefactoron the NaDodS04 / 
polyacrylamide gel electrophoresis patterns of immunoprecipitated 
radiolabeled ,13-galactosidase from control fibroblasts and ,13-gal-/ 
neur- cells. Lanes: A, radiolabeled marker proteins; B, control fibro· 
blasts; C, control fibroblasts plus leupeptin; D, ,13-gal-/neur- cells; E, 
Jl-gal-/neur- cells plus leupeptin; F, Jl-gal-/neur- fibroblasts plus 
corrective factor. The cells were grown in the presence of leupeptin or 
factor for 2 days. 
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to those of precursor f3-galactosidase in control cells. The ex-
cessive degradation of f3-galactosidase in ,13-gal-/neur- fibro-
blasts therefore cannot be due to ao abnormality of the pre-
cursor fonn. 
In immunoprecipitation studies the main mutaot character-
istics of f3-gal-/neur- cells are a decreased amount of mature 
f3-galactosidase and the absence of a nonenzymic 32,000-Dal 
component. Pulse-chase experiments in the mutant cells dem-
onstrated conversion of the 85,000-Dal precursor to a 66,000-
Dal form. Both forms disappear within 20 hr without the ap-
pearance of the mature 64,000-Dal f3-galactosidase, which be-
came apparent in control cells. 
Addition of leupeptin to both normal and f3-gal-/neur- fi-
broblasts results in ao increase of the 85, 000-Dal precursor and 
of the 66,000-Dal form. This suggests that during normal pro-
cessing the 85.000-Dal precursor may be degraded to some 
extent by intralysosomal proteases. The accumulation of the 
66,000-Dal form possibly is due to leupeptin inhibition of the 
last maturation step to the 64,000-Dal form [like /3-hexosamini-
dase (29)]. In experiments not reported here we found that the 
effect of the corrective factor was not inhibited by leupeptin. 
It is therefore unlikelv that this factor is involved in this final 
maturation step. Inst;ad. the corrective factor seems to protect 
f3-galactosidase monomer against excessive degradation aod. at 
the same time, enables its aggregation into the high molecular 
weight forms that were absent from /3-gal-/neur- fibroblasts 
(2). 
Our immunoprecipitation studies demonstrate complete lack 
of a 32,000-Dal component that is present in control cells (Figs. 
1 and 2) and in other mutant cells (unpublished data). Similarly. 
in the culture medium of f3-gal-/neur- cells a 54,000-Dal com-
ponent is absent. Together with the results of pulse-chase ex-
periments. this indicates that the latter larger form is a pre-
cursor of the 32,000-Dal component. The exact relationship 
between intracellular 51.000- and 54,000-Dal forms is not vet 
understood. Keither of them has f3-galactosidase activity but 
apparently they are copurified with the precursor and mature 
forms of f3-galactosidase. 
We propose that the 32.000-Dal component is the genetically 
defective factor causing the combined f3-galactosidase/neur-
aminidase deficiencY and is identical to the corrective factor 
described by Hooge~een et al. (19). It is able to convert the /3-
galactosidase labeling pattern completely to normal (Fig. 3). 
Unlike leupeptin, it allows complete processing of the precur-
sor form to a 64,000-Dal mature f3-galactosidase which can ac-
cumulate normallv. 
The 32.000-Dai glycoprotein lacking in ''I-ce!!" disease (19) 
apparently plays a role in a final intralysosomal step leading to 
protection of f3-galactosidase against excessive proteolytic deg-
radation. It also stabilizes neuraminidase but, unlike the case 
with f3-galactosidase. the presence of the 32,000-Dal glycopro-
tein seems to be essential to neuraminidase's catalytic activity. 
After our report that leupeptin results in an increased activity 
of both f3-galactosidase and neuraminidase in one cell strain 
(7). Suzuki et al. (30) did not find an effect of protease inhibition 
on neuraminidase in cells from their /3-gal-/neur- patients. 
These observations and our analvses of the corrective factor in 
different types of f3-gal-/neur- ·fibroblasts (unpublished data) 
point to molecular heterogeneity within this group of patients. 
It may well be that the 32,000-Dal glycoprotein is normally 
required to unite f3-galactosidase monomers and neuraminidase 
in a complex attached to the lysosomal membrane. Further 
studies on the nature of this mutation which affects the protec-
tion of lysosomal enzymes against the aggression of neighboring 
"colleague enzymes" are likely to give more insight in the nor-
mal cell biology of lysosomal enzymes. 
Biochemistry: D' Azzo et al. 
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Cultured skin fibroblasts from patients with the ly-
sosomal storage disease galactosialidosis lack a 54-kDa 
protein which is a precursor of 32-kDa and 20-kDa 
proteins, which immunoprecipitate with human anti-
~-galactosidase antiserum. The lack of a 32-kDa "pro-
tective protein" results in a combined deficiency of P-
galactosidase and sialidase. The mechanism of protec-
tion of lysosomal ~-galactosidase against proteolytic 
degradation is elucidated by sucrose density gradient 
centrifugation and immunoprecipitation studies. In 
normal fibroblasts at the low intralysosomal pH, more 
than 85% of ~-galactosidase exists as a high molecular 
weight (600-700 kDa) multimer and about 10% as a 
monomer of 64-kDa. In mutant cells from galactosiali-
dosis patients, the residual enzyme activity, about 10%, 
is present as a monomer and no multimer exists. After 
addition of the 54-kDa precursor form of the protective 
protein, the density pattern of ~-galactosidase in gal-
actosialidosis cells is normalized. Immunoprecipitation 
studies after sucrose density gradient centrifugation 
on homogenate and on purified ~-galactosidase from 
normal fibroblasts show that the protective protein is 
associated only with the multimeric form of ~-galac­
tosidase. We propose that intralysosomal protection 
against proteolysis of ~-galactosidase and sialidase is 
accomplished by aggregation into a high molecular 
weight complex consisting of multimeric ,8-galactosid-
ase, sialidase, and protective protein. The genetic de-
ficiency of the latter, as in galactosialidosis, results in 
a rapid degradation of monomeric ~-galactosidase and 
a loss of sialidase activity. 
The lysosomal enzyme 1)-D-galactosidase (EC 3.2.1.23) cat-
alyzes the hydrolysis of the 1)-D-galactosyl moiety from GM,-
ganglioside.1 asialo-G,wganglioside, galactose containing gly-
cosaminoglycans, and a variety of synthetic substrates (1, 2). 
Genetic deficiencies in man involving f)-galactosidase have 
been found in patients with different types of lysosomal 
storage disease; biochemical and genetic studies of cultured 
skin fibroblasts from such patients have contributed to our 
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understanding of both the normal and mutant enzyme (for 
reviews, see Refs. 2-4). 
In normal human tissues and cultured cells, active lysoso-
mal (3-galactosidase exists as a monomeric form with a molec-
ular mass of 64-kDa and a high molecular mass aggregate of 
the same polypeptide of approximately 700-kDa (5, 6). In 
purified preparations from human placenta (7) and porcine 
spleen (8), additional proteins with a molecular mass of 31-
kDa and 21-kDa have been designated as contaminants. Re-
cently, d'Azzo et al. (9) reported the absence of these latter 
proteins in cells from patients with galactosialidosis, an au-
tosomal recessive inherited lysosomal storage disease which 
is associated with a coexistent deficiency of (3-galactosidase 
and sialidase (10, 11). The same investigators also showed 
that the lack of these 32-kDa and 20-kDa proteins leads to 
enhanced intralysosomal degradation of I)-galactosidase. It 
was postulated that in normal cells a 32-kDa protective pro-
tein is required to protect ~-galactosidase against the action 
of intralysosomal proteases (9). 
The purpose of the present study was to investigate the 
relationship between the protective protein(s) and the absence 
of the high molecular weight form of !l-galactosidase which 
was previously found in cells from galactosialidosis patients 
(6). Using sucrose density gradient centrifugation followed by 
immunoprecipitation studies with anti-I)-galactosidase anti-
serum, we show that the 32-kDa and 20-kDa protective pro-
teins are derived from a 54-kDa precursor protein and that 
these proteins are essential for the aggregation of monomeric 
I)-galactosidase. When I)-galactosidase is not aggregated into 
a high molecular weight form, it is rapidly degraded by lyso-
somal cathepsins. The functional significance of this obser-
vation is discussed. 
EXPERIMENTAL PROCEDURES 
Preparation of Cell Materials-Human skin fibroblasts from a 
normal individual and from a patient with galactosialidosis described 
by Kleijer et al. (12) were obtained from the Rotterdam Cell Reposi-
tory (Dr. M. F. Niermeijer). The cells were cultivated in Ham's FlO 
medium (Flow Laboratories, McLean, VA) supplemented with 10% 
fetal calf serum and antibiotics (Gibco). Early passages of the cell 
strains were grown in 75 cm2 Falcon flasks to a density of 1 to 2 mg 
of protein/flask. The cells from one flask were harvested by trypsin-
ization, rinsed in saline, and centrifuged (10 min at 90 X g) as reported 
earlier (13). The cell pellet was lysed by suspending in 100 ,ul of 20 
mM Na phosphate, pH 6.0, containing 100 mM NaCl and 1% (w/v) 
Zwitterionic detergent 3-12 (Calbiochem) (Buffer A). This sample is 
centrifuged at 10,000 rpm during 10 min at 4 ~c. The supernatant 
was used for further studies. 
Sucrose Density Gradient Centrifugation-Sucrose density gradient 
centrifugation was performed by the method of Martin and Ames 
(14). Linear gradients of 20 to 40% (w/v) sucrose in Buffer A were 
prepared in a total volume of 5 ml. Samples of 100 J.tl of supernatant 
were layered on to the top of the gradient and centrifugation was 
carried out at 40,000 rpm for 15 h at 4 oc in a Beckman L5-65 
ultracentrifuge with an SW 50-1 rotor. After centrifugation, 175-J.tl 
fractions were collected and f)-galactosidase assays with 1 mM 4-
methylumbelliferyl-!3-D-galactopyranoside as a substrate were per-
formed on 10-J.tl samples as described earlier (13). 
I mmunoprecipitation of Radioactive {3-Galactosidase-This immu-
noprecipitation was performed according to procedures described 
earlier (9, 1.5). At 3-4 days before labeling, the Ham's FlO medium 
was replaced by Dulbecco's modification of Eagle's medium (Flow 
Laboratories) supplemented with 10% fetal calf serum and antibiot-
ics. One hour prior to labeling, this medium was replaced by Dulbec-
cu 's medium free of leucine. Subsequently, replacement by 6 ml of 
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this same medium supplemented with 0.2 ml of dialyzed fetal calf 
serum and 0.2 ml of L-[4,5-'H]leucine is performed (0.2 mCi, 135 Ci/ 
mmol, Amer§ham Radiochemical Centre). The cells were grown for 
48 h in the presence of this labeled medium. After incubation, the 
cells were harvested and centrifuged as described earlier (15). 
The cell pellet was either lysed in Buffer A and directly layered on 
the sucrose gradient, or ,6-galactosidase in the lysate was first purified 
using affinity chromatography (16) before sucrose density gradient 
centrifugation. For this latter purpose, the cell pellet from one or two 
Falcon flasks was lysed in 500 ~~ of 20 mM Na acetate, pH 5.2, 
containing 0.1 M NaCJ, 1% (w/v) Zwitterionic detergent and 0.2% 
(w/v) bovine serum albumin (Buffer B). This sample was applied to 
a 60-J.tl p-aminophenylthiogalactoside-CH-Sepharose affinity matrix 
(16). The column was washed with 600 .u.l of Buffer B supplemented 
with 0.5 M NaCl, and eluated in buffer B supplemented with 0.1 M ')'-
galactonolactone. The eluate was dialyzed against buffer A supple-
mented with 0.2% (w/v) bovine serum albumin, according to Penefski 
(17). 
Pooled fractions were mixed with excess of conventional anti-.6-
galactosidase antiserum raised against human placental enzyme (9) 
and incubated for 1 hat 20 "C followed by 15 hat 4 "C. Polyacrylamide 
gel electrophoresis in the presence of sodium dodecyl sulfate was 
performed on 12% slab gels according to Laemmli (18) with modifi-
cations described by Hasilik and Neufeld (15). Fluorography was 
carried out according to Bonner and Laskey (25) and the [14C]methyl-
labeled protein molecular weight standards {phosphorylase b, 92,000; 
bovine serum albumin, 65,000; lgG, 55,000; ovalbumin, 46,000; car-
bonic anhydrase, 30,000 (Amersham)) were used. Visualization of the 
labeled proteins was possible after 1-2 weeks of exposure to X-Omat 
Kodak film. 
Correction of the combined .6-galactosidase and neuraminidase 
deficiency in galactosialidosis fibroblasts was studied in two ways. 
Firstly, the intralysosomal proteolytic degradation of the lysosomal 
enzymes was inhibited by addition to the medium of leupeptin 
(Sigma) at a final concentration of0.02 mM for 4 days prior to sucrose 
density gradient centrifugation. Secondly, the "corrective factor" (19) 
and 54-kDa identified glycoprotein (9) was prepared by addition of 
10 mM NH4Cl to the medium above GM 1-gangliosidosis fibroblasts 
during 2 days followed by concentration on an Amicon PMlO filter 
to a final volume of 1 ml as described before (9, 19). An aliquot of 40 
.u.l of this concentrate was added per 1 ml of the Ham's FlO medium 
above galactosialidosis fibroblasts during 4 days and then sucrose 
density gradient centrifugation was performed to study the t)-galac-
tosidase pattern in the mutant cells. 
Finally, radioactively labeled corrective factor was prepared in the 
same way but after addition of both [:1H]leucine (see above) and 
NH4 Cl during 2 days prior to preparation of the concentrate. The 
radiolabeled concentrate was dialyzed against Ham's FlO medium 
added to galactosialidosis fibroblasts for 4 days and subsequently 
immunoprecipitation studies with anti-{3-galactosidase antiserum 
were carried out to identify the "corrective protein" and its fate after 
being taken up by the mutant fibroblasts. 
RESULTS AND DISCUSSION 
Protective Protein for {3-Galactosidase-In previous studies 
(9), it was shown that galactosialidosis fibroblasts lack a 32-
kDa protein which precipitated with an antiserum against 
human #-galactosidase but which did not show any hydrolytic 
activity. In all other human cells tested, including those with 
a /3-galactosidase deficiency, this 32~kDa protein is present. 
On the basis of pulse-chase experiments and the absence of a 
54-kDa glycoprotein in ammonium chloride-stimulated me-
dium above galactosialidosis fibroblasts, d'Azzo et al. (9) pos-
tulated that the 54-kDa protein is the precursor of the 32-kDa 
protective protein.'' In immunoprecipitation studies summa-
rized in Fig. 1, experimental evidence is presented for this 
hypothesis. Ammonium chloride-stimulated and ["H]leucine-
labeled medium above control fibroblasts contains the 85-
kDa precursor of #-galactosidase and a 54-kDa glycoprotein 
(Fig. 1b). When this medium is given to galactosialidosis cells, 
a 32-kDa and 20-kDa protein band becomes apparent (Fig. 
1d). This is not the case when NH,Cl-stimulated and radio-
labeled medium derived from galactosialidosis cells (Fig. 1c), 
which lacks the 54-kDa protein, is added (Fig. 1e). These 
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FIG. 1. Polyacrylamide gel electrophoresis of immunopre-
cipitated ,8-galactosidase. a, Standards. b, NH4Cl-stimulated me-
dium above control fibroblasts. c, NH4Cl-stimulated medium above 
galactosialidosis {fJ-gal-/neur-) cells. d, Galactosialidosis fibroblasts 
after addition of medium mentioned under b. e, Galactosialidosis 
fibroblasts after addition of medium mentioned under c. 
results show that the 54-kDa protein is the precursor form of 
the 32-kDa and 20-kDa proteins; the stronger 32-kDa protein 
is thought to be required to protect f)-galactosidase against 
intralysosomal proteolytic degradation (9). 
Sucrose Density Gradient Centrifugation-The relationship 
between the 32-kDa protective protein and I)-galactosidase 
was further investigated with sucrose density gradient cen-
trifugation. In a lysate in buffer A of control fibroblasts, two 
peaks are demonstrated at pH 6.0 (Fig. 2a). About 15% of the 
total activity is present as a monomer and 85% as a high 
molecular weight multimer. Previous studies using gel filtra-
tion had already shown that I)-galactosidase exists in two 
forms i.e. a monomer of about 64kDa and a high molecular 
weight aggregate of about 600 to 700kDa (5~8). In contrast to 
previous observations, we find that most of the enzyme exists 
as a multimer which might be due to the experimental con-
ditions used in this study. When the cell sample was homog-
enized by sonication or freeze-thawing, nearly all enzyme was 
found to occur as a monomer. The ratio monomer:multimer 
is also pH-dependent because, under our conditions avoiding 
sonication or freeze-thawing and using Zwittergent as a de-
tergent, all ,a-galactosidase activity exists as a multimer at pH 
4.0. In the in vivo situation within the lysosome where the pH 
is in the order of 5.0 (20), most of the #-galactosidase presum-
ably exists as a high molecular weight aggregate. 
As is shown in Fig. 2b, a lysate from a patient with galac-
tosialidosis only shows the monomer peak after sucrose den-
sity gradient centrifugation. This finding is in agreement with 
earlier gel filtration studies, which indicated a marked de-
crease of high molecular weight (J-galactosidase in galactosi-
alidosis cells ( 6). This figure also shows that when these 
mutant cells are treated with leupeptin, which inhibits intra-
lysosomal cathepsins, the $-galactosidase activity rises but 
the density pattern remains unchanged (Fig. 2b). The in-
creased activity seems thus to be due to an increase in mon · 
omeric !)-galactosidase. When cells with other types of #-
galactosidase deficiency such as those derived from patients 
with GM 1-gangliosidosis are treated with leupeptin, there is 
no significant rise of $-galactosidase activity (data not 
shown). 
Addition to galactosialidosis fibroblasts of NH,-stimulated 
medium from control fibroblasts known to contain the 54-
kDa precursor of the 32-kDa protective protein results in a 
normalization of the density pattern of /3-galactosidase in the 
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FIG. 2. Sucrose density gradient centrifugation of lysoso~ 
mal ,8-galactosidase in normal and mutant human fibroblasts. 
a, Density pattern of !3-galactosidase in normal fibroblasts (D---0); 
and · · · indicate the respective indices of the linear sucrose gradient 
from 20 to 40% in 20 mM Na phosphate, pH 6.0, containing 100 mM 
NaCl and 1% (w/v) Zwitterionic detergent. b, Pattern in galactosiali-
dosis cells (X--X) and of the same cells after inhibition of lysosomal 
cathepsins by leupeptin (A- - -A). c, Pattern in galactosialidosis cells 
before (X-X) and after addition of NH4Cl-stimulated medium 
containing the 54-kDa precursor of the protective protein (0--- -0). 
mutant cells (Fig. 2c). After 4 days administration of this 
"corrective factor", about two-thirds of the enzyme appears 
as a high molecular weight multimer. These results suggest 
that the 54-kDa precursor and the 32-kDa protein derived 
from it is required for the aggregation of monomeric {3-galac-
tosidase into a high molecular weight form. This observation 
explains previous results by Hoeksema et al. (6), who found a 
normalization of the gel filtration pattern of f)-galactosidase 
after somatic cell hybridization of f)-galactosidase-deficient 
GM1 -gangliosidosis fibroblasts and galactosialidosis cells. The 
former cells will synthesize the 32-kDa and 20-kDa proteins 
whereas the nucleus of the galactosialidosis cells will code for 
normal f)-galactosidase polypeptide chains. 
Immunoprecipitation-A lysate of [3H]leucine-labeled con-
trol fibroblasts was exposed to sucrose density gradient cen-
trifugation. Fractions 1-4, 5-11, and 14-20, corresponding to 
the pattern illustrated in Fig. 2, were pooled and treated with 
conventional antiserum against human (3-galactosidase. After 
immunoprecipitation, polyacrylamide gel electrophoresis was 
carried out under denaturing conditions and the results are 
shown in Fig. 3. In the fractions 1-4, no f)-galactosidase and 
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FIG. 3. Polyacrylamide gel electrophoresis of immunopre-
cipitated .B-galactosidase in pooled fractions after sucrose den-
sity gradient centrifugation. a, Standards. b, Immunoprecipitate 
of the total lysate of control fibroblasts. c, Cell lysate after sucrose 
density gradient centrifugation; pooled fractions 5-11. d, The same; 
pooled fractions 14-20. e, Purified j)-galactosidase from control fibro-
blasts; pooled fractions 5-11. {, The same; pooled fractions 14-20. g, 
Immunoprecipitate of the unretained material of the affinity column 
used for the purification of j)-galactosidase. 
minor quantities of the 32-kDa and 20-kDa proteins are 
present. The fractions 5-11 corresponding with the monomer 
(Fig. 2) contain the expected amount of 64-kDa f)-galactosid-
ase accompanied by large quantities of the 32-kDa and 20-
kDa proteins (Fig. 3, lane c). The fractions 14-20 correspond-
ing with the multimeric form contain the majority of the 64-
kDa f)-galactosidase and about equal amounts of the 32-kDa 
protein and only traces of the 20-kDa protein (Fig. 3, lane d). 
Similar immunoprecipitation studies were performed after 
purification of {3-galactosidase from control fibroblasts using 
affinity column chromatography. When the eluate of the 
column is exposed to sucrose density gradient centrifugation, 
a similar pattern of f)-galactosidase activity with two peaks 
(Fig. 2) is obtained. The results of immunoprecipitation stud-
ies on the pooled fractions 5-11 and 14-20 are shown in the 
right-hand part of Fig. 3. Hardly any bands are visible in the 
fractions 1-4. In fractions 5-11, again a faint 64-kDa f)-
galactosidase band is seen, but contrary to the studies on total 
cell lysate, hardly any 32-kDa and no 20-kDa proteins are 
present in this purified preparation (Fig. 3, lane e). In the 
fractions 14-20, most of the 64-kDa f)-galactosidase and the 
32-kDa protein and minor quantities of the 20-kDa protein 
are present (Fig. 3lane f). When immunoprecipitation studies 
were performed on the unretained material of the affinity 
column used for purification of /3-galactosidase, most of the 
32-kDa and 20-kDa proteins were found there (Fig. 3, lane g). 
These immunoprecipitation studies suggest that the 32-
kDa component found in the low density fraction of cell lysate 
is not bound to the f)-galactosidase monomer and the latter is 
easily separated from it using affinity chromatography. On 
the other hand, affinity chromatography of the f)-galactosid-
ase in the high density fraction copurifies apparently equal 
amounts of the 32-kDa protein. This strongly suggests that 
these two components are intimately bound in the high mo-
lecular weight aggregate. 
CONCLUSION 
We have shown that in normal human fibroblasts a 54-kDa 
precursor protein is processed into a 32-kDa glycoprotein, 
which in turn is required for the aggregation of monomeric 
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(64-kDa) (J-galactosidase into a high molecular mass multimer 
of 600 to 700-kDa. There seems to be an excess amount of 
32-kDa protein in proportion to the amount of (J-galactosidase 
monomer. This has also been observed for the microsomal 
accessory protein egasyn which binds (J-glucuronidase to the 
endoplasmic reticulum in mouse (21). 
We have found for human fibroblasts that at the low 
intralysosomal pH, most of the (J-galactosidase exists as a 600 
to 700-kDa multimer and that the 32-kDa protective protein 
is firmly bound to this high molecular mass aggregate. Pre-
vious studies of human placenta (7) and porcine spleen (8) 
have also demonstrated the presence of low molecular weight 
proteins together with the high molecular weight fraction of 
!)-galactosidase but these have wrongly been considered as 
contaminants. Verheijen et al. (22) recently showed that sial-
idase and the high molecular weight form of (J-galactosidase 
exist as a complex. It is likely that this complex is membrane-
bound. Cheetham and Dance (23) suggested earlier that the 
high molecular weight form of (J-galactosidase consists of low 
molecular weight enzyme bound to small fragments of the 
lysosomal membrane. 
d' Azzo et al. (9) have recently shown that the autosomal 
recessive lysosomal storage disease galactosialidosis is asso-
ciated with the absence of the 54-kDa precursor protein of 
the 32-kDa and 20-kDa glycoproteins mentioned above. They 
explained the combined deficiency of f)-galactosidase and 
sialidase as being due to enhanced degradation of {3-galacto-
sidase whereas the protective protein would also be required 
to activate sialidase. 
In the present study. we have shown that the protection of 
f)-galactosidase is realized by aggregation of monomers into 
high molecular weight multimers. This is supported hy the 
observation that the stability of f)-galactosidase increases with 
conditions favoring the formation of multimers (24). When 
the aggregation of monomers cannot take place, as in galac-
tosialidosis. /3-galactosidase remains in its monomeric form 
which apparently is very sensitive to intralysosomal proteo-
lytic degradation. It seems likely that sialidase needs to be 
incorporated into a membrane-bound high molecular weight 
complex with (J-galactosidase in order to become active (22). 
If no such complex can be formed, as in galactosialidosis, 
sialidase remains inactive (9, 22). 
Further studies are now under way to investigate the role 
of monomeric f)-galactosidase and of the high molecular 
weight complexes of multimeric /3-galactosidase, protective 
protein(s), and sialidase in the hydrolysis of various sub-
strates. 
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Processing of Human .a-Galactosidase in aMI-Gangliosidosis and 
Morquio B Syndrome* 
(Received for publication, August 10, 1983) 
Andre T. Hoogeveen, Hiroko GrahamcKawashima:j:, Alessandra d' Azzo, and Hans Galjaard§ 
From the Department of Cell Biology and Genetics, Erasmus University, Rotterdam, the Netherlands 
The nature of the molecular defect resulting in the 
P-galactosidase deficiency in different forms of GMt-
gangliosidosis and mucopolysaccharidosis IV B (Mor-
quio B syndrome) was investigated. Normal and mu-
tant cultured skin fibroblasts were labeled in vivo with 
[ 3 H]leucine and immunoprecipitation studies with hu-
man anti-,8-galactosidase antiserum were performed, 
followed by polyacrylamide gel electrophoresis and 
fluorography. In Morquio B syndrome, the mutation 
does not interfere with the normal processing and in-
tralysosomal aggregation of P-galactosidase. In cells 
from infantile and adult GM,-gangliosidosis, 85-kDa 
precursor $-galactosidase was found to be synthesized 
normally but more than 90% of the enzyme was sub-
sequently degraded at one of the early steps in post-
translational processing. The residual 5-10% P-galac-
tosidase activity in adult GM,-gangliosidosis is 64-kDa 
mature lysosomal enzyme with normal catalytic prop-
erties but with a reduced ability of the monomeric form 
to aggregate into high molecular weight multimers. 
Knowledge of the exact nature of the molecular defect 
underlying P-galactosidase deficiency in man may lead 
to a better understanding of the clinical and patholog-
ical heterogeneity among patients with different types 
of GM1-gangliosidosis and Morquio B syndrome. 
A genetic deficiency of lysosomal !}-galactosidase (EC 
3.2.1.23) in man is responsible for the lysosomal storage 
diseases GM1-gangliosidosis (1, 2) 1 and mucopolysaccharidosis 
IV B or Morquio B syndrome (3, 4). On the basis of different 
clinical and pathological manifestations, infantile, juvenile. 
and adult forms of GM1-gangliosidosis are distinguished (for 
reviews, see Refs. 2 and 5). Somatic cell hybridization studies 
have shown that the different forms of GM,-gangliosidosis and 
Morquio B syndrome are based on different mutations in the 
gene on chromosome 3, which codes for the !}-galactosidase 
polypeptide (6-8). 
The !}-galactosidase activity in cultured fibroblasts from 
patients with infantile or juvenile GM,-gangliosidosis is less 
than 1% of control values whereas the residual enzyme activ-
ity varies from 5 to 10% in cells from patients with adult GM1-
gangliosidosis or Morquio B syndrome (2-5, 9, 10). Immuno-
logical studies using antisera against purified human )3-galac-
* The costs of publication of this article were defrayed in part by 
the payment of page charges. This article must therefore be hereby 
marked "advertisement" in accordance with 18 U.S.C. Section 1734 
solely to indicate this fact. 
:j: Working as a fellow from the Department of Pediatrics, Kana-
zawa University, Kanazawa, ,Japan. 
§To whom reprint requests should be addressed at the Department 
of Cell Biology and Genetics, Erasmus University, P.O. Box 1738, 
:3000 DR Rotterdam, the Netherlands. 
1 GM 1 refers to N-acetylneuraminylgangliotetraglycosylceramide. 
tosidase showed the presence of normal amounts of cross-
reactive material in liver or fibroblasts from patients with 
infantile or adult GM1-gangliosidosis (11, 12). 
Studies after in vivo labeling of normal fibroblasts with 
[ 3H]leucine followed by immunoprecipitation with anti-f)-
galactosidase antiserum and polyacrylamide gel electropho-
resis have shown that !}-galactosidase is synthesized as a 85-
kDa precursor molecule which is processed via intermediate 
forms into 64-kDa mature enzyme (13). This finding was in 
agreement with previous studies on mouse macrophage )3-
galactosidase (14). Within the lysosome, this molecule aggre-
gates into a high molecular mass form (600- to 700-kDa) in 
the presence of a 32-kDa ''protective protein," which prevents 
rapid proteolytic degradation of f)-galactosidase (13, 15). 
The purpose of the present work was to obtain a better 
insight into the nature of the molecular defect in the infantile 
and adult forms of GM1-gangliosidosis by analyzing the proc-
essing of mutant )3-galactosidase using immunoprecipitation. 
In addition, the aggregation pattern of the residual !}-galac-
tosidase in mutant fibroblasts was studied using sucrose den-
sity gradient centrifugation. 
EXPERIMENTAL PROCEDURES 
Materials-Skin fibroblasts from patients with the infantile form 
of GMt-gangliosidosis were kindly provided by Dr. L. Pinsky (Mon-
treal), Drs. P. Aula and P. Amma.Ia (Helsinki), Dr. T. T¢nnesen 
(Glostrup), and Drs. M. C. B. Loonen and W. F. Arts (Rotterdam). 
Cells from patients with the adult form of GM 1-gangliosidosis were 
obtained from Dr. D. Wenger (Denver) (case II-4, Ref. 10) and Dr. 
Y. Suzuki (Tokyo) (cases 5 and 6, Ref. 9), and Dr. K. von Figura 
(MUnster) provided fibroblasts from a patient with Morquio B syn-
drome (case 2, Ref. 4). All fibroblasts were cultured in Ham's F-10 
medium supplemented with 10% fetal calf serum and antibiotics. 
Preparation and Enzyme Assays-For intracellular enzyme assays, 
cells were grown in 75-cm~ Falcon flasks to a density of 1 to 2 mg of 
protein/flask. The cells were harvested by trypsinization, rinsed in 
saline, and centrifuged (10 min at 90 X g), the cell pellet was lysed in 
distilled water, and !3-galactosidase and 13-N-acetylhexosaminidase 
activities were measured with the appropriate 4-methylumbelliferyl 
substrates (Koch-Light) as reported earlier (5). The effect of protease 
inhibition on the activity of #-galactosidase was studied by addition 
of leupeptin (Sigma) to the culture medium in a final concentration 
of 0.02 mM. To measure the activity of lysosomal enzymes secreted 
into the culture medium, fibroblasts were seeded in 24-well (16-mm 
diameter) tissue culture plates (2 X 105 cells/well), and 2 days later, 
when the cells had reached confluency, the medium was replaced by 
500 f.il of fresh medium with 5% inactivated (60 "C for 3 h) fetal calf 
serum and NH4Cl at a final concentration of 10 mM. After 2 days, 
the medium was collected and centrifuged (5 min at 90 x g) and 
enzymatic activities were measured in 10-.ul aliquots. 
Immunoprecipitation and Polyacrylamide Gel Electrophoresis-
Cells were labeled with 0.2 mCi of L-[4,5-'H]leucine (135 Ci/mmol, 
Amersham Radiochemical Centre) for periods varying from 2 h to 3 
days and processed for immunoprecipitation using anti-/3-galactosid-
ase antiserum raised against human placental enzyme as described 
(13, 16). The immunoprecipitates were subjected to polyacrylamidP 
gel electrophoresis in the presence of sodium dodecyl sulfate as 
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described, and the radioactive bands were visualized in fluorography 
(13, 16). Quantitative measurements of incorporated radioactivity in 
distinct protein bands were performed by liquid scintillation counting 
of dissected pieces of acrylamide gel; the total incorporaton of [3H] 
leucine in cellular proteins was determined in 10-JLl aliquots of cell 
~. ;enate. 
"· .:rose density gradient centrifugation was performed according 
to Martin and Ames (17). After harvesting and centriguation as 
described above, the fibroblast pellet from one Falcon flask was lysed 
by suspension in 100 ,ul of 20 mM sodium phosphate, pH 6.0, contain-
ing 100 roM NaCl and 1% (w/v) zwitterionic detergent 3-12 (Calbi-
ochem). Linear gradients of 20 to 40% (w/v) sucrose in this same 
buffer were prepared in a total volume of 5 mi. Samples of 100-,ul 
supernatant were layered onto the top of the gradient and centrifu-
gation was carried out at 40,000 rpm for 15 h at 4 oc in a Beckman 
L5-65 ultracentrifuge with an SW 50-1 rotor. After centrifugation, 
175-,ul fractions were collected and !5-galactosidase assays with 1 mM 
4-methylumbelliferyl-P-o-galactopyranoside as a substrate were per-
formed on 10-,ul samples. 
RESULTS 
The intracellular {3-galactosidase activity of the fibroblasts 
derived from all five patients with infantile GM1-gangliosidosis 
was less than 1% of control values (normal range, 400-1400 
nmol·h-1·mg-1 protein; mean activity, 760). The residual 
activity in the cells from the patient with Morquio syndrome 
and from three patients with the adult form of GM1-ganglio-
sidosis was 30-60 nmol·h-1·mg-1 protein (4-9% of controls). 
The Km measured with 4-methylumbelliferyl-{3-D-galactopy-
ranoside in GM1-gangliosidosis fibroblasts was the same as in 
control fibroblasts, i.e. 0.33 mM. With the anti-{3-galactosidase 
antiserum, 97% of the {3-galactosidase enzyme activity was 
precipitated both in control fibroblasts and adult GM,-gan-
gliosidosis cells. 
After NH,Cl stimulation, the activity of the secreted 88-
kDa precursor {3-galactosidase could be measured in the cul-
ture m'edium. The average activity above control fibroblasts 
was 376 pmol·h-1/10 Ill of medium and above cells from 
infantile or adult GM1-gangliosidosis 11 to 13 pmol·h-1/10 Ill 
of medium. As a control, hexosaminidase activities were mea-
sured and these were the same in medium above control 
fibroblasts and the mutant cells tested (16,000-20,000 pmol· 
h-1/10 Ill medium). The Km value of the {3-galactosidase in 
medium above GM1-gangliosidosis fibroblasts could not be 
determined because of too low activities. 
Control and mutant fibroblasts were labeled for 3 days with 
['H) leucine· and the incorporation of radioactivity into {3-
galactosidase was studied by immunoprecipitation, followed 
by gel electrophoresis and fluorography (Fig. 1, a-d). Intra-
cellularly, in control cells 85-kDa precursor {3-galactosidase 
and the 64-kDa mature lysosomal {3-galactosidase are seen; in 
addition, the 32-kDa "protective protein," a 20-kDa protein 
and their 54-kDa precursor react with the anti-{3-galactosidase 
antiserum. In NH,Cl-stimulated medium above control cells 
(Fig. 1e), only 88-kDa secreted precursor {3-galactosidase and 
the 54-kDa secreted precursor of the protective protein are 
present. 
In the infantile and adult GM1-gangliosidosis cells (Fig. 1, b 
and c), no mature 64-kDa {3-galactosidase can be detected. 
Scintillation counting of slices of gel cut from the 64-kDa 
position showed 4-12% radioactivity in both types of G..,-
gangliosidosis cells compared with controls. 
Both in the infantile and adult GM1-gangliosidosis cells, the 
85-kDa precursor form of {3-galactosidase is present (Fig. 1, b \ 
and c). After NH,Cl stimulation, equal amounts of the 88-
kDa precursor are found in the culture medium above control 
fibroblasts (Fig. 1e) and the two types of GM1-gangliosidosis 
cells (Fig. 1, f and g). 
Intracellularly, equal amounts of 32-kDa protective protein 
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FIG. 1. Immunopreeipitation studies of ,B~galactosidase 
after [3H]Ieucine labeling of normal and mutant fibroblasts 
followed by sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis. Lanes: a, control fibroblasts; b, infantile GM1-ganglio-
sidosis fibroblasts; c, adult GMrgangliosidosis fibroblasts; d, Morquio 
B fibroblasts; e, medium above control fibroblasts after NILCl stim-
ulation; f, medium above infantile ~rgangliosidosis fibroblasts; g, 
medium above adult GMx-gangliosidosis fibroblasts. 
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FIG. 2. Pulse labeling of normal and mutant fibroblasts fol~ 
lowed by different periods of chase, immunoprecipitation of 
{J~galactosidase and sodium dodecyl sulfatewpolyacrylamide 
gel electrophoresis. Lanes a-d, control fibroblasts; e-h, infantile 
~1-gangliosidosis; i-~ adult ~1-gangliosidosis. a, e, and~ 2-h label-
ing with [3H]leucine; b, f, andj, 2-h labeling followed by 2-h chase; c, 
g, and k, 2-h labeling followed by 4-h chase; d, h, and I, 2-h labeling 
followed by 24-h chase. 
are present in control and mutant fibroblasts; this is also true 
for its secreted 54-kDa precursor in the medium above both 
types of cells after NH.Cl treatment. 
The immunoprecipitation pattern of cells from a Morquio 
B patient (Fig. ld) is the same as in control cells, i.e. both 85-
kDa precursor and 64-kDa mature {3-galactosidase are present. 
To study the dynamics of the processing of {3-galactosidase 
in GM1~gangliosidosis, pulse-chase experiments were carried 
out (Fig. 2). Control and mutant fibroblasts were labeled with 
[ 3H]leucine for 2 h. The medium was then replaced by unla-
beled medium and subsequently the cells were harvested after 
0, 2, 4, and 24 h of chase, and immunoprecipitation studies 
were performed. In control fibroblasts, the 85-kDa precursor 
133 
(3-Galactosidase in GM1-Gangliosidosis 
1500 
1200 
900 l"" 600 1 380 a 300 1 370 :0 
"' 1 360 
> 
~ 
" 
100 
t:; 
75 <i 
w 
'" 50 '~" e '" 25 :::' u <i <i 
"' 100 
' ~
75 .~ 50 25 
10 15 20 25 
FRACTION NUMBER 
FIG. 3. Sucrose density gradient centrifugation of lysoso-
mal {3-galactosidase in normal and mutant human fibroblasts. 
Top: 0, control fibroblasts: the dotted line indicates the refractive 
indices of the linear sucrose gradient from 20 to 40% in 20 mM Na 
phosphate, pH 6.0, containing 100 mM NaCl and 1% (w/v) zwitter~ 
ionic detergent. Middle: 8, adult GM 1-gangliosidosis: 0, infantile GM1-
gangliosidosis. Bottom: X, Morquio B syndrome. 
/]-galactosidase is observed at 0 and 2 h after labeling and 
then disappears because it is processed via intermediates into 
64-kDa mature !l-galactosidase within 24 h (Fig. 2. a-d). In 
the infantile and adult form of GM 1-gangliosidosis, the 85-
kDa precursor is normally synthesized and disappears as in 
controls between 4 and 24 h. However, 64-kDa mature ll-
galactosidase does not appear in the GM,-gangliosidosis cells 
(Fig. 2, e-h and Fig. 2, i-1). 
To prevent intralysosomal proteolytic degradation, 0.02 mM 
leupeptin was added to the medium above GM,-gangliosidosis 
cells. No effect on the immunoprecipitation pattern of !l-
galactosidase was observed nor did the intracellular !l-galac-
tosidase activity increase. 
The aggregation pattern of the residual !l-galactosidase 
activity in GM1-gangliosidosis cells and Morquio B was studied 
by sucrose density gradient centrifugation (Fig. 3). In control 
fibroblasts at pH 6.0, about 85% of the !l-galactosidase activity 
exists as a high molecular mass (600-70G-kDa) multimer and 
10-15% as a monomer of 64-kDa (Fig. 3, top). In infantile 
GM1-gangliosidosis, only a minor quantity of monomeric !l-
galactosidase was detected. In adult GM1-gangliosidosis, about 
25% of the total activity was multimeric and the rest mono-
meric /]-galactosidase (Fig. 3, middle). In Morquio B fibro-
blasts, the residual enzyme activity is equally divided over the 
monomeric and multimeric form (Fig. 3, bottom). 
DISCUSSION 
The most remarkable finding in the immunoprecipitation 
studies reported here is the absence of 64-kDa mature !l-
galactosidase in GM1-gangliosidosis fibroblasts. Previous in-
vestigations using immunotitration (2, 11) and immunodif-
fusion (12) showed the presence of normal quantities of cross-
reactive material in fibroblasts and liver from patients with 
infantile and adult GM1-gangliosidosis using anti-f]-galactosid-
ase antisera. In cells from patients with the juvenile form, 
some investigators also found normal amounts of cross-reac-
tive material (2, 11) whereas others reported a reduction (18) 
or increase compared with controls. These discrepancies may 
be explained by different aggregation states of /]-galactosidase, 
depending on the source of material and the way of its 
preparation (15). The precipitation of monomeric /]-galacto-
sidase might require relatively more antibody than that of 
enzyme present as a multimer. In addition, we now know that 
the antisera used not only react with mature !l-galactosidase 
but also with its 85-kDa precursor and with the 32-kDa 
protective protein and its precursor (13), which were not 
known at the time of the immunological studies mentioned 
(11, 12, 18). 
The absence of 64-kDa !l-galactosidase in GM1-gangliosi-
dosis shown in the present study cannot be explained by an 
inability of the antiserum to react with mutated enzyme. Our 
antiserum does react with (mutated) 85-kDa precursor ll-
galactosidase in GM1-gangliosidosis and also with mutated 
precursor and mature enzyme in Morquio B. Also, virtually 
all residual enzyme activity in adult GM1-gangliosidosis can 
be precipitated with our antiserum, so we could not have 
missed a band at the 64-kDa position if there had been normal 
amounts of enzymatically deficient enzyme. 
In GM,-gangliosidosis, the mutation on chromosome 3 must 
affect the 85-kDa precursor !l-galactosidase in such a way 
that the molecule is degraded at one of the early processing 
steps. Similar molecular defects have recently been reported 
in the late onset form of glycogenosis type II (19, 20), multiple 
sulfatase deficiency (21) and some variants of Tay-Sachs 
disease (22, 23). Pulse-chase studies in the different forms of 
GM,-gangliosidosis indicate that the 85-kDa precursor !l-ga-
lactosidase is normally synthesized but during its early proc-
essing the enzyme is degraded and hardly any 64-kDa mature 
enzyme is formed (see Fig. 2). A genetic deficiency of one of 
the enzymes involved in this processing is unlikely since there 
is no accumulation of the 85-kDa precursor and its rate of 
disappearance is similar as in controls. 
Inhibition of proteolytic degradation by leupeptin does not 
result in the appearance of mature 64-kDa !l-galactosidase or 
one of its precursors. Thiol cathepsins which are inhibited by 
leupeptin seem therefore not responsible for the degradation 
of the precursor enzyme. This is in contrast with the situation 
in galactosialidosis (24), where the !l-galactosidase and siali-
dase deficiency was found to be due to the absence of a 32-
kDa glycoprotein (13). This protein is normally required for 
the aggregation of monomeric /]-galactosidase into high mo-
lecular weight aggregates which form a complex with the 
membrane-bound sialidase (25). The absence in galactosiali-
dosis cells of the protective protein results in the rapid intra-
lysosomal degradation of 66-kDa !l-galactosidase, which deg-
radation can be inhibited by leupeptin. 
In GM1-gangliosidosis and Morquio B, the 32-kDa protective 
protein and its 54-kDa precursor were found to be present 
and functional (26). This enables in principle the aggregation 
of mature monomeric !l-galactosidase (Fig. 3). In Morquio B, 
the processing of !l-galactosidase proceeds normally (27). ma-
ture 64-kDa enzyme is present in normal quantities (see Fig. 
1d), and about half of these molecules aggregate into 60-70-
kDa multimers, whereas in controls this is more than 85%. 
This difference may be due to the genetic alteration of the f)-
galactosidase molecule which may interfere with its aggrega-
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tion despite the presence of a normal amount of protective 
protein. Previous work (27) has shown that the mutation in 
Morquio B mainly affects the hydrolysis of galactose from 
keratan sulfate. 
Both in infantile and adult GM,-gangliosidosis 4-12% ra-
dioactivity was found to be present in sodium dodecyl sulfate 
gels at the 64-kDa position. This might imply that not all 
mutated precursor /)-galactosidase is degraded and that about 
4-12% is processed into the mature form. In infantile GM1-
gangliosidosis, the mutation seems to affect the active site of 
the enzyme since there is less than 1% catalytic activity 
toward different natural and artificial substrates (2, 5). In 
adult GM1-gangliosidosis, there is 5-10% residual /)-galactosid-
ase activity and the kinetic properties and the half-life of the 
enzyme (28) are normal. As is shown in Fig. 3, aggregation of 
/)-galactosidase does occur in fibroblasts from adult GM1-
gangliosidosis; the large proportion of monomeric enzyme 
might be explained by a high amount of 85-kDa precursor 
enzyme relative to the 5-10% remaining 64-kDa mature en-
zyme. 
It is possible that in the adult form the genetically altered 
part of the /)-galactosidase molecule is removed during the 
last processing step resulting in normal 64-kDa mature I)-
galactosidase; the bulk of mutated precursor is degraded as in 
the infantile form. The ultimate experimental proof must 
await the identification of the exact nature of the molecular 
defect using sequencing of (mutant) /)-galactosidase or of the 
gene on chromosome 3 coding for it. 
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Cultured fibroblasts from different variants of GM,-
gangliosidosis synthesize normal amounts of 88-kDa 
(3-galactosidase precursor. Yet the amount of the ma-
ture 64-kDa form is reduced to 5-15% of normal val-
ues. In this communication it is shown that the muta-
tion in the infantile and adult form of GM,-gang!iosi-
dosis interferes with the phosphorylation of precursor 
(3-galactosidase. As a result the precursor is secreted 
instead of being compartmentalized into the lysosomes 
and further processed. The impaired phosphorylation 
might be due to conformational changes of the precur-
sor molecule. 
Human lysosomal (3-galactosidase (EC 3.2.1.23) is synthe-
sized as a 88-kDa precursor form which is processed via 
intermediate forms into the 64-kDa mature enzyme (1). 
Within the lysosome the mature form aggregates into a high 
molecular weight complex of {:1-galactosidase. a 32-kDa "pro-
tective" protein and the lysosomal neuraminidase (2, 3). The 
(3-galactosidase deficiency in a number of clinical variants of 
the inherited disease GM1-gangliosidosis1 (4) is due to allelic 
mutations of the gene on chromosome 3 coding for the 88-
kDa polypeptide (5, 6). In recent biochemical studies on 
mutant cultured skin fibroblasts from different forms of GMt-
gangliosidosis 4-12% cross-reactive material of the mature (3-
galactosidase molecules was detected (7). Since the synthesis 
of the 88-kDa precursor was found to be normal it was 
hypothesized that most of the enzyme was degraded during 
one of the early steps of posttranslation modification. 
The purpose of the present study was to elucidate the 
molecular nature of such defects in different (3-galactosidase-
deficient variants. 
EXPERIMENTAL PROCEDURES 
Materials-Human skin fibroblasts from normal individuals and 
from patients with the infantile form of GM1-gangliosidosis and I-Cell 
disease were obtained from the Rotterdam Cell Repository (Dr. M. 
F. Niermeijer); cells from patients with the adult form of GMr 
gangliosidosis were kindly provided by Dr. Y. Suzuki 1(Department of 
Pediatrics, University of Tokyo). The cells were cultured in Ham's 
* The costs of publication of this article were defrayed in part by 
the payment of page charges. This article must therefore be hereby 
marked "advertisement" in accordance with 18 U.S.C. Section 1734 
solely to indicate this fact. , 
:j:: To whom correspondence should be addressed: Dept. of Cell 
Biology and Genetics, Erasmus University, P. 0. Box 1738, 3000 DR 
Rotterdam, The Netherlands. 
1 The abbreviation used is: GMrgangliosidosis, N-acetylneurami-
nylgangliotetraglycosylceramide-gangliosidosis. 
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F-10 medium (Flow Laboratories, Mclean, VA) supplemented with 
10% fetal calf serum and antibiotics (Gibco). Early passages of the 
cell strains were grown in 25-cm2 plastic culture flasks to a density 
of about 1 mg of protein/flask before analysis. 
Radioactive Labeling-For labeling,Jiam's F-10 medium was re-
placed by Dulbecco's modified Eagle's medium free ofleucine, and 4 
ml of this medium was supplemented with 2% fetal calf serum 
dialyzed against 0.9% NaCl and with 150 ~1 of 1 [ 4,5-3H]leucine (150 
,uCi:l35 Cijmmol; Amersham Corp.) to study the biosynthesis of (3-
galactosidase. Secretion of precursor forms of lysosomal enzymes was 
induced by addition to the medium of NH4Cl in a final concentration 
of 10 mM during 2 days. Phosphorylation and glycosylation of the 
secreted precursor forms was studied by replacing Ham's F-10 me-
dium by Dulbecco's modified Eagle's medium free of phosphate or 
glucose supplemented with dialyzed fetal calf serum. To a 25-cm2 
Falcon flask, 150 ,uCi of [2-3H]mannose (10-20 Ci/mmol) or 200 ,uCi 
of carrier-free [32P]phosphate was added. 
Immunoprecipitation-After 48-h labeling, the medium was col-
lected and mixed with an excess of polyclonal anti-(3-galactosidase 
antibodies raised against human placental enzyme (1) and left for 15 
hat 4 QC. The immunoprecipitates were subjected to polyacrylamide 
gel electrophoresis in the presence of sodium dodecyl sulfate on 10% 
slab gels and the radioactive bands were visualized by fluorography 
(8), with minor modifications (1). 
Uptake Studies-Radioactively labeled (3-galactosidase was pre-
pared by the addition of 10 mM NH,Cl and [3H]leucine to the medium 
above control and G:-.u·gangliosidosis fibroblasts during 2 days. The 
radioactively labeled medium from a 25-cm:! Falcon flask was concen-
trated and dialyzed against Ham's F-10 medium and added to control 
fibroblasts for 4 days. Subsequently, immunoprecipitation studies 
were carried out with anti-(3-galactosidase antibodies to study the 
uptake and processing of labeled ,8-g3.lactosidase after uptake in 
control fibroblasts. 
RESULTS 
Secretion of precursor forms of /3-galactosidase was studied 
in normal and mutant fibroblasts before and after treatment 
with NH,Cl. The results of immunoprecipitation studies on 
culture media after [3H]leucine labeling of the cells are shown 
in Fig. 1. After NH,Cl treatment normal fibroblasts are known 
to secrete tlte precursor forms of virtually all lysosomal gly-
coproteins and this is also the case for the 88-kDa precursor 
of (3-galactosidase as well as for the 54-kDa precursor of the 
32-kDa protective protein which also reacts with the conven-
tional antiserum used (Fig. 1, lane a). 
The enzymatic activity of (3-galactosidase precursor se-
creted by control fibroblasts after NH,Cl treatment is 10-15 
nmol of methylumbelliferon/h/ml of medium. In the medium 
above GM1-gangliosidosis fibroblasts, no catalytic activity 
could be measured despite the presence of a considerable 
amount of (3-galactosidase precursor molecules. Without 
NH,Cl treatment, control cells secrete only 10-20% of the (3-
galactosidase precursor as measured both by enzyme activity 
and scintillation counting of bands cut from the gels (Fig. 1, 
lane b). 
GM,-gangliosidosis fibroblasts, however, secrete virtually all 
their 88-kDa (3-galactosidase precursor even without NH,Cl 
treatment (Fig. 1, lane c), in a similar fashion as fibroblasts 
from patients with I-Ce!! disease (Fig. 1, lane d). The speci-
ficity of this effect is illustrated by the fact that the 54-kDa 
precursor of the protective protein is hardly secreted, this in 
contrast with NH,Cl treatment. No difference was found in 
the secretion pattern between cells from patients with the 
infantile and those with the adult form of GM,-gangliosidosis 
(Fig. 2). 
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FIG. 1. Immunoprecipitation studies of ,8-galactosidase 
after [3H]leucine labeling of medium above normal and mutant 
fibroblasts followed by sodium dodecyl sulfate-polyacrylam-
ide gel electrophoresis. Lane a, medium above control cells after 
NH4Cl treatment; lane b, same without NH4Cl treatment; lane c, 
medium above GM1-gangliosidosis cells; lane d, medium above 1-Cells. 
MEDIUM 
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FIG. 2. Immunoprecipitation studies of .B-galactosidase 
after f3 H]leucine labeling of medium above GMt-gangliosidosis 
fibroblasts, followed by sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis. Lane a, medium above infantile GM 1-
gangliosidosis cells after NH4Cl treatment; lane b, same without 
treatment; lane c, adult GM 1~gangliosidosis after NH4Cl treatment; 
lane d, same without treatment. 
Uptake experiments were then performed to investigate the 
properties of the secreted precursor forms. After NH4Cl stim~ 
ulation of ['H]leucine-labeled cells, medium above normal 
and mutant fibroblasts was collected and used to incubate 
unlabeled fibroblasts for 4 days. The result in Fig. 3 shows 
that the 88-kDa iJ-galactosidase precursor secreted by normal 
fibroblasts is ingested and processed into the 64-kDa mature 
form (Fig. 3, lane a). The secreted 54-kDa p•ecursor of the 
protective protein is also ingested and processed into a 32-
and 20-kDa protein. The 88-kDa mutant iJ-galactosidase pre-
cursor secreted by GM1~gangliosidosis fibroblasts, however, is 
not detected in the recipient cells (Fig. 3, lane b). This 
indicates a lack of uptake specific foq)-galactosidase precur-
sor since the 54~kDa precursor form of the protective protein 
secreted by the mutant cells is taken up and processed further. 
To investigate whether the spontaneous secretion of the {3~ 
!(alactosidase precursor by GM1-gangliosidosis fibroblasts and 
the impaired uptake of the precursor by normal fibroblasts 
was related to a defective binding to the mannose-6-phosphate 
receptor, phosphorylation studies were carried out. Normal 
FIBROBLASTS 
a b 
FIG. 3. Immunoprecipitation of [3H]leucine-labeled .B-galac-
tosidase in control fibroblasts followed by polyacrylamide gel 
electrophoresis. Lane a, control fibroblasts after uptake of 3H-
labeled proteins from medium above control fibroblasts; lane b. con-
trol fibroblasts after uptake of 3H-labeled proteins from medium 
above GM 1-gangliosidosis fibroblasts. 
and mutant cells were labeled with carrier-free [·"P]phosphate 
and the secretion of the precursor protein was stimulated with 
NH4Cl. Immunoprecipitation studies of {3~galactosidase in the 
medium (Fig. 4) show that {3-galactosidase precursor secreted 
by normal fibroblasts is phosphorylated (Fig. 4, lanes a and 
b), but no labeling is found for /3-galactosidase precursor 
secreted by infantile or adult GMt ~gangliosidosis fibroblasts 
(Fig. 4, lanes c and d). The defective phosphorylation is 
restricted to {3~galactosidase since the .54-kDa precursor of the 
protective protein is heavily phosphorylated both in normal 
and GM1 cells. 
The defective phosphorylation in the GM 1-gangliosidosis 
fibroblasts does not seem to be due to an altered glycosylation 
because immunoprecipitation studies after [3H}mannose la~ 
beling gave a similar pattern in normal and mutant cells (Fig. 
5). 
DISCUSSION 
In the present study we provide an explanation for the 
marked reduction in the amount of 64-kDa mature f)-galac-
tosidase molecules in different variants of GM 1-gangliosidosis. 
The 88~kDa precursor, which is synthesized normally, is not 
phosphorylated probably as a result of a defective recognition 
of the mutant protein by N-acetylglucosaminylphospho-
transferase. As a consequence there is no binding to the 
mannose~6~phosphate receptor, required for a correct lysoso~ 
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FIG. 4. Immunoprecipitation studies of 32Pwlabeled ,8-galac-
tosidase from medium above control and GM1-gangliosidosis 
fibroblasts after NH4 Cl treatment, followed by sodium dode-
cyl sulfate-polyacrylamide gel electrophoresis. Lanes a and b, 
medium above control fibroblasts; lane c, medium above infantile 
GM 1-gangliosidosis cells; lane d, medium above adult GMrgangliosi-
dosis cells. 
MEDIUM 
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a b 
FIG. 5. Immunoprecipitation studies of [3 H]mannose-la-
beled ,8-galactosidase from medium after NH4 Cl stimulation. 
followed by sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis. Lane a, medium above control fibroblasts: lane b, me-
dium above GM1-gangliosidosis fibroblasts. 
mal compartmentalization (9, 10), instead the iJ-galactosidase 
precursor is secreted. 
This defect is different from that in I-cell disease where the 
absence of the mannose-6-phosphate marker on a variety of 
lysosomal glycoproteins is caused by a deficiency of the en-
zyme N-acetylglucosaminylphosphotransferase (11-13). 
In GM1-gangliosidosis a mutation in the gene on chromo-
some 3 apparently alters the structure of the 88-kDa 11-
galactosidase precursor in such a way that it is not phospho-
rylated. The fact that this defect is found in all GM, -gangliosi-
dosis variants, may indicate that the various allelic mutations 
change the conformation of the iJ-galactosidase precursor in 
such a way that the recognition site for N-acetylglucos-
aminylphosphotransferase is lost. 
Recent studies (14) indicate that the latter enzyme can only 
recognize lysosomal glycoproteins in their native conforma-
tion, suggesting the importance of protein conformation for 
the exposure of the recognition marker. The experimental 
data described in the present paper indicate that GM,-gangli-
osidosis fibroblasts might be a useful model for further studies 
on this subject. 
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Immunocytochemistry- fibroblasts- fJ-galactosidase-
GM,-gangliosidosis- galactosialidosis 
lmmunoelectron microscopy was performed to study the biosyn-
thesis of lysosomal ~-galactosidase (~-gal) in normal and mutant 
human fibroblasts. Using polyclonal and monoclonal antibodies 
we show in normal cells precursor forms of ~-gal in the rough en-
doplasmic reticulum (RER) and in the Golgi apparatus throughout 
the stack of cisternae. In the lysosomes virtually all ~-gal exists as a 
high molecular weight multimer of mature enzyme. In the autoso-
mal recessive disease GM 1-gangliosidosis caused by a ~-gal defi-
ciency and in galactosialidosis, associated with a combined defi-
ciency of lysosomal neuraminidase and ~-gal, precursor forms of 
the latter enzyme are found in RER, Golgi and some labeling is 
present at the cell surface. The lysosomes remain unlabeled, indi-
cative for the absence of enzyme molecules in this organelle. In 
galactosialidosis fibroblasts also no mature ~-gal is found in the 
lysosomes but in these cells the presence of the monomeric form 
can be increased by leupeptin (inhibition of proteolysis) whereas 
addition of a partly purified 32 kDa "protective protein" results in 
the restoration of high molecular weight ~-gal multimers in the 
lysosomes. 
Introduction 
About 30 autosomal recessive disorders in man are based 
on a lysosomal enzyme deficiency [5]. During the last few 
years it has become clear that a number of these deficien-
cies are due to abnormal posttranslational processing of 
the precursor forms of the enzymes. Such processing de-
fects can be related to a structural abnormality of the poly-
peptide itself or they can be caused by a genetic deficiency 
of other proteins involved in the modification and com-
partmentalization of the enzyme(s) (for reviews see [1, 4]). 
The ~-galactosidase deficiency in GM1-gangliosidosis [17] 
appears to be an example of the former. The 85 kDa pre-
cursor of ~-galactosidase is synthesized normally but no 
mature 64 kDa enzyme is detected in the lysosome [13]; re-
cently we have found that the structural mutation inter-
feres with the phosphorylation of the precursor form 
which is then secreted into the medium (to be published) 
lJ Rob Willemsen, Department of Cell Biology and Genetics, 
Erasmus University, P. 0. Box 1738, 3000 DR Rotterdam/The 
Netherlands. 
as is the case in some variants of a-glucosidase deficiency 
in glycogenesis II [20]. 
Galactosialidosis, an inherited disease associated with 
deficiencies of lysosomal ~-galactosidase and neuramini-
dase [26], was found to be due to a deficiency of a 32 kDa 
"protective protein" [2] which normally is required for the 
aggregation of monomeric ~-galactosidase into high mo-
lecular weight aggregates [12] and which forms a complex 
with neuraminidase [24]. 
These studies thus far are all based on biochemical ana-
lyses mostly on homogenates from normal and mutant fi-
broblasts. The availability of polyclonal and monoclonal 
antibodies against ~-galactosidase in its different aggrega-
tion forms [21] and the possibility of immunoelectron mi-
croscopy on frozen sections [7. 23] enabled us to relate the 
different steps of posttranslational processing of ~-galacto­
sidase to the various subcellular compartments in normal 
and mutant human fibroblasts. 
Materials and methods 
Human skin fibroblasts from normal individuals and from patients 
with the adult type GM 1-gangliosidosis [22] and the early infantile 
variant of galactosialidosis [14] were obtained from the Rotterdam 
Cell Repository (Prof. Dr. M. F. Niermeijer). The cells were culti-
vated in Ham"s FlO medium (Flow Laboratories, McLean, VA) 
supplemented with 10% fetal calf serum and antibiotics (Gibco). 
Early passages of the cell strains were grown in 75 em:! Falcon 
flasks to a density of 1 to 2 mg of protein per ilask. After trypsini-
zation cells were harvested, rinsed twice with fresh medium and 
kept in suspension in a rotating tube for 2 h at 37 oc to recover 
from possible damage by trypsin. 
Antibodies 
For immunocytochemistry rabbit polyclonal antibodies against hu-
man placental ~-galactosidase described by d'Azzo et al. [2] were 
used; these react with monomeric and multimeric forms of mature 
enzyme, its 85 kDa precursor and with the 32 kDa protective pro-
tein required for the aggregation of monomeric 64 kDa ~-galactosi­
dase and its 54 kDa precursor. 
Mouse monoclonal antibodies (3C7 /B4) react with the 64 kDa 
monomeric ~-galactosidase and its 85 kDa precursor only, as re-
ported by Sips et al. [21]. Additional data concerning the isolation 
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and characterization of monoclonal antibodies against ~-galactosi­
dase will be published separately. In applying the monoclonal an-
tibodies for immunocytochemistry a rabbit anti-( mouse lgG) was 
used as an intermediate step. 
Immunocytochemistry 
Cells were collected by centrifugation and taken up in 0.1 M phos-
phate buffer (PB), pH 7.3, containing 1% acrolein and 0.4% glutar-
aldehyde. After fixation for 60 min at 4 °C, the cells were rinsed 
twice in 0.1 M PB and resuspended in 10% (w/v) gelatin in 0.1 M 
PB at 37oC. After centrifugation the pellet was solidified on ice, 
and postfixation to cross-link the gelatin was performed in the 
same fixative as used before. The gelatin-embedded cells were 
stored in 1% paraformaldehyde in 0.1 M PB containing 1M su-
crose, at 4 oc [6]. Ultracryotomy was carried out as described by 
Tokuyasu [23] using an LKB Nova ultramicrotome equipped with 
the Cryo Nova. 
The methods used for immunoelectron microscopy were those 
described by" Geuze et a!. [71 with the following minor modifica-
tions. Prior to incubation with the first antibody, the sections were 
treated for 10 min with sodium borohydride (2 mg/ml PB) to re-
duce residual aldehyde groups of the fixative [3, 25]. Antigen-anti-
body complexes were visualized by using goat anti-(rabbit IgG) 
coupled to 10 nm colloidal gold (GAR 10, Janssen Pharmaceutica, 
Beerse/Belgium). Sections were stained with uranyl acetate and 
embedded in 1.5% methylcellulose [9]. Control sections were 
treated with rabbit anti-(human albumin) or rabbit anti-(mouse 
IgG) and GAR 10 only. Background labeling appeared to be negli-
gible. 
Correction experiments 
Correction of the combined ~-galactosidase and neuraminidase 
deficiency in galactosialidosis cells was established in two ways. 
Firstly, the intra1ysosomal proteolytic degradation of the lysoso-
mal enzymes was inhibited by the addition of teupeptin (Sigma, 
final concentration 0.02 mM) to culture medium above the mutant 
fibroblasts for 4 days. 
Secondly, a concentrate of the 54 kDa precursor of the 32 kDa 
protective protein [12] was prepared by addition of 10 mM NH 4 CI 
to the medium above GM 1-gangliosidosis fibroblasts during 2 days 
followed by concentration on an Am icon PM 1n filter to a final vol-
ume of 1 ml as described [11]. An aliquot of 40 111 of this concen-
trate was added per rnl medium of galactosialidosis cells during 4 
days. 
Results 
Processing of (3-galactosidase in normal fibroblasts 
The polyclonal antibodies against ~-galactosidase are 
known to react with the 85 kDa p'ecursor, the 64 kDa ma-
ture monomeric er.zyme, the 600 to 700 kDa multimeric 
aggregate and with the 32 kDa protective protein and its 
54 kDa precursor. Using this antibody, immunogold label-
ing of ultrathin frozen sections of normal fibroblasts show 
a random distribution of gold particles within the lyso-
somes (Fig. I). The rough endoplasmic reticulum (RER) 
(Fig. 1) and the Golgi-complex (Fig. 2) are labeled too. The 
Golgi complex was labeled from cis to trans throughout 
the stack of cisternae. Also a weak labeling at the plasma 
membrane and occasionally of a small vesicle just below 
was observed (not shown). 
With the monoclonal antibody, known to react with the 
85 kDa ~-galactosidase precursor and the monomeric ma-
ture enzyme only, gold labeling was found in the RER 
(Fig. 3), the Golgi complex (not shown), at the plasma 
membrane and in small vesicles just below the plasma 
membrane (Fig. 4). No gold particles were detected in the 
lysosomes (Fig. 3). 
Processing of (3-galactosidase in mutant fibroblasts 
In fibroblasts from a patient with GM 1-gangliosidosis no 
difference was found between the labeling pattern using 
the polyclonal or the monoclonal antibodies. Most lyso-
somes remained unlabeled although occasionally a single 
gold particle was observed (Figs. 5, 6). The labeling of the 
RER and the Golgi complex is similar to that shown for 
normal cells. 
Cells from a patient with galactosialidosis had a similar 
labeling pattern as described above for GM 1-gangliosidosis: 
again no labeling of virtually all Iysosomes (Fig. 7) and 
weak labeling of the RER, Golgi complex and plasma 
membrane. 
Correction of the defect 
Addition of leupeptin which inhibits thiolcathepsins, 
blocks the enhanced degradation of monomeric ~-galacto­
sidase molecules. The latter is responsible for the ~-galac­
tosidase deficiency in galactosialidosis [2]. Addition of leu-
peptin to galactosialidosis fibroblasts causes a marked in-
crease of gold labeling in the lysosomes using monoclonal 
antibodies (compare Figs. 7 and 8); similar results were 
obtained with polyclonal antibodies, as expected. 
Addition of the precursor form of the 32 kDa protective 
protein to galactosialidosis cells is known to aggregate 
monomeric ~-galactosidase into high molecular weight ag-
gregates and to activate neuraminidase, thereby correcting 
the combined enzyme deficiency [12]. At the subcellular 
level ingestion of exogenous 54 kDa precursor of the pro-
tective protein results in a marked increase of gold labeling 
using polyclonal anti-~-galactosidase antibodies. However, 
when monoclonal antibodies were used no labeling was 
observed (Figs. 9, 10). 
Figs. 1 to 10. Ultrathin cryosections of normal and mutant hu-
man skin fibroblasts. The sections were indirectly labeled with 
goat anti-(rabbit lgG) conjugated with 10 nm colloidal gold for the 
demonstration of ~-galactosidase.- Bars 0.2 11m. 
Figs. 1 to 4. Subcellular localization of ~-galactosidase in normal 
fibroblasts.- Fig. 1. Polyclonal anti ~-galactosidase. Labeling is 
observed in the RER (R) and in lysosomes (L).- Fig. 2. Poly-
clonal anti ~-galactosidase. Labeling can be seen throughout the 
stack of Golgi cisternae (G).- Fig. 3. Monoclonal anti ~-galacto­
sidase. Gold particles are present only in the RER (R), and the 
lysosomes (L) remain unlabeled.- N Nucleus.- Fig. 4. Mono-
clonal anti ~-galactosidase. Labeling is observed at the plasma 
membrane {PM) and occasionally in a small vesicle just below (ar-
row). 
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Figs. 5. 6. Subcellular localization of B-ga\actosidase in fibro-
blasts from the adult form of GM 1-gangliosidosis.- Fig. 5. Poly-
clonal anti p-galactosidase.- Fig. 6. Monoclonal anti B-galactosi-
Discussion 
The present study is the first to follow the intracellular 
processing of ~-galactosidase in normal and mutant hu-
man fibroblasts. The labeling of the RER and Golgi com-
plex most likely represents the 85 kDa precursor form of 
~-galactosidase. since an identical labeling is observed us-
ing either monoclonal or polyclonal antibodies against ~­
galactosidase. The fact that labeling is observed from cis to 
trans throughout the stack of cisternae is in agreement with 
the biochemical data about the glycosylation. phosphory-
lation and the uncovering of the mannose-6-P-recognition 
site of lysosomal (enzyme) proteins [8. 19]. On the basis of 
the combined data with polyclonal and monoclonal anti-
bodies. the labeling of lysosomes in normal fibroblasts us-
ing polyclonal antibodies is indeed the result of the pres-
ence of high molecular weight aggregates of the 64 kDa 
mature ~-galactosidase. The immunocytochemical findings 
are thus in accordance with the biochemical evidence for 
such aggregates in the lysosomes. as previously described 
[12]. Furthermore. no lysosomal labeling is observed with 
the monoclonal antibodies that react with monomeric 
forms of ~-galactosidase only. 
The weak labeling at the plasma membrane and very 
small vesicles below might indicate a minor second path-
way of precursor molecules leaving the cell via the plasma 
membrane. Such a pathway has been suggested previously 
on the basis of biochemical studies [I 0]. 
In GM 1-gangliosidosis fibroblasts a normal synthesis of 
85 kDa precursor ~-galactosidase and absence of the 
64 kDa mature form has been described [13]. Our immuno-
cytochemical studies support this observation: no cross-
dase. In both instances the RER is labeled whereas the lysosomes 
remain unlabeled although occasionally a single gold particle is 
seen in a lysosome (Fig. 5). 
reactive material is seen in the lysosomes. It has been dem-
onstrated that GM 1-gangliosidosis fibroblasts also contain a 
normal amount of functional 32 kDa protective protein 
[II]: apparently the 32 kDa protective protein is not or 
hardly immunoreactive under the conditions appropriate 
for immunoelectron microscopy. Recently. evidence has 
been obtained that the structural mutation of the ~-galacto­
sidase precursor molecule interferes with its phosphoryla-
tion and results in secretion of the precursor by GM 1-gan-
gliosidosis fibroblasts (to be published). In previous stud-
ies. however. the presence of cross-reactive material was 
reported in different variants of G" 1-gangliosidosis [15. 16] 
but in these studies human liver was used. It is known that 
the intracellular routing is different in various cell types 
which will of course determine the ultimate effect of age-
netic processing defect [ 18]. 
Our results on galactosialidosis are -especially interesting 
since they show the absence of ~-galactosidase molecules 
in the lysosomes. an increase of monomeric form after ad-
dition of leupeptin and a correction of the metabolic de-
fect after administration of the 32 kDa protective protein 
precursor i.e. aggregation into high molecular weight com-
plex of ~-galactosidase molecules. The latter finding indi-
cates that the aggregation of 64 kDa monomeric ~-galacto­
sidase takes place in the lysosome. Since it is known that 
Figs. 7. 8. Subcellular localization of [3-galactusidase in galacto-
sialidosis fibroblasts.- Fig. 7. Monoclonal anti ~-galactosidase. 
Most \ysosomes show no labeling, occasionally a single gold par-
ticle is detected in a lysosome.- Fig. 8. Monoclonal anti B-galac-
tosidase. After addition of leupeptin a marked increase of the 
number of gold particles is observed in the Jysosomes. 
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Figs. 9, 10. Subcellular localization of ~-galactosidase in galacto-
sialidosis fibroblasts corrected by addition of the precursor of the 
32 kDa protective protein.- Fig. 9. Polyclonal anti ~-galactosi-
the 32 kDa protective protein is essential for this aggrega-
tion our data on correction also suggest that the processing 
of 54 kDa precursor to 32 kDa protective protein also oc-
curs within the lysososome. Studies to corroborate this 
with an affinity-purified monospecific antibody prepara-
tion against the 32 kDa protective protein are in progress. 
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Ganglioside GM1 metabolism in living human fibroblasts 
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Summary. The uptake and catabolism of [3H-ccramide]-GMt 
was followed in living fibroblasts from patient with different 
forms of ~-galactosidase deficiency. Gangliosides are iden-
tified according to the nomenc!ature of Svennerholm (1963). 
A total inability to metabolize the ingested substrate was 
found in infantile G\11 -gangliosidosis whereas cells from an 
adult GJ\u-gangliosidosis variant showed a slower rate of de-
gradation, compared with controls. Morquio B fibroblasts had 
a comparable catabolism of GMt as controls. Fibroblasts from 
different types of galactosialidosis, a recessive disease associ-
ated with a coexistent f3-galactosidase/neuraminidase deficien-
cy all showed degradation of ingested GMt· In view of the 
molecular defect in this disease, this catabolism must be due 
to the 10--20% of monomeric f3-galactosidase molecules pre-
sent in the lysosomes. Unexpectedly, in the.;;c cells an im-
paired metabolism of G~n was found. The same finding was 
observed when cells with an isolated neuraminidase deficiency 
(mucolipidosis I) were loaded with GJ\II· A hypothesis is pre-
sented to explain these results. 
Introduction 
Several human genetic diseases are associated with a deficien-
cy of lysosomal-~-galactosidasc (EC.3.2.1.23) alone like GMt· 
gangliosidosis (Okada and O'Brien 1968) and Morquio B syn-
drome (O'Brien ct a!. 1976; Groebe eta!. 1980) or in combi-
nation with a deficiency of neuraminidase (EC.3.2.1.18) as in 
ga!actosialidosis (Wenger et al. 1978; Hoogeveen eta!. 1980). 
During the last few years progress has been made to elucidate 
the exact nature of the molecular defect in these lysosomal 
storage diseases. In GJ\u-gangliosidosis the structural mutation 
in chromosome 3 affects the 85 kilodalton precursor ~-galac­
tosidase so that it is secreted instead of being properly proces-
sed and compartmentalized into the lysosome (Hoogeveen et 
a!. 1986). In Morquio B syndrome the mutatiory affects the af-
finity and catalytic properties towards glycosaminoglycans and 
ganglioside G,..,11 (Paschke and Kresse 1982; Vander Horst et 
a!. 1983). 
The combined f3-galactosidase and neuraminidase defi-
ciency in patients with galactosialidosis appears to be due to a 
deficiency of a 32 kilodalton "protective protein" (d'Azzo et 
~On leave from Department of Pediatrics. University of Siena, Italy 
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Genetics. Era::.mus University Rotterdam. Postbus 1738, NL-3000 
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aL 1982) which normally is required for the aggregation of f3-
galactosidase monomers into a high molecular weight complex 
with neuraminidase (Verheijen et al. 1982; Hoogevecn eta!. 
1983). Deficiency of this protein results in enhanced proteo-
lytic degradation of f3-galactosidase monomers whereas 
neuraminidase remains inactive because the 32 kilodalton pro-
tein is an essential subunit for this enzyme (Verheijen et al. 
1985). 
For each of the genetic diseases mentioned above different 
clinical variants, concerning age of onset, involvement of dif-
ferent organs, and mental retardation, have been reported 
(Andria et al.1981; O'Brien 1983; Van Gemund et a!. 1983; 
Galjaard ct a!. 1984). These are probably based on different 
rates of ganglioside GM1 catabolism que to different molecular 
types of the deficient enzyme (Conzclmann and Sandhoff 1983/ 
!984). The synthesis of [3H-ceramide] GMt-ganglioside en-
abled us to investigate under in vivo conditions the metabo-
lism of ganglioside GM 1 in normal fibroblasts and in the vari-
ous types of mutant cells mentioned above. 
Materials and methods 
Fibroblasts from patients with the infantile or adult form of 
GM 1-ganglim.idosis, with the infantile or adult form of galac-
tosialidosis. with mucolipidosis I, and with Morquio B syn-
drome were obtained from the Rotterdam Cell Repository 
(Professor Dr, M. F. Niermeijer). Early passages of the cell 
strains were cultured in Ham's FlO medium supplemented with 
10% fetal calf serum (FCS) and antibiotics. The activities of~­
galactosidase and neuraminidase were measured with the ap-
propriate 4-methylumbelliferyl substrates as described by Gal· 
jaard (1980). 
G.urf3-galactosidase activity in cell homogenares 
The preparation of [3H-GMJ]-ganglioside labeled in the galac-
tose moiety and the determination of GM1-f3-galactosidase ac-
tivity was performed as previously described (Svennerholm et 
a!. 1979). 
Merabolism in living fibroblasts 
of {'H-ceramide] ganglioside-Cui 
Ganglioside GM1 was labeled in the ceramide portion with 
tritium (specific activity: 57mCi/mmol) (Schwarzmann 1978). 
Labeled GM1 ganglioside was dissolved in Ham's FlO medium 
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at a concentration of 5 ~moll! and added to 25 cm2 Falcon 
flasks with fibroblasts grown to confluency. After 16h of incu-
bation in labeled medium and S-48h of ''chase", the cells were 
harvested using 0.25% trypsin, washed extensively with phos-
phate buffered saline (PBS) to remove unspecifically bound 
ganglioside and, after centrifugation, the pellet was disrupted 
by suspending in 500 ).ll of water. A small sample of the pellet 
(25 J.ll) was dissolved in Soluene 350 (Packard) and counted in 
Dimilume 30 (Packard) to assess the total ganglioside uptake. 
The lipids were extracted from 400 J.ll of cell suspension by 
adding methanol and chloroform to a final ratio of C-M-W 
4:8:3 (v/v/v). The insoluble material was removed by cen-
trifugation. The clear supernatant was evaporated to dryness 
under nitrogen, dissolved in C-M-W 60:30:4.5 (v/v/v), and 
desalted through a small Sephadex G25 column. From differ-
ent samples equal amounts of counts were applied to a HP-TLC 
plate (Merck) and run in C-M-0.25 KCL (50:40: !O:v/v/v). 
The radiolabeled compounds were visualized by fluorography. 
Correction studies 
Correction of the defect in galactosialidosis cells was estab-
lished in two ways. First. the intralysosomal proteolytic degra-
dation of ~-galactosidase monomers was inhibited by addition 
to the medium of leupeptin (Sigma), a thiol protease inhibitor_ 
at a final concentration of 0.02mM for 5 days. as described 
previously (Hoogeveen et al. 1983). prior to labeling with 
fH]-GMl· Second, both the aggregation of galactosidase and 
activation of neuraminidase was established by adding the 
precursor form of the 32 kilodalton protective protein. This 
was prepared by addition of !OmM NH,Cl to the medium 
above GM1-gangliosidosis fibroblasts for 2 days. followed by 
concentration on an Amicon PMlO filter to a final volume 
of lml. as previously described (Hoogeveen et al. 1981). A 
sample of 40J.ll of the concentrate was added per ml of 
medium above galactosialidosis fibroblasts. After 5 days the 
cells were labeled with ['H]-G, 1• 
Results and discussion 
The residual activities in the different types of mutant fibro-
blasts used arc summarized in Table 1. In the infantile form of 
G:-1 1-gangliosidosis the residual activity with both natural and 
artificial substrate is less than 1%. in Morquio B 3-4%. and in 
adult GJ\u-gangliosidosis the activity is of the order of 10%, as 
it is in both galactosialidosis variants. The apparent Km to-
wards [-'H)-galactose G:-11 was found to be l.2mM in control 
fibroblasts which is in agreement with previous findings (Sven-
ncrholm eta!. 1979). The same values were observed in adult 
GJ\1 1-gangliosidosis and in both galactosialidosis variants. We 
could not obtain reliable data on the Km for the other mutant 
cell strains with a very low residual enzyme activity. Various 
investigators have, however. questioned the reliability of Km 
studies on gangliosides in aqueous solutions (Scheel et al. 
19~2: Vcnerando et al. 1985). 
To study the metabolism of gangliosides under in vivo con-
ditions. GMt 3H-labeled in its ccramide portion was adminis-
tered to the various mutant fibroblasts and after uptake the 
ganglioside pattern was analyzed by thin layer chromato-
graphy. After a period of !6h 5-7% (0.9nmol) of the total 
amount of ganglioside GM 1 in the medium was ingested and 
part of it ought to be localized in the lysosomes since the de-
Table 1. Enzyme activities in fibroblast homogenates 
~-Galactosidase" 
4-MU-~-GAL ['H]-GMI 
Controls Range: 450-1250 60-120 
(N~20) (N~3) 
Mean: 850 90 
Infantile 2.0 0.02 
GM 1 -gangliosid~sis 
Adult 30.0 10.0 
GMt-gangliosidosis 
Morquio disease 35.0 2.5 
TypeB 
Adult 79.0 9.1 
galactosialidosis 
Infantile 70.0 17.N 
galactosialidosis 
Infantile 2711 
galactosia!idosis 
+ lcupcptin 
+ protective pro- 300 
tein precursor 
" Specific activities expressed in nmol/h/mg protein 
I 
OTHER i 
6M3 ' 
GM2 
GMl ~ 
Neuraminidase" 
4-MU-NANA 
40-150 
(N~20) 
95 
0.5 
11.7 
20 
-... 
-... 
Fig.l. Loading of living fihrobla:-t<. with ['H-ccramidc] G,11 • Control 
fibrob!asb: 16h bbeling (a) followed hv.Sh (h). 2-th (c). ~tnd ..J.~h (d) 
of "chase ... For expcri~ental condition~ :-cc text 
gradation into GM~ and G\t3 is known to he catalyzed hy the 
lysosomal enzymes ~-galactosidase and ~-N-acetylglucos­
aminidasc (E.C.3.2.!.52) respectively (Sonderfc!d ct a!. I YX5). 
As is shown in Fig. 1 after 48 h incubation in non-lahelcd 
medium (''chase") ~uch of GJ\1 1 is metabolized and in all suh-
sequent analyses of mutant fibroblasts a period of 16 h laheling 
followed by 48 h chase was used. 
The results in Fig. 2 indicate that cells from the patient with 
infantile G\wgangliosidosis do not metabolize any of the in-
gested ganglioside GM 1: the .same was true after longer periods 
of labeling (data not shown). Adult G\u-gangliosidosis fibro-
blasts. however. do show some metabolism of GM 1 into G:-.e 
and GM.> (compare Fig.2a,c). It is known that in adult G\w 
gangliosidosis 5-10% of the normal amount of ~-galactosida:-e 
molecules is present in the lysosomes and that these molecules 
GM3-
GM2-
GM1--!IIIIilllllllll>-
a 
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-
d 
Fig.2. Loading of living fibroblast:-. with [3H-ceramide] G~;11 • Lane a: 
contrLll fibrohlasts: lane b: infantile G~wgang!iosidosis: tune c: adult 
G,wgangliosidosi~; lane d: Morquio disease type B 
have normal properties (van Diggclen ct a!. 198L Hoogcveen 
ct al. l9S6). The early onset of neurologic symptoms in infan-
tile G,,11 -gangliosidosis and the late onset in adult Gr.w 
gangliosidosis seem to be related to the difference in the 
number of ~-galactosidase molecules available in the lyso-
some. 
Morquio B fibroblasts exhibit a !:>imilar catabolism of GM 1 
as control cells (Fig. 2d). Here, the lysosomes arc known to 
contain P-galactosidasc molecules, which have a decreased af-
finity for their substrates. In test tube assays using ganglioside 
G\1 1 as a substrate a residual activity of 20--50(Yo is found when 
physiologic :..tmounts of activator protein arc present (ht5chke 
r!nd Kresse 1982). 
In both varianb of galactosialidosb (Fig.3). ingested Gr-,11 
is degraded to G,\c and G.\L'· but unexpectedly, thb latter 
gang!io-:.ide b not further metabolized. The catabolism of Gr-,u 
to G\!3 must be due to the I 0-20% of monomeric p~galac­
to':,idase known to be left in the lvsosomcs (Hoogcveen et a!. 
19X3). Administration of lcupe-ptin. which in ... hibits intra~ 
ly:-.o:-.omal proteolysb results in an increase of monomeric 0-
gaJactosida~c and thi:-; accounts for the higher enzvmc activitv 
Tn cdl homogenate (Table 1 ). Under in vivo conditions. ho;~ 
ever. leupcptin docs not seem to affect the catabolism of in-
ge .... ted G\ll (Fig. 3d). The high molecular weight aggregates. 
predominantly pre~ent in control cells. seem therefore to be 
not c~~ential for the hydrolysis of GMI· This implies that the 
lfJ--2()(/;J monomeric p~galactosidasc is sufficient for the GM 1 
catabolbm under the experimental conditions. In normal 
eel b. however. P-ga!actosidase is predominantly present as a 
high molecular weight aggregate which normally must be re~ 
~pon:-.ihlc for the caw holism of Gr-,11 (Fig. 1). 
When the basic genetic defect in galactosialidosis is cor~ 
rected by administrating a preparation containing the 54 kilo-
dalton precursor of the 32 kilodalton prote~tive protein. the in 
vivo metabolism of GM 1 almost normalizes (Fig.3e). This 
might be related to the restoration of high molecul;r weight p~ 
galactosidase complexes (Hoogeveen et al. 1983) which in 
turn arc essential for the expression of lysosomal neuramini-
da>c activity (Table I) (Verhcycn et al. 1985). The latter is 
probably responsible for the normalization of GM3 catabolism. 
Further support for a role of this neuraminidase in lysosomal 
ganglioside degradation was obtained by the observation that 
mucolipidosis I fibroblasts. which have an isolated lysosomal 
neuraminidase deficiency. also show a clear degradation of in-
GM3-
---GM2-
M1-------
-
-
Fig.3. Loading of Jiving fibroblasts with [:''H~ceramide] Gr.u· Lane a: 
control fibroblasts: lane b: ~alactosialidosis. adult form: lanes c-e: 
galactosialidosb, infantile fo~m: c: without treatment~ d: after addi-
tion of leU'"pcptin: e: after correction of the 32 kilodalton protective 
protein deficiency; lanef: mucolipidosis I 
gested GMt to G:.e and Gr-,0 and an accumulation of the latter 
(Fig.3f). 
This finding is surprising because previous studies on cell 
homogenates has shown that sialic acid is released from differ-
ent types of gangliosides. including GMJ· by both mueoli-
pidosis I cells (Cantz and Messer 1979) and galactosialidosis 
fibroblasts (Wenger et al. 1978; Miyatake et al. 1979). The lat-
ter report mentions. however. a marked accumulation of 
gnngliosidcs in sympathetic ganglia of the patient. This might 
either be compatible with the hypothesis of an in vivo inhibi~ 
tion of neuraminidase by storage products (protein-bound 
sialic acid) or our experiments indicate that lysosomal neur-
aminidase plays a role in ganglioside degradation in living 
fibroblasts. 
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